Quinoxaline compounds

ABSTRACT

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

FIELD OF THE INVENTION

There is provided by the present invention compounds that are CCK2receptor modulators. More particularly, there is provided by the presentinvention quinoxalines that are CCK2 receptor modulators useful for thetreatment of disease states mediated by CCK2 receptor activity.

BACKGROUND OF THE INVENTION

This invention relates to gastrin and cholecystokinin (CCK) receptorligands. The invention also relates to methods for preparing suchligands and to compounds that are useful intermediates in such methods.The invention further relates to pharmaceutical compositions comprisingsuch ligands and methods for preparing such pharmaceutical compositions.

The gastrins and cholecystokinins are structurally related neuropeptidesthat exist in gastrointestinal tissue, gastrinomas and, in the case ofthe cholecystokinins, the central nervous system (J. H. Walsh,Gastrointestinal Hormones, L. R. Johnson, ed., Raven Press, New York,1994, p. 1).

Several forms of gastrin are found including 34-, 17- and 14-amino acidspecies with the minimum active fragment being the C-terminaltetrapeptide (TrpMetAspPhe-NH2), which is reported in the literature tohave full pharmacological activity (H. J. Tracy and R. A. Gregory,Nature (London), 1964, 204:935-938). Much effort has been devoted to thesynthesis of analogs of this tetrapeptide (and the N-protectedderivative Boc-TrpMetAspPhe-NH2) in an attempt to elucidate therelationship between structure and activity.

Natural cholecystokinin is a 33 amino acid peptide (CCK-33), theC-terminal 5 amino acids of which are identical to those of gastrin.Also found naturally is the C-terminal octapeptide (CCK-8) of CCK-33. Areview of CCK receptors, ligands and the activities thereof may be foundin P. de Tullio et al. (Exp. Opin. Invest. Drugs, 2000, 9(1):129-146).

Gastrin and cholecystokinin are key regulators of gastrointestinalfunction. In addition, cholecystokinin is a neurotransmitter in thebrain. Gastrin is one of the three primary stimulants of gastric acidsecretion. In addition to the acute stimulation of gastric acid, gastrinhas a trophic effect on the gastrointestinal mucosa and is implicated asa trophic hormone of several adenocarcinomas, including pancreatic,colorectal, esophageal and small cell lung.

Cholecystokinin stimulates intestinal motility, gallbladder contraction,and pancreatic enzyme secretion, and is known to have trophic actions onthe pancreas thus increasing, inter alia, pancreatic enzyme production.Cholecystokinin also inhibits gastric emptying and has various effectsin the central nervous system, including regulation of appetite andpain.

Gastrin acts on CCK2 (otherwise known as gastrin/CCK-B receptors)whereas cholecystokinin acts on both CCK2 and CCK1 receptors (otherwiseknown as cholecystokinin/CCK-A receptors). Compounds that bind tocholecystokinin and/or gastrin receptors are important because of theirpotential pharmaceutical use as antagonists of the natural peptides ormimetics of the natural peptides acting as partial or full agonists atthe cholecystokinin and/or gastrin receptors. A selective gastrinreceptor antagonist has not yet been marketed. However, several arecurrently undergoing clinical evaluation. JB95008 (gastrazole) is beingdeveloped by The James Black Foundation and Johnson & JohnsonPharmaceutical Research & Development LLC for the potential treatment ofadvanced pancreatic cancer (pancreatic adenocarcinoma), and is currentlyin Phase II clinical trials. ML Laboratories and Panos are developingL-365,260 (Colycade), which is in Phase II clinical trials for pain.Other potential indications included eating disorders and cancer. YF-476(formerly YM-220), under joint development by Yamanouchi and FerringResearch Institute, is in Phase I clinical trials for gastro-esophagealreflux disease (GERD). In Phase I trials, Zeria Pharmaceutical isinvestigating Z-360, an orally available 1,5-benzodiazepine derivative(WO-09825911), as a potential treatment for gastroduodenal ulcers andreflux esophagitis. CR 2945 (itriglumide), an orally active anthranilicacid derivative, has been investigated by Rotta in Phase I trials foranxiety disorders, cancer (particularly colon cancer) and peptic ulcer.

Gastrimmune, Aphton Corporation's anti-gastrin vaccine, which works bychemical neutralization of the hormone, is undergoing late stageclinical trials for cancer indications, in particular, pancreatic andgastric tumors.

In addition to those indications described above, gastrin (CCK2)antagonists have been proposed for the following gastrin-relateddisorders: gastrointestinal ulcers, Barrett's esophagus, antral G cellhyperplasia, pernicious anaemia, Zollinger-Ellison syndrome, and otherconditions in which lower gastrin activity or lower acid secretion isdesirable.

Cholecystokinin (CCK1) receptors have been shown to mediatecholecystokinin-stimulated gallbladder contraction, pancreatic enzymesecretion, satiety, gastric emptying inhibition and regulation ofperistalsis, indicating a key role in the integrated physiologicalgastrointestinal response to a meal. In addition, there is evidence thatcholecystokinin receptors mediate a mitogenic action of cholecystokininon some adenocarcinomas. Consequently, selective cholecystokininreceptor antagonists, for example, devazepide (Merck), lorglumide(Rotta), 2-NAP (JBF), dexloxiglumide (Rotta), and lintitript (Sanofi)have been examined in the clinic for potential applications in, interalia, irritable bowel syndrome, chronic constipation, non-ulcerdyspepsia, acute and chronic pancreatitis, biliary disease andpancreatic cancer. Additional roles of cholecystokinin receptors includethe regulation of appetite and metabolism, indicating potentialtherapeutic applications in the treatment of disorders such as obesityand anorexia nervosa. Other possible uses are in the potentiation ofopiate (for example morphine) analgesia and in the treatment of cancers,especially of the pancreas. Moreover, ligands forcholecystokinin/gastrin receptors in the brain have been claimed topossess anxiolytic activity, and gastrin receptor antagonists would beexpected to act as neurological agents towards the relief of anxiety andrelated neuroses and psychoses.

SUMMARY OF THE INVENTION

The invention features a quinoxaline sulfonamide compound of formula(I):

wherein

-   R¹ and R² are each independently selected from the group consisting    of    -   a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,        C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point of        attachment is a carbon atom adjacent to the ring junction,        C₃₋₇cycloalkylC₁₋₇alkyl,    -   b) naphthyl-(CR^(s) ₂)—, benzoylC₀₋₃alkyl-(CR^(s) ₂)-, phenyl,        said phenyl optionally fused at two adjacent carbon atoms to        R^(f), phenyl-(CR^(s) ₂)—, said phenyl optionally fused at two        adjacent carbon atoms to R^(f),    -   R^(f) is a linear 3- to 5-membered hydrocarbon moiety having 0        or 1 unsaturated bonds and having 0, 1 or 2 carbon members which        is a carbonyl,    -   c) Ar⁶—(CR^(s) ₂)-, where Ar⁶ is a 6-membered heteroaryl having        carbon as a point of attachment, having 1 or 2 heteroatom        members which are —N=and optionally benzo fused,    -   d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-membered heteroaryl having        carbon as a point of attachment, having 1 heteroatom member        selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,        having 0 or 1 additional heteroatom member which is —N=and        optionally benzofused,    -   e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the point of        attachment and fused to a 6-membered heteroaryl having 1 or 2        heteroatom members which are —N═,    -   f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ is phenyl having the point of        attachment and fused to a 5-membered heteroaryl having 1        heteroatom member selected from the group consisting of O,        S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatom        member which is —N═,    -   g) C₁₋₄alkylO— and HSC₁₋₄alkyl,    -   where R¹ and R² are not simultaneously H and, except in        positions where R^(s) is indicated, each of a) to g) is        substituted with 0, 1, 2, or 3 of R^(q),    -   R^(q) is independently selected from the group consisting of        C₁₋₄alkyl, hydroxy, fluoro, chloro, bromo, iodo,        trifluoromethyl, aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,        diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl,        HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy and C₁₋₄alkylS-,    -   R^(s) is independently selected from the group consisting of H,        C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,        aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl,        diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl, HS—C₁₋₄alkyl,        C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl and phenyl;    -   or, alternatively,-   R¹ and R² may be taken together with the nitrogen to which they are    attached and are selected from the group consisting of    -   i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl, optionally        mono- or di-substituted with R^(p),    -   R^(p) is independently selected from the group consisting of        hydroxy, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl, mono-, di- or        tri-halo substituted phenyl and hydroxyphenyl,    -   ii) a 4-7 membered heterocyclic ring said heterocyclic ring        having 0 or 1 additional heteroatom members separated from the        nitrogen of attachment by at least one carbon member and        selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2        unsaturated bonds, having 0, 1 or 2 carbon members which is a        carbonyl, optionally having one carbon member which forms a        bridge and having 0, 1 or 2 substituents R^(p),    -   iii) a benzo fused 4-7 membered heterocyclic ring said        heterocyclic ring having 0 or 1 additional heteroatom members        separated from the nitrogen of attachment by at least one carbon        member and selected from O, S, —N═, >NH or >NR^(p), having 0 or        1 additional unsaturated bonds, having 0, 1 or 2 carbon members        which is a carbonyl, having 0, 1, 2, or 3 halo substituents on        the benzene ring only and having 0, 1 or 2 substituents R^(p),    -   iv) a 4-7 membered heterocyclic ring said heterocyclic ring        having 0 or 1 additional heteroatom members separated from the        nitrogen of attachment by at least one carbon member and        selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2        unsaturated bonds, having 0, 1 or 2 carbon members which is a        carbonyl and optionally having one carbon member which forms a        bridge, the heterocyclic ring fused at two adjacent carbon atoms        forming a saturated bond or an adjacent carbon and nitrogen atom        forming a saturated bond to a 4-7 membered hydrocarbon ring,        having 0 or 1 possibly additional heteroatom member, not at the        ring junction, selected from O, S, —N═, >NH or >NR^(p), having        0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members        which is a carbonyl and having 0, 1 or 2 substituents R^(p);    -   v)        8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,        optionally having 0, 1 or 2 substituents R^(p);-   R^(a) is independently selected from the group consisting of    C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, phenyl, furanyl, thienyl,    benzyl, pyrrol-1-yl, —OH, —OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl,    -Obenzyl, —SH, —SC₁₋₆alkyl, —SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl,    —CN, —NO₂, —N(R^(y))R^(z) (wherein R^(y) and R^(z) are independently    selected from H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl),    —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and —COOC₁₋₄alkyl, or,    alternatively, two adjacent R^(a), may be taken together with the    carbons of attachment to form a fused ring and selected from the    group consisting of phenyl, pyridyl and pyrimidinyl;-   or alternatively, R² and one of R^(a) can be taken together to be    —CH₂— or >C═O and to form a fused ring to the phenyl;-   R^(b) is, independently, selected from the group consisting of    C₁₋₄alkyl and halogen;-   and enantiomers, diastereomers, hydrates, solvates and    pharmaceutically acceptable salts, esters and amides thereof.

The invention also features pharmaceutical compositions containing suchcompounds and methods of using such compositions in the treatment orprevention of disease states mediated by CCK2 receptor activity.

DETAILED DESCRIPTION

Preferably, R¹ and R² are independently selected from the groupconsisting of H,

-   -   a) C₁₋₇alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl,        cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl,        cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl,        6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl,        cyclobutylC₁₋₄alkyl, cyclopentylC₁₋₄alkyl, cyclohexylC₁₋₄alkyl,        cycloheptylC₁₋₄alkyl,    -   b) phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl,        optionally 5,6,7,8 or 9 oxo substituted,        5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-yl, optionally 5,6, 7        or 8 oxo substituted, benzyl,        6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl,        optionally 5,6,7,8 or 9 oxo substituted,        5,6,7,8-tetrahydro-naphthalen-1,2,3 or 4-ylmethyl, optionally        5,6,7 or 8 oxo substituted, 1-phenyleth-1-yl, benzhydryl,        naphthylmethyl, benzoylmethyl, 1-benzoyleth-1-yl,    -   c) pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl,        pyridazinylmethyl, quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3        or 4-ylmethyl, quinazolin-2 or 4-ylmethyl, quinoxalin-2 or        3-ylmethyl,    -   d) furanylmethyl, thiophenylmethyl, 1-(H or        C₁₋₄alkyl)pyrrolylmethyl, oxazolylmethyl, thiazolylmethyl,        pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl,        isothiazolylmethyl, benzofuran-2 or 3-ylmethyl, benzothiophen-2        or 3-ylmethyl, 1-(H or C₁₋₄alky)-1H-indol-2 or 3-ylmethyl, 1-(H        or C₁₋₄alkyl)-1H-benzimidazol-2-ylmethyl,        benzooxazol-2-ylmethyl, benzothiazol-2-ylmethyl,    -   e) quinolin-5,6,7 or 8-ylmethyl, isoquinolin-5,6, 7 or        8-ylmethyl, quinazolin-5,6,7 or 8-ylmethyl, quinoxalin-5,6, 7 or        8-ylmethyl,    -   f) benzofuran-4,5,6 or 7-ylmethyl, benzothiophen-4,5,6 or        7-ylmethyl, 1-(H or C₁₋₄alky)-1H-indol-4,5,6 or 7-ylmethyl, 1-(H        or C₁₋₄alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl,        benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5,6 or        7-ylmethyl,    -   g) C₁₋₄alkylO— and HSC₁₋₄alkyl,        where each of a) to g) is substituted with 0, 1, 2, or 3 of        R^(q) and for those groups in which R^(s) is hydrogen, up to one        R^(s) may be other than hydrogen.

Most preferably, R¹ and R² are independently selected from the groupconsisting of hydrogen, methyl, ethyl, butyl, hexyl, phenyl,6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxosubstituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl,1-benzoyleth-1-yl, methylO-, cyclohexyl, cyclohexylmethyl, pyridylethyl,naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, whereeach member is substituted with 0, 1, 2, or 3 of R^(q) and, optionally,for those groups in which R^(s) is hydrogen, up to one R^(s) may beother than hydrogen.

Specific R¹ and R² are independently selected from the group consistingof hydrogen, methyl, ethyl, butyl, phenyl, benzyl, 2-bromobenzyl,2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl,2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl,4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl,2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl,2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfanylbenzyl,2-trifluoromethylbenzyl, 1-phenyleth-1-yl, 1-phenylprop-1-yl,1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl,1-(2,4-dibromophenyl)eth-1-yl, 1-(2,4-dichlorophenyl)eth-1-yl,1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl,2-fluoro-1-(2,4-difluorophenyl)eth-1-yl,2-fluoro-1-(4-fluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl,1-methyl-1-phenyleth-1-yl, 2,2,2-trifluoro-1-phenyleth-1-yl,2,2,2-trifluoro-1-(2,4-difluorophenyl)eth-1-yl,1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl, cyclohexyl,1-cyclohexyleth-1-yl, furan-2-ylmethyl, naphth-1-ylmethyl, methoxy,methylSethyl, 6-methyl-6-hydroxyhept-2-yl, pyrid-2-ylethyl,1,2,3,4-tetrahydro-naphthalen-1-yl, 1-phenyl-2-hydroxyeth-1-yl,benzhydryl, 4-hydroxymethylpiperidin-1-yl, 1-furan-2-yl-2-phenyleth-1-yland 9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl.

It is preferred that one of R¹ and R² is H or C₁₋₄alkyl where the otheris not H or C₁₋₄alkyl. It is also preferred that one of R¹ and R² is H,methyl or ethyl.

In another preferred embodiment, at least one of R¹ and R² are selectedfrom the groups consisting of

with the proviso that said R^(s) is not hydrogen, said phenyl isoptionally fused at two adjacent carbon atoms to R^(f) and, except inpositions where “R^(s)” or “H” is specifically indicated, each member issubstituted with 0, 1, 2, or 3 of R^(q).

Preferably, R^(f) is selected from the group consisting of —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— and —(C═O)CH₂CH₂CH₂—.

Preferably, R^(s) is selected from the group consisting of hydrogen,methyl, ethyl, propyl, trifluoromethyl, halomethyl, aminomethyl,methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl,thiomethyl, methylthiomethyl and phenyl.

Most preferably, R^(s) is selected from the group consisting of H,methyl, ethyl, hydroxymethyl, fluoromethyl and dimethylaminomethyl.

Preferably, R^(q) is selected from the group consisting of methyl,ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo, iodo,trifluoromethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl,hydroxymethyl, methoxymethyl, thiomethyl, methylthiomethyl, methoxy,ethoxy, methylmercapto and ethylmercapto.

Most preferably, R^(q) is selected from the group consisting of methyl,hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl.

Preferably, R¹ and R² taken together with the nitrogen to which they areattached are selected from the group consisting of

-   -   i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,    -   ii) 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl,        2-imidazolin-1-yl, 3-(H or R^(p))imidazolidin-1-yl,        piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 3-(H or        R^(p))piperazin-1-yl, azepan-1-yl, thiazolidin-3-yl,        oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl, azetidin-1-yl, where        each member of ii) in each ring has 0 or 1 unsaturated bond and        has 0, 1 or 2 carbon members which is a carbonyl,    -   iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl,        2,3-dihydro-indol-1-yl, 1,3-dihydro-isoindol-2-yl,        1-oxo-1,3-dihydro-isoindol-2-yl, tetrahydro-benzo[b, c or        d]azepin-1-yl, 2,3-dihydro-benzo[e or f][1,4]oxazepin-4-yl,        where each member of iii) in each ring has 0 or 1 unsaturated        bond and has 0, 1 or 2 carbon members which are a carbonyl,    -   iv) decahydro-quinolin-1-yl, octahydro-isoquinolin-2-yl,        octahydro-[1 or 2]pyrindin-1 or 2-yl, octahydro-indol-1-yl,        octahydro-isoindol2-yl, hexahydro-cyclopenta[b]pyrrol-1-yl,        hexahydro-cyclopenta[c]pyrrol-2-yl, (5,6,7 or 8-H or        R^(p))-decahydro-[1,5 or 1,6 or 1,7 or 1,8]naphthyridin-1-yl,        (5,6,7 or 8-H or R^(p))-decahydro-[2,5 or 2,6 or 2,7 or        2,8]naphthyridin-2-yl, 1-H or        R^(p)-octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H or        R^(p)-octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H or        R^(p)-octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H or        R^(p)-octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H or        R^(p)-octahydro-pyrrolo[3,4-b]pyridin-1-yl, 1-H or        R^(p)-octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H or        R^(p)-octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H or        R^(p)-octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H or        R^(p)-octahydro pyrrolo[3,4-b]pyridin-6-yl, 7-H or        R^(p)-octahydro-pyrrolo[2,3-b]pyridin-1-yl,        octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where        each member of iv) in each ring has 0, 1 or 2 carbon members        which is a carbonyl, each ring of attachment has 0 or 1        unsaturated bonds and each secondary ring has 0, 1 or 2        unsaturated bonds,    -   v)        8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,        where each member of i), ii), iii), iv) or v) is further        substituted with 0, 1 or 2 of R^(p).

Most preferably, R¹ and R² taken together with the nitrogen to whichthey are attached are selected from the group consisting of10-oxa-4-aza-tricyclo[5.2.1.0^(2.6)]dec-4-yl, 2-pyrrolin-1-yl,3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl,piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl,azepan-1-yl, tetrahydro-benzo[c]azepin-1-yl,tetrahydro-halobenzo[c]azepin-1-yl,2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,2,3-dihydro-halobenzo[f][1,4]oxazepin-4-yl, thiazolidin-3-yl,oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl,8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl,3,4-dihydro-2H-quinolin-2-yl, where each member is further substitutedwith 0, 1 or 2 of R^(p).

Specific R¹ and R² taken together with the nitrogen to which they areattached are selected from the group consisting of1-methyl-10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl, azetidin-1-yl,pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl,2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl,2-methylpiperidin-1-yl, 4-hydroxypiperidin-1-yl,4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl,tetrahydro-benzo[c]azepin-1-yl, 7-fluoro-tetrahydro-benzo[c]azepin-1-yl,2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,8-fluoro-2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,6,8-difluoro-2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl,2-methylmorpholin-4-yl, 2,6-dimethylmorpholin-4-yl,octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl,2,5-dimethyl-2,5-dihydro-pyrrol-1-yl,8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yland 3,4-dihydro-2H-quinolin-2-yl.

Preferably, R^(p) is selected from the group consisting of hydroxy,methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, phenyl,p-halophenyl, m-halophenyl, o-halophenyl, phenyl and p-hydroxyphenyl.

Most preferably, R^(p) is selected from the group consisting of hydroxy,methyl, ethyl, hydroxymethyl, hydroxyethyl, phenyl,mono-fluorosubstituted phenyl and mono-chlorosubstituted phenyl.

Preferably, R^(a) is selected from the group consisting of methyl,ethyl, propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl,furanyl, thienyl, pyrrol-1-yl, benzyl, methoxy, ethoxy, propoxy,cyclopropoxy, cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, —SH,-Smethyl, -Sethyl, —S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, nitro,cyano, amino, dimethylamino, (cyclohexylmethyl)amino, acetyl, —SCF₃, I,F, Cl, Br, trifluoromethyl, —OCF₃ and carboxymethyl.

Preferably, there is one R^(a). More preferably, there is one R^(a)positioned on the ring para to the amide substituent.

Preferably, where two adjacent R^(a) are taken together with the carbonsof attachment to form a fused ring, the fused ring is phenyl.

Most preferably, R^(a) is selected from the group consisting of nitro,cyano, F, Cl, Br, fused phenyl, I, CF₃, methoxy, ethoxy, propoxy,i-propoxy, ethenyl, cyclopentoxy, 2-propenyl, phenyl, furanyl, thienyl,amino, pyrrol-1-yl, dimethylamino, (cyclohexylmethyl)amino, —SCH₃,-Sethyl, —S-t-butyl, -Sbenzyl, —SCF₃, i-propyl and methyl.

Preferably, R^(b) is absent or selected from the group consisting ofmethyl, ethyl, I, F, Cl and Br.

Most preferably, R^(b) is absent.

Pharmaceutically acceptable salts include amino addition salts that arepharmacologically effective. Representative salts include hydrobromide,hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate,oleate, palmitate, stearate, laurate, borate, benzoate, lactate,phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate,naphthylate, mesylate, glucoheptonate, lactiobionate, andlaurylsulfonate. See example, S. M. Berge, et al., “PharmaceuticalSalts,” J. Pharm. Sci., 1977, 66:1-19, which is incorporated herein byreference.

Preferred compounds of the present invention are selected from the groupconsisting of: EX CHEMICAL NAME 1(R)-4-Bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 2(R)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 3(R)-4-Chloro-N-[1-(2,4-difluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 5(R)-4,5-Dichloro-N-[1-(2,4-difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 7(R)-4-Chloro-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 8(R)-4-Bromo-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 9(S)-4-Chloro-N-[1-(2,4-dichlorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 15(R)-N-[1-(2,4-Difluorophenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 164-Bromo-N-(2-chloro-4-fluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 174-Bromo-N-(2,4-difluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 29(S)-4-Chloro-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 30(S)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 33(R)-4-Bromo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 34(R)-4-Iodo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 35N-(4-Fluorobenzyl)-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 36(R)-N-[1-(2,4-Difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethylbenzamide; 37(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-4-fluoro-2-(quinoxaline-5-sulfonylamino)-benzamide; 38(R)-4-Cyano-N-[1-(2,4-difluoro-phenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 41N-Benzyl-4-bromo-N-methyl-2-(quinoxaline-5-sulfonylamino)- benzamide; 42N-Benzyl-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)- benzamide; 43(R)-4-Chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 444-Chloro-N-(4-fluoro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 454-Bromo-N-(4-fluoro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 464-Chloro-N-(4-chloro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 474-Bromo-N-(4-chloro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 48N-(4-Chloro-benzyl)-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide; 494-Chloro-N-[1-(4-chloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 504-Bromo-N-[1-(4-chloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 51N-[1-(4-Chloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 524-Chloro-N-[1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 534-Bromo-N-[1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 54N-[1-(4-Fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 554-Chloro-N-(2,4-difluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 56N-(2,4-Difluoro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 57N-(2,4-Difluoro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 58 4-Chloro-N-(2,4-dichloro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 594-Bromo-N-(2,4-dichloro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 60N-(2,4-Dichloro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 61 4-Chloro-N-(2-chloro-4-fluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 62(R)-4-Chloro-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide; 63(R)-N-[1-(4-Fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 64(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 65(S)-4-Bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 66(S)-N-[-(2,4-Dichloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 67(S)-N-[1-(2,4-Difluoro-phenyl)-2,2,2-trifluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 68(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzamide; 69(R)-4-Cyano-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 70(R)-N-[1-(2,4-Difluoro-phenyl)-ethyl]-4-fluoro-2-(quinoxaline-5-sulfonylamino)-benzamide; 71(S)-4-Bromo-N-[2-fluoro-1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 72(S)-4-Chloro-N-[2-fluoro-1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 73(S)-N-[2-Fluoro-1-(4-fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 744-Bromo-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 75N-[1-(2,4-Difluoro-phenyl)-2-fluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 76(S)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; 77(S)-N-[1-(2,4-Difluoro-phenyl)-2-fluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide; 78(S)-4-Chloro-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide; and 96 Quinoxaline-5-sulfonicacid [6-bromo-2-(2,4-difluoro-benzyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-amide.

Additional preferred compounds of the present invention are selectedfrom the group consisting of: EX CHEMICAL NAME 4 Quinoxaline-5-sulfonicacid [5-iodo-2-(piperidine-1-carbonyl)- phenyl]-amide; 6Quinoxaline-5-sulfonic acid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide; 10 Quinoxaline-5-sulfonic acid [5-bromo-2-(1,3,4,5-tetrahydrobenzo[c]azepine-2-carbonyl)phenyl]-amide; 11(R)-Quinoxaline-5-sulfonic acid [5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide; 12 (R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3- methylmorpholine-4-carbonyl)-phenyl]-amide; 13(R)-Quinoxaline-5-sulfonic acid [5-chloro-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide; 14(R)-Quinoxaline-5-sulfonic acid [5-chloro-2-(morpholine-4-carbonyl)phenyl]-amide; 18 Quinoxaline-5-sulfonic acid[2-(azepane-1-carbonyl)-5- iodophenyl]-amide; 19(R)-Quinoxaline-5-sulfonic acid [5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide; 20 Quinoxaline-5-sulfonic acid[4,5-dichloro-2-(morpholine-4- carbonyl)-phenyl]-amide; 21Quinoxaline-5-sulfonic acid [2-(azepane-1-carbonyl)-5-bromophenyl]-amide; 22 Quinoxaline-5-sulfonic acid[5-chloro-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide; 23(S)-Quinoxaline-5-sulfonic acid [5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide; 24 Quinoxaline-5-sulfonic acid[5-bromo-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide; 25(R,S)-Quinoxaline-5-sulfonic acid [2-(3,5-dimethylmorpholine-4-carbonyl)-5-iodophenyl]-amide; 26 Quinoxaline-5-sulfonic acid[2-(4-hydroxy-piperidine-1- carbonyl)-5-iodo-phenyl]-amide; 27meso-Quinoxaline-5-sulfonic acid [2-(3,5-dimethylmorpholine-4-carbonyl)-5-bromophenyl]-amide; 28 (S)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3- methylmorpholine-4-carbonyl)-phenyl]-amide; 31Quinoxaline-5-sulfonic acid [2-(4-hydroxy-piperidine-1-carbonyl)-5-bromo-phenyl]-amide; 32 Quinoxaline-5-sulfonic acid[5-bromo-2-(piperidine-1-carbonyl)- phenyl]-amide; 39Quinoxaline-5-sulfonic acid [5-bromo-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)phenyl]-amide; 40Quinoxaline-5-sulfonic acid [5-chloro-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide; 79Quinoxaline-5-sulfonic acid [5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide; 80 Quinoxaline-5-sulfonic acid[5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide; 81 Quinoxaline-5-sulfonicacid [5-iodo-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide; 82 Quinoxaline-5-sulfonicacid [5-bromo-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide; 83Quinoxaline-5-sulfonic acid [2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide; 84(S)-Quinoxaline-5-sulfonic acid [5-chloro-2-(3-methyl-morpholine-4-carbonyl)-phenyl]-amide; 85 meso-Quinoxaline-5-sulfonicacid [5-chloro-2-(3,5-dimethyl- morpholine-4-carbonyl)-phenyl]-amide; 86Quinoxaline-5-sulfonic acid [5-chloro-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide; 87Quinoxaline-5-sulfonic acid [2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-5-iodo-phenyl]-amide; 88Quinoxaline-5-sulfonic acid [2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide; 89 Quinoxaline-5-sulfonic acid[5-chloro-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide; 90Quinoxaline-5-sulfonic acid [2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide; 91Quinoxaline-5-sulfonic acid [2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide; 92 Quinoxaline-5-sulfonic acid[2-(morpholine-4-carbonyl)-5- trifluoromethyl-phenyl]-amide; 93Quinoxaline-5-sulfonic acid [5-bromo-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide; 94Quinoxaline-5-sulfonic acid [2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide; and 95Quinoxaline-5-sulfonic acid [2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-trifluoromethyl-phenyl]- amide.

The features and advantages of the invention are apparent to one ofordinary skill in the art. Based on this disclosure, including thesummary, detailed description, background, examples, and claims, one ofordinary skill in the art will be able to make modifications andadaptations to various conditions and usages. Publications describedherein are incorporated by reference in their entirety.

The amidophenyl-sulfonylamino-quinoxalines of formula (I) may beproduced by a number of reaction schemes. In Scheme A, sulfonylation isthe final step of the process and in Scheme B, sulfonylation is theinitial step of the process. Persons skilled in the art will recognizethat certain compounds are more advantageously produced by one scheme ascompared to the other.

Referring to Scheme A, commercially available aminonaphthoic acid A1 isreacted with triphosgene and Hünig's base to produce the benzofusedisatoic anhydride species of the genus A2. Various isatoic anhydrides A2are available commercially. An amine is acylated with the isatoicanhydride A2 to produce a benzamide A5. Benzamide A5 may also beobtained from commercially available anthranilic acid A3 through peptidecoupling.

Benzamide A5 may additionally be obtained from commercially availablenitrobenzoic acid A4 through peptide coupling followed by reduction ofthe nitro group. In one synthetic pathway, benzamide A5 is sulfonylatedwith quinoxaline sulfonyl chloride D1 to produce quinoxaline sulfonamidecompounds (I). In a second synthetic pathway, benzamide A5 is firstsulfonylated with the sulfonyl chloride to produce benzothiadiazolecompounds A6. This first step is followed by reduction of thebenzothiadiazole to extrude sulfur resulting in phenylene diamine A7,which is condensed with glyoxal to produce quinoxaline sulfonamidecompounds (I). Where R^(a) or R^(b) is a primary or secondary amine orhydroxy, they can be protected with common protecting groups. In thecase of the primary or secondary amine, there can be employed Boc orCbz. In the case of hydroxy, there can be employed TBS, TES or benzyl.Of course, a precursor substituent may be employed in the reaction stepsand later transformed into the desired substituent. For example, whereA6 is produced with R^(a) as nitro, the nitro may be reduced to theamine, and the amine may be, for example, alkylated, acylated,diazotized, etc.

Referring to Scheme B, aniline B1 is sulfonylated to sulfonamide B2. Inthe case that R″ is ester or cyano, the ester or cyano is hydrolyzed tothe carboxylic acid B3. In a first route, acid B3 undergoes peptidecoupling under standard conditions with an amine to producebenzothiadiazole compounds A6. This coupling is followed by reduction ofthe benzothiadiazole to extrude sulfur resulting in phenylene diamineA7, which is condensed with a two carbon synthon to produce quinoxalinesulfonamide compounds (I). In a second route, acid B3 is reduced toextrude sulfur resulting in phenylene diamine B4, which is condensedwith a two-carbon synthon to produce quinoxaline sulfonamide C3.Sulfonamide C3 undergoes peptide couple coupling under standardconditions to produce quinoxaline sulfonamide compounds (I). Where R^(a)or R^(b) is a primary or secondary amine or hydroxy, it can be protectedwith common protecting groups. In the case of the primary or secondaryamine, there can be employed Boc or Cbz. In the case of hydroxy, therecan be employed TBS, TES or benzyl. Of course, a precursor substituentmay be employed in the reaction steps and later transformed into thedesired substituent. For example, where B4 is produced with R^(a) asnitro, the nitro may be reduced to the amine and the amine may be, forexample, alkylated, acylated, diazotized, etc. R′ may be selected fromsuitable protecting groups, including alkyl protecting groups, benzylprotecting group and silyl protecting groups.

Referring to Scheme C, aniline C1 is sulfonylated to quinoxaline C2. Inthe case that R″ is an ester or cyano, the ester or cyano is hydrolyzedto the acid C3. Acid C3 undergoes peptide coupling under standardconditions with an amine to produce quinoxaline sulfonamide compounds(I). Where R^(a) or R^(b) is a primary or secondary amine or hydroxy, itcan be protected with common protecting groups. In the case of theprimary or secondary amine, there can be employed Boc or Cbz. In thecase of hydroxy, there can be employed TBS, TES or benzyl. Of course, aprecursor substituent may be employed in the reaction steps and latertransformed into the desired substituent. For example, where B4 isproduced with R^(a) as nitro, the nitro may be reduced to the amine andthe amine may be, for example, alkylated, acylated, diazotized, etc. R′may be selected from suitable protecting groups, including alkylprotecting groups, benzyl protecting group and silyl protecting groups.

Referring to Scheme D, phenylene diamine is condensed with glyoxal toproduce hydroxy quinoxaline. This is followed by acylation withthionocarbamoyl chloride producing a thionocarbamate. Thethionocarbamate is isomerized by heating to a thiocarbamate, where goodyields are obtained with heating to 240 C for about 45 minutes. Finally,the thiocarbamate is saponified to the corresponding thiol andimmediately thereafter oxidized to the sulfonylchloride.

The compounds of the present invention are CCK2 modulators and, asdisclosed herein, many are demonstrated CCK2 antagonists. As such, thecompounds are useful in the treatment of CCK2 mediated disease states.Particularly, the compounds may be used in the treatment or preventionof pancreatic adenocarcinoma, pain, eating disorders, gastro-esophagealreflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety,colon cancer, peptic ulcers, pancreatic tumors, gastric tumors,Barrett's esophagus, antral G cell hyperplasia, pernicious anaemia andZollinger-Ellison syndrome. Particularly, CCK2 antagonists are now indevelopment for the treatment or prevention of pancreaticadenocarcinoma, pain, gastro-esophageal reflux disease, gastroduodenalulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers,pancreatic tumors and gastric tumors.

It is anticipated that the compounds of the invention can beadministered by oral or parenteral routes, including intravenous,intramuscular, intraperitoneal, subcutaneous, rectal and topicaladministration, and inhalation. For oral administration, the compoundsof the invention will generally be provided in the form of tablets orcapsules or as an aqueous solution or suspension. Tablets for oral usemay include the active ingredient mixed with pharmaceutically acceptableexcipients such as inert diluents, disintegrating agents, bindingagents, lubricating agents, sweetening agents, flavoring agents,coloring agents and preservatives. Suitable inert diluents includesodium and calcium carbonate, sodium and calcium phosphate and lactose.Cornstarch and alginic acid are suitable disintegrating agents. Bindingagents may include starch and gelatin. The lubricating agent, ifpresent, will generally be magnesium stearate, stearic acid or talc. Ifdesired, the tablets may be coated with a material such as glycerylmonostearate or glyceryl distearate, to delay absorption in thegastrointestinal tract. Capsules for oral use include hard gelatincapsules in which the active ingredient is mixed with a solid diluentand soft gelatin capsules wherein the active ingredient is mixed withwater or an oil such as peanut oil, liquid paraffin or olive oil. Forintramuscular, intraperitoneal, subcutaneous and intravenous use, thecompounds of the invention will generally be provided in sterile aqueoussolutions or suspensions, buffered to an appropriate pH and isotonicity.Suitable aqueous vehicles include Ringer's solution and isotonic sodiumchloride. Aqueous suspensions according to the invention may includesuspending agents such as cellulose derivatives, sodium alginate,polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such aslecithin. Suitable preservatives for aqueous suspensions include ethyland n-propyl p-hydroxybenzoate.

Effective doses of the compounds of the present invention may beascertained by conventional methods. The specific dosage level requiredfor any particular patient will depend on a number of factors, includingseverity of the condition being treated, the route of administration andthe weight of the patient. In general, however, it is anticipated thatthe daily dose (whether administered as a single dose or as divideddoses) will be in the range 0.01 to 1000 mg per day, more usually from 1to 500 mg per day, and most usually from 10 to 200 mg per day. Expressedas dosage per unit body weight, a typical dose will be expected to bebetween 0.0001 mg/kg and 15 mg/kg, especially between 0.01 mg/kg and 7mg/kg, and most especially between 0.15 mg/kg and 2.5 mg/kg.

EXAMPLES

In order to illustrate the invention, the following examples areincluded. These examples do not limit the invention. They are only meantto suggest a method of practicing the invention. Those skilled in theart may find other methods of practicing the invention, which areobvious to them. However, those methods are deemed to be within thescope of this invention.

Protocol for Preparative Reversed-Phase HPLC

-   Gilson® instrument-   Column: YMC-Pack ODS-A, 5 μm, 75×30 mm-   Flow rate: 10 mL/min-   Detection: λ=220 & 254 nm-   Gradient (acetonitrile/water, 0.05% trifluoroacetic acid)-   1) 0.0 min 20% acetonitrile/80% water-   2) 20.0 min 99% acetonitrile/1% water

Protocol for HPLC (Reversed-Phase)

-   Hewlett Packard Series 1100-   Column: Agilent ZORBAX® C8, 5 μm, 4.6×150 mm-   Flow rate: 1 mL/min-   Detection: λ=220 & 254 nm-   Gradient (acetonitrile/water, 0.05% trifluoroacetic acid)-   1) 0.0 min 1% acetonitrile/99% water-   2) 8.0 min 99% acetonitrile/1% water

Mass spectra were obtained on an Agilent series 1100 MSD usingelectrospray ionization (ESI) in either positive or negative modes asindicated.

NMR spectra were obtained on either a Bruker model DPX400 (400 MHz) orDPX500 (500 MHz) spectrometer. The format of the ¹H NMR data below is:chemical shift in ppm down field of the tetramethylsilane reference(multiplicity, coupling constant J in Hz, integration).

EXAMPLE 1

(R)-4-Bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. Diethylthiocarbamic acid O-quinoxalin-5-yl ester. A mixture of5-hydroxyquinoxaline (2.13 g, 14.6 mmol), finely ground K₂CO₃ (4.0 g, 29mmol), and DMF (50 mL) was stirred at 23° C. for 1 h. Soliddiethylthiocarbamoyl chloride (2.43 g, 16.1 mmol) was then added in asingle portion. The resulting mixture was stirred for 2 h, then wasdiluted with H₂O (150 mL) and extracted with diethyl ether (2×100 mL).The combined ethereal extracts were washed with H₂O (100 mL) and brine(100 mL), then dried and concentrated to a viscous orange oil, which wasused without purification in the subsequent step (3.63 g, 95%). MS(ESI): Calculated for C₁₃H₁₅N₃OS, 261.1; found, m/z 262 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃): 8.85-8.65 (m, 2H), 7.96 (dd, J=8.5, 1.1 Hz, 1H), 7.71(t, J=7.9 Hz, 1H), 7.46 (dd, J=7.6, 1.18 Hz, 1H), 3.87 (q, J=7.1 Hz,2H), 3.78 (q, J=7.1 Hz, 2H), 1.38 (t, J=7.1 Hz, 3H), 1.28 (t, J=7.1 Hz,3H). ¹³C NMR (125 MHz, CDCl₃): 186.6, 149.4, 144.9, 144.5, 143.4, 137.0,128.9, 127.0, 123.1, 48.2, 44.5, 13.1, 11.5.B. Diethylthiocarbamic acid S-guinoxalin-5-yl ester. Neatdiethylthiocarbamic acid O-quinoxalin-5-yl ester (0.52 g, 2.0 mmol) washeated to 240° C. for 1 h. The resulting brown oil was chromatographed(20 to 50% EtOAc/hexanes), providing a pale yellow oil (0.49 g, 94%). MS(ESI): Calculated for C₁₃H₁₅N₃OS, 261.1; found, m/z 262 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃): 8.93 (d, J=1.8 Hz, 1H), 8.87 (d, J=1.8 Hz, 1H), 8.18(dd, J=8.4, 1.2 Hz, 1H), 8.13 (dd, J=7.3, 1.2 Hz, 1H), 7.81 (dd, J=7.3,1.0 Hz, 1H), 3.61 (br s, 2H), 3.43 (br s, 2H), 1.38 (br s, 3H), 1.16 (brs, 3H).C. Quinoxaline-5-sulfonyl chloride. A solution of diethylthiocarbamicacid S-quinoxalin-5-yl ester (3.20 g, 12.3 mmol), KOH (6.89 g, 123 mmol)and methanol (100 mL) was heated at reflux for 16 h. The solution wasallowed to cool to 23° C., and then AcOH (7 mL) was added. The mixturewas diluted with H₂O (100 mL) and extracted with EtOAc (2×100 mL). Thecombined extracts were washed with H₂O (100 mL) and brine (100 mL), thendried and concentrated to a tan solid (1.90 g). A portion of this thiol(0.22 g, 1.4 mmol) was combined with DCM (50 mL), formic acid (25 mL),and H₂O (25 mL), and the resulting biphasic mixture was cooled to 0° C.Chlorine gas was bubbled through this mixture with rapid stirring for 5min. The mixture was transferred to a separatory funnel, and the organicphase was collected. The aqueous phase was extracted with DCM (50 mL),and the combined organic phases were washed with 1 M NaOH (50 mL) andbrine (50 mL), then dried. The solution was concentrated to afford thetitled compound as a light yellow crystalline solid (0.28 g, 86%). ¹HNMR (500 MHz, CDCl₃): 9.17 (d, J=1.8 Hz, 1H), 9.07 (d, J=1.8 Hz, 1H),8.60 (dd, J=7.5, 1.4 Hz, 1H), 8.53 (dd, J=8.4, 1.4 Hz, 1H), 7.96 (dd,J=8.6, 0.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): 146.9, 146.8, 143.7,140.4, 139.0, 138.4, 132.4, 128.8.D. 4-Bromo-2-nitrobenzoic acid. A mixture of 4-bromo-2-nitrotoluene (5.0g, 23 mmol), KMnO₄ (1 g, 70 mmol), and H₂O (250 mL) was heated at refluxovernight in a 1 L round-bottom flask fitted with a reflux condenser.The brown suspended MnO₂ was removed by filtration through a pad ofdiatomaceous earth. The filter cake was washed with H₂O. The basicfiltrate was acidified to pH ˜1 with concentrated HCl and extracted withEtOAc (3×300 mL). The combined organic layers were dried (MgSO₄) andconcentrated in vacuo to provide the pure benzoic acid (1.22 g, 22%). MS(ESI) calculated for C₇H₄BrNO₄, 244.9; found, m/z 244 [M−H]⁻. ¹H NMR(400 MHz, CD₃OD): 8.07 (d, J=1.9 Hz, 1H), 7.85 (dd, J=8.2, 1.9 Hz, 1H),7.65 (d, J=8.2 Hz, 1H).E. Methyl 2-amino-4-bromobenzoate. To a stirred solution of4-bromo-2-nitrobenzoic acid (3.8 g, 15 mmol) in DMF (30 mL) at 0° C. wasadded 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (10.0 mL, 75.0 mmol)followed by iodomethane (4.7 mL, 75 mmol). The reaction mixture wasstirred 15 min at 0° C., then was allowed to warm to room temperatureand was stirred overnight. The mixture was poured into H₂O and extractedwith EtOAc (2×). The combined organic extracts were washed with H₂O(2×), dried (MgSO₄), and concentrated in vacuo. The residue was purifiedby flash chromatography (hexanes/EtOAc) to afford methyl4-bromo-2-nitrobenzoate as a pale yellow solid (3.52 g, 0.90%). To asolution of the nitrobenzoate (3.52 g, 13.5 mmol) in 1:1 EtOAc/DCM (30mL) at room temperature was added SnCl₂.2H₂O (15 g, 67 mmol). Thereaction mixture was allowed to stir overnight. The solvents wereevaporated in vacuo, and the residue was partitioned between satd. aq.NaHCO₃ and DCM. The layers were separated, and the aqueous layer wasfurther extracted with DCM (2×). The combined organic layers were dried(MgSO₄) and concentrated in vacuo to provide the pure aminobenzoate as awhite solid (2.89 g, 93%). ¹H NMR (400 MHz, CDCl₃): 7.70 (d, J=8.6 Hz,1H), 6.84 (d, J=1.9 Hz, 1H), 6.75 (dd, J=8.6, 1.9 Hz, 1H), 5.78 (br s,2H), 3.86 (s, 3H).F. 4-Bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester. Asolution of quinoxaline-5-sulfonyl chloride (0.50 g, 2.2 mmol), methyl2-amino-4-bromobenzoate (0.50 g, 2.2 mmol), pyridine (0.87 mL, 11 mmol),and DCM (15 mL) was maintained at 23° C. for 16 h. The reaction mixturewas diluted with EtOAc (50 mL) and washed with satd. aq. NaHCO₃ (50 mL),then dried and concentrated. The residue was purified by flashchromatography (5 to 40% EtOAc/hexanes) to afford the sulfonamide as awhite solid (0.78 g, 84%). MS (ESI) calculated for C₁₆H₁₂BrN₃O₄S, 421.0;found, m/z 422 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃): 11.39 (s, 1H), 8.96 (d,J=1.7 Hz, 1H), 8.94 (d, J=1.7 Hz, 1H), 8.61 (dd, J=7.4, 1.4 Hz, 1H),8.33 (dd J=8.5, 1.4 Hz, 1H), 8.02 (d, J=1.9 Hz, 1H), 7.89 (dd, J=8.4,1.0 Hz, 1H), 7.69 (d, J=8.5, 1H), 7.06 (dd, J=8.5, 1.9 Hz, 1H), 3.90 (s,3H).G. 4-Bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid. A solution ofLiOH.H₂O (0.36 g, 8.6 mmol) in H₂O (5 mL) was added to a solution of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester (0.73g, 1.7 mmol) and THF (10 mL), and the biphasic mixture was rapidlystirred for 16 h. The mixture was concentrated to a volume of 5 mL, andthen was adjusted to pH 5 with 1 M HCl. The resulting precipitate wascollected by filtration, providing the acid as a white solid (0.68 g,96%). MS (ESI) calculated for C₁₅H₁₀BrN₃O₄S, 407.0; found, m/z 408[M+H]⁺. ¹H NMR (500 MHz, CDCl₃): 14.1 (br s, 1H), 9.11 (d, J=1.4 Hz,1H), 8.99 (d, J=1.4 Hz, 1H), 8.63 (d, J=7.4 Hz, 1H), 8.42 (d, J=8.4 Hz,1H), 8.06 (t, J=8.3 Hz, 1H), 7.77 (d, J=1.6 Hz, 1H), 7.71 (d, J=8.5 Hz,1H), 7.20 (dd, J=8.5, 1,6 Hz, 1H).H. S-(S)-2-Methyl-propane-2-sulfinic acid 2,4-dichloro-benzylideneamide.A suspension of 2,4-dichlorobenzaldehyde (0.75 g, 4.3 mmol),(S)-tert-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrousCuSO₄ (1.2 g, 7.8 mmol) in DCM (8 mL) was stirred overnight. Thereaction mixture was filtered, and the filter cake was washed with DCM.The filtrate was concentrated in vacuo to give the crude N-sulfinylimine as white solid. Purification by flash chromatography(EtOAc/hexanes) provided 0.97 g (90%) of the N-sulfinyl imine as a whitesolid. ¹H NMR (400 MHz, CDCl₃): 8.98 (s, 1H), 8.01 (d, J=8.5 Hz, 1H),7.48 (d, J=2.1 Hz, 1H), 7.35-7.32 (m, 1H), 1.27 (s, 9H).I. S-(S)-2-Methyl-propane-2-sulfinic acid1-(R)-[1-(2,4-dichloro-Phenyl)-ethyl]-amide. To a stirred solution ofthe above N-sulfinyl imine (0.97 g, 3.5 mmol) in DCM (20 mL) at −50° C.was added a solution of methyl magnesium bromide (3.0 M in diethylether, 2.3 mL, 6.9 mmol). The reaction mixture was stirred at −50° C.for 1 h then allowed to warm slowly to room temperature overnight. Thereaction was quenched by the addition of satd. aq. NH₄Cl, and themixture was poured into H₂O and extracted with DCM (3×). The combinedorganic layers were dried (Na₂SO₄) and concentrated in vacuo.Purification by flash chromatography (EtOAc/hexanes) provided the titlecompound as a colorless solid (1.02 g, 99%, 76% de). Major diastereomer:¹H NMR (400 MHz, CDCl₃): 7.43-7.35 (m, 2H), 7.26-7.23 (m, 1H), 5.01 (dq,J=6.7, 4.0 Hz, 1H), 3.39 (d, J=3.7 Hz, 1H), 1.53 (d, J=6.7 Hz, 3H), 1.21(s, 9H).J. (R)-1-(2,4-Dichlorophenyl)-ethylamine hydrochloride. To a stirredsolution of the above sulfinamide (76% de, 1.02 g, 3.47 mmol) in 7:4methanol/DCM (11 mL) at room temperature was added 2 mL of a satd.solution of HCl (g) in methanol. After several minutes, precipitatedamine hydrochloride was visible. The reaction mixture was allowed tostir for 2 h at room temperature. The heterogeneous mixture wasconcentrated in vacuo until approximately 2 mL remained, and then theamine hydrochloride was fully precipitated by the addition of diethylether (10 mL). The HCl salt was collected by suction filtration, washedwith diethyl ether, and dried in vacuo to give fine white crystals (722mg, 92%, 76% ee). ¹H NMR (400 MHz, CD₃OD): 7.62 (d, J=2.2 Hz, 1H), 7.57(d, J=8.4 Hz, 1H), 7.50 (dd, J=8.4, 2.2 Hz, 1H), 1.62 (d, J=6.8 Hz, 3H).K.(R)-4-Bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.To a solution of 4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid(0.021 g, 0.051 mmol) in a mixture of THF (0.08 mL) and DMF (0.40 mL) atroom temperature was added pyridine (0.012 mL, 0.15 mmol) followed byO-(7-azabenzotriazol-1-yl)-N,N, N′,N′-tetramethyluroniumhexafluorophosphate (HATU) (0.038 g, 0.12 mmol). The reaction mixturewas agitated for 1 h on a shaker. (R)-1-(2,4-Dichlorophenyl)-ethylaminehydrochloride (0.038 g, 0.10 mmol) and N,N-diisopropylethylamine(Hünig's base) (0.017 mL, 0.10 mmol) were added. The reaction mixturewas agitated for 1 h. TFA (0.050 mL) was added to quench the reaction.The mixture was diluted with DMF (1 mL), and the product amide wasobtained by purification of the resulting mixture by preparativereverse-phase chromatography. The title amide was obtained as a solid(24 mg, 83%). MS (ESI): mass calculated for C₂₃H₁₇BrCl₂N₄O₃S, 577.96;m/z found, 577/579/581 [M−H]⁻. HPLC (reverse phase): R_(T)=10.34 min. ¹HNMR (500 MHz, CDCl₃): 11.32 (s, 1H), 8.85. (d, J=1.8 Hz, 1H), 8.76 (d,J=1.8 Hz, 1H), 8.55 (dd, J=7.4, 1.4 Hz, 1H), 8.31 (dd, J=7.4, 1.4 Hz,1H), 7.94 (d, J=1.8 Hz, 1H), 7.87 (dd, J=8.4, 7.4 Hz, 1H), 7.44 (d,J=1.7 Hz, 1H), 7.35-7.15 (m, 3H), 7.09 (dd, J=8.4, 1.8 Hz, 1H), 6.36 (brd, J=6.5 Hz, 1H), 5.49-5.30 (m, 1H), 1.52 (d, J=7.0 Hz, 3H).

EXAMPLE 2

(R)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.Method 1.A. S—(S)-2-Methylpropane-2-sulfinic acid 2,4-difluorobenzylideneamide. Asuspension of 2,4-difluorobenzaldehyde (0.61 g, 4.3 mmol),(S)-tert-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrousCuSO₄ (1.24 g, 7.8 mmol) was stirred in DCM (8 mL) overnight. Thereaction mixture was filtered, and the filter cake was washed with DCM.The filtrate was concentrated in vacuo to give the crude N-sulfinylimine as a viscous yellow oil. Purification by flash chromatography(EtOAc/hexanes) provided 0.81 g (84%) of the N-sulfinyl imine as a paleyellow viscous oil. ¹H NMR (400 MHz, CDCl₃): 8.83 (s, 1H), 8.05-7.99 (m,1H), 7.01-6.96 (m, 1H), 6.94-6.87 (m, 1H), 1.27 (s, 9H).B. S-(S)-2-Methylpropane-2-sulfinic acid1-(R)-[1-(2,4-difluorophenyl)-ethyl]-amide. To a stirred solution ofS-(S)-2-methylpropane-2-sulfinic acid 2,4-difluorobenzylideneamide (0.77g, 3.1 mmol) in DCM (20 mL) at −50° C., was added a solution of methylmagnesium bromide (3.0 M in diethyl ether, 2.1 mL, 6.3 mmol). Thereaction mixture was stirred at −50° C. for 1 h then allowed to warmslowly to room temperature overnight. The reaction was quenched by theaddition of satd. aq. NH₄Cl, and the mixture was poured into H₂O, andextracted with DCM (3×). The combined organic layers were dried (Na₂SO₄)and concentrated in vacuo. Purification by flash chromatography(EtOAc/hexanes) provided the title compound as a colorless, viscous oil(0.80 g, 99%, 90% de). Major diastereomer: ¹H NMR (400 MHz, CDCl₃):7.37-7.28 (m, 1H), 6.88-6.83 (m, 1H), 6.82-6.76 (m, 1H), 4.82 (dq,J=6.8, 4.5 Hz, 1H), 3.32 (d, J=4.1 Hz, 1H), 1.56 (d, J=6.8 Hz, 3H), 1.19(s, 9H).C. (R)-1-(2,4-Difluorophenyl)ethylamine hydrochloride. To a stirredsolution of S-(S)-2-methylpropane-2-sulfinic acid1-(R)-[1-(2,4-difluorophenyl)-ethyl]-amide (0.80 g, 3.1 mmol, 90% de) inmethanol (7 mL) at room temperature, was added 2 mL of a satd. solutionof HCl (g) in methanol. After several minutes, precipitated aminehydrochloride was visible. The reaction mixture was allowed to stir for2 h at room temperature. The heterogeneous mixture was concentrated invacuo until approximately 2 mL remained, and then the aminehydrochloride was fully precipitated by the addition of diethyl ether(10 mL). The HCl salt was collected by suction filtration, washed withdiethyl ether, and dried in vacuo to provide fine white crystals (570mg, 95%, 99% ee). Enantiomeric purity was determined by HPLC analysis onthe benzamide derivative of the amine. Chiralcel AS column, 90:10hexanes/isopropyl alcohol, 0.7 mL/min. R enantiomer, R_(T)=18.1 min. Senantiomer, R_(T)=21.0 min. [α]_(D) ²⁰=−3.7° (c 4.37, H₂O). ¹H NMR (400MHz, CD₃OD): 7.60-7.53 (m, 1H), 7.14-7.06 (m, 2H), 4.72 (q, J=7.0 Hz,1H), 1.65 (d, J=6.8 Hz, 3H).D.(R)-4-Bromo-N-[1-(2,4-difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.4-Bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G;21 mg, 0.052 mmol) was coupled with(R)-1-(2,4-difluoro-phenyl)ethylamine hydrochloride (27 mg, 0.14 mmol)according to the general procedure described in EXAMPLE 1, Step K toprovide the desired amide (24 mg, 89%). mp=200-200.5° C.; MS (ESI): masscalculated for C₂₃H₁₇BrF₂N₄O₃S, 546.0; m/z found, 547/549 [M+H]⁺. HPLC(reverse phase): R_(T)=9.76 min. Anal. calcd. for C₂₃H₁₇BrF₂N₄O₃S: C,50.47; H, 3.13; N, 10.24, S 5.86; found: C 50.10, H 3.18, N 10.06, S5.88. ¹H NMR (500 MHz, CDCl₃): 11.33 (s, 1H), 8.83 (d, J=1.8 Hz, 1H),8.78 (d, J=1.8 Hz, 1H), 8.55 (dd, J=7.4, 1.4 Hz, 1H), 8.30 (dd, J=7.4,1.4 Hz, 1H), 7.92 (d, J=1.8 Hz, 1H), 7.86 (dd, J=8.4, 7.4 Hz, 1H), 7.30(dd, J=8.5, 2.2 Hz, 1H), 7.16 (d, J=8.4, 1H), 7.08 (dd, J=8.4, 1.8 Hz,1H), 6.92-6.80 (m, 2H), 6.33 (br d, J=6.5 Hz, 1H), 5.31 (quint, J=7.5Hz, 1H), 1.53 (d, J=7.0 Hz, 3H).Alternatively, the title compound can be prepared via the followingprocedure:Method 2.A. (R)-4-Bromo-N-[1-(2,4-difluorophenyl)ethyl]-2-nitrobenzamide. Asuspension of 4-bromo-2-nitrobenzoic acid (EXAMPLE 1, Step G; 8.0 g, 32mmol) in thionyl chloride (25 mL) was heated at reflux for 30 min. Thereaction became homogeneous. The mixture was cooled to room temperatureand concentrated in vacuo to provide the acid chloride as a yellowliquid. The liquid was re-concentrated from DCM (3×) to ensure completeremoval of thionyl chloride. ¹H NMR (400 MHz, CDCl₃): 8.20 (d, J=1.9 Hz,1H), 7.92 (dd, J 8.3, 1.9 Hz, 1H), 7.65 (d, J=8.3 Hz, 1H). To a solutionof the acid chloride (32.5 mmol) in DCM (60 mL) at 0° C. was added(R)-1-(2,4-difluorophenyl)-ethylamine hydrochloride (6.61 g, 34.1 mmol)and Hünig's base (14 mL, 81 mmol). The mixture was allowed to warm toroom temperature and was stirred for 1 h. The reaction mixture waswashed twice with 1 N HCl, and each aqueous wash was back-extracted withDCM. The combined organic layers were dried (Na₂SO₄) and concentrated invacuo to give the desired amide as a pale yellow solid (12.3 g, 98%).HPLC (reverse phase): R_(T)=9.190 min. ¹H NMR (500 MHz, CDCl₃): 8.20 (d,J=1.8 Hz, 1H), 7.79 (dd, J=8.1, 1.8 Hz, 1H), 7.35 (ddd, J=8.6, 8.6, 6.3Hz, 1H), 6.91-6.85 (m, 2H), 6.20 (br d, J=6.7 Hz, 1H), 5.38 (quint,J=7.5 Hz, 1H), 1.61 (d, J=7.0 Hz, 3H).B. (R)-2-Amino-4-bromo-N-[1-(2,4-difluorphenyl)ethyl]-benzamide. To astirred solution of(R)₄-bromo-N-[1-(2,4-difluorophenyl)-ethyl]-2-nitro-benzamide (12.3 g,32.0 mmol) in 1:1 DCM/EtOAc (400 mL) at room temperature was addedSnCl₂.2H₂O (29.0 g, 128 mmol). A mild exotherm was observed as the tinchloride slowly dissolved. The mixture was stirred for 14 h at roomtemperature. The reaction mixture was made basic by the addition ofsatd. NaHCO₃ (800 mL), causing precipitation of tin salts. Diatomaceousearth (30 g) was added and the slurry was mixed thoroughly. The mixturewas filtered through a pad of diatomaceous earth, washing with excessEtOAc. The biphasic filtrate was separated, and the aqueous layer wasextracted once with EtOAc. The combined organic layers were dried(Na₂SO₄) and concentrated to give the desired aminobenzamide as a paleyellow solid (11.1 g, 98%). TLC (silica, 66% EtOAc/hexanes): R_(f)=0.39.HPLC (reverse phase): R_(T)=9.461 min. ¹H NMR (500 MHz, CDCl₃): 7.30(ddd, J=8.6, 8.6, 6.4 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H), 6.90-6.78 (m,3H), 6.75 (dd, J=8.4, 1.8 Hz, 1H), 6.35 (br d, J=7.0 Hz, 1H), 5.60 (brs, 2H), 5.34 (quint, J=7.2 Hz, 1H), 1.57 (d, J=7.00 Hz, 3H).C.(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluoro-phenyl)ethyl]-benzamide.To a solution of(R)-2-amino-4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-benzamide (11.1 g,31.2 mmol) and benzo[1,2,5]thiadiazole-4-sulfonyl chloride (11 g, 44mmol) in DCM (100 mL) at 0° C. was added pyridine (12.6 mL, 156 mmol)slowly via syringe. The resulting orange mixture was allowed to stir for16 h at room temperature then was washed with 1 N HCl (2×100 mL). Eachaqueous wash was back-extracted with DCM. The combined organic layerswere dried (Na₂SO₄) and concentrated to give the crude sulfonamide. Thecrude tan solid was purified by trituration with diethyl ether (300 mL).The product was collected by suction filtration, washed with additionaldiethyl ether, and dried in vacuo to provide the pure sulfonamide as atan solid (15.3 g, 88%). MS (ESI): mass calculated for C₂₁H₁₅BrF₂N₄O₃S₂,552.0; m/z found, 553 [M+H]⁺. HPLC (reverse phase): R_(T)=10.17 min. ¹HNMR (500 MHz, CDCl₃): (rotameric broadening) 11.52 (s, 1H), 8.35 (dd,J=7.0, 1.0 Hz, 1H), 8.20 (dd, J=8.8, 1.0 Hz, 1H), 70 (d, J=1.8 Hz, 1H),7.70 (dd, J=8.8, 7.0 Hz, 1H), 7.31 (dt, J=8.4, 6.2 Hz, 1H), 7.16 (d,J=8.4 Hz, 1H), 7.10 (dd, J=8.4, 1.8 Hz, 1H), 6.92-6.80 (m, 2H), 6.37 (d,J=7.6 Hz, 1H), 5.33 (quint, J=7.5 Hz, 1H), 1.56 (d, J=7.0 Hz, 3H).D.(R)-4-Bromo-N-[1-(2,4-difluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.To a solution of(R)-2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[1-(2,4-difluorophenyl)ethyl]benzamide(15.3 g, 27.6 mmol) in ACOH (200 mL) at 50° C. was added zinc dust (18.0g, 275 mmol) in small portions. After addition was complete, thereaction was stirred at 50° C. for 2 h. The reaction mixture wasfiltered through a pad of diatomaceous earth with excess methanol. Thefiltrate was concentrated in vacuo to provide the reduced phenylenediamine as a yellow-orange heterogeneous mixture containing zinc saltsand AcOH. HPLC (reverse phase): R_(T) 9.15 min (single peak). Theunpurified mixture was combined with glyoxal bisulfite adduct (22 g, 83mmol), NaOAc (2.3 g, 28 mmol), H₂O (80 mL), ACOH (12 mL), and methanol(240 mL) and heated at reflux for 4 h. The dark orange suspension wasfiltered through a pad of diatomaceous earth and washed with excess DCM(˜1.5 L). The filtrate was concentrated in vacuo and partitioned betweenH₂O and DCM. The layers were separated, and the aqueous layer wasextracted with DCM (4×). The combined organic layers were dried (Na₂SO₄)and concentrated to give a dark orange oil. The oil was passed through aplug of silica gel and eluted with a mixture of EtOAc/hexanes (gradientfrom 30 to 70%), and then was triturated with methanol to provide thetitle compound as a dark tan solid (8.80 g, 58%).

EXAMPLE 3

(R)-4-Chloro-N-[1-(2,4-difluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. 4-Chloro-2-(Quinoxaline-5-sulfonylamino)benzoic acid methyl ester. Asolution of methyl 2-amino-4-chlorobenzoate (0.33 g, 1.8 mmol),quinoxaline-5-sulfonyl chloride (0.40 g, 1.8 mmol), pyridine (0.71 mL,8.8 mmol), and DCM (10 mL) was maintained at 23° C. for 16 h. EtOAc (75mL) was added and the solution was washed with satd. aq. NaHCO₃ (50 mL),then dried and concentrated to a solid. Chromatographic purification ofthis residue (3 to 40% EtOAc/hexanes) delivered the titled compound as awhite solid (0.60 mg, 90%). MS (ESI): mass calculated for C₁₆H₁₂ClN₃O₄S,377.0; m/z found, 378 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 11.44 (s, 1H),8.97 (d, J=1.8 Hz, 1H), 8.95 (d, J=1.8 Hz, 1H), 8.61 (dd, J=7.4, 1.4 Hz,1H), 8.33 (dd, J=8.5, 1.4 Hz, 1H), 7.89 (dd, J=8.4, 1.0 Hz, 1H), 7.84(d, J=2.0 Hz, 1H), 7.77 (d, J=8.6 Hz, 1H), 6.89 (dd, J=8.6, 2.0 Hz, 1H),3.90 (s, 3H).B. 4-Chloro-2-(Quinoxaline-5-sulfonylamino)benzoic acid. A solution ofLiOH.H₂O (0.32 g, 7.7 mmol) in H₂O (5 mL) was added to a solution of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester (0.58g, 1.5 mmol) and THF (10 mL). The biphasic mixture was stirred rapidlyat 23° C. for 16 h, then adjusted to pH 5 with 1 M HCl. The resultingprecipitate was collected by filtration to afford the acid as a whitesolid (0.51 g, 92%). MS (ESI): calculated for C₁₅H₁₀ClN₃O₄S, 363.0; m/zfound, 364 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆): 14.20 (br s, 1H), 11.73(s, 1H), 9.12 (d, J=1.6 Hz, 1H), 9.00 (d, J=1.5 Hz, 1H), 8.65 (d, J=7.3Hz, 1H), 8.42 (d, J=8.3 Hz, 1H), 8.06 (t, J=7.8 Hz, 1H), 7.80 (d, J=8.5Hz, 1H), 7.63 (d, J=2.0 Hz, 1H), 7.07 (dd, J=8.4, 1.9 Hz, 1H).C.(R)-4-Chloro-N-[1-(2,4-difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.The title compound was prepared and purified by the HATU-mediatedcoupling of 4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid and(R)-1-(2,4-difluorophenyl)ethylamine hydrochloride (EXAMPLE 2, Method 1,Step C) as described by the general procedure in EXAMPLE 1, Step K. MS(ESI): mass calculated for C₂₃H₁₇ClF₂N₄O₃S, 502.1; m/z found, 501[M−H]⁻. HPLC (reverse phase): R_(T)=9.75 min. ¹H NMR (500 MHz, CDCl₃):11.34 (s, H), 8.84 (d, J=1.8 Hz, 1H), 8.80 (d, J=1.8 Hz, 1H), 8.57 (dd,J=7.4, 1.4 Hz, 1H), 8.31 (dd, J=7.4, 1.4 Hz, 1H), 7.86 (dd, J=8.4, 7.4Hz, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.35-7.25 (m, 1H), 7.22-7.19 (m, 1H),7.08 (dd, J=8.4, 1.8 Hz, 1H), 6.93-6.87 (m, 2H), 6.34 (br d, J=6.5 Hz,1H), 5.35-5.25 (m, 1H), 1.54 (d, J=7.0 Hz, 3H).

EXAMPLE 4

Quinoxaline-5-sulfonic acid[5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide.A. 4-Iodo-2-nitrobenzoic acid. 4-Iodo-2-nitrotoluene (9.0 g, 34 mmol),KMnO₄ (22.0 g, 139 mmol), and H₂O (340 mL) were heated at reflux for 5h. The resulting brown suspension was filtered through a pad ofdiatomaceous earth, and the filter cake was washed with H₂O. The basicfiltrate was acidified with concentrated HCl causing precipitation ofthe desired acid. The solid was collected by suction filtration anddried, affording 1.86 g of the acid. The mother liquor was extractedwith DCM (3×200 mL), and the combined extracts were dried (Na₂SO₄) andconcentrated in vacuo to afford an additional 0.16 g of the benzoic acid(total 2.02 g, 20%). ¹H NMR (400 MHz, CD₃OD): 8.13 (d, J=1.6 Hz, 1H),8.01 (dd, J=8.1, 1.6 Hz, 1H), 7.50 (d, J=8.1 Hz, 1H).B. Methyl 2-amino-4-iodobenzoate. To a stirred solution of4-iodo-2-nitrobenzoic acid (2.3 g, 7.9 mmol) in DMF (30 mL) at 0° C. wasadded DBU (2.4 mL, 16 mmol) followed by iodomethane (1.5 mL, 24 mmol).The reaction mixture was stirred 15 min at 0° C., then was allowed towarm to room temperature and was stirred overnight. The mixture waspoured into H₂O and extracted with EtOAc (2×). The combined organicextracts were washed with H₂O (2×), dried (MgSO₄), and concentrated invacuo. The residue was purified by flash chromatography (hexanes/EtOAc)to afford methyl 4-iodo-2-nitrobenzoate as a pale yellow solid (2.30 g,95%). To a solution of the nitrobenzoate (2.3 g, 7.4 mmol) in 1:1EtOAc/DCM (10 mL) at room temperature was added SnCl₂.2H₂O (8.3 g, 37mmol). The reaction mixture was allowed to stir overnight. The solventswere evaporated in vacuo, and the residue was partitioned between satd.aq. NaHCO₃ and DCM. The layers were separated, and the aqueous layer wasfurther extracted with DCM (2×). The combined organic layers were dried(MgSO₄) and concentrated in vacuo to provide the pure aminobenzoate as ayellow solid (1.87 g, 91%). ¹H NMR (500 MHz, CDCl₃): 7.52 (d, J=8.5 Hz,1H), 7.07 (d, J=1.6 Hz, 1H), 6.96 (dd, J=8.5, 1.6 Hz, 1H), 5.72 (br s,2H), 3.86 (s, 3H).C. 4-Iodo-2-(Quinoxaline-5-sulfonylamino)benzoic acid methyl ester. Asolution of methyl 2-amino-4-iodobenzoate (1.2 g, 4.4 mmol),quinoxaline-5-sulfonyl chloride (1.2 g, 5.3 mmol), pyridine (1.7 mL, 22mmol) and DCM (25 mL) was maintained at 23° C. for 24 h. The reactionmixture was diluted with DCM (200 mL) and washed with satd. aq. NaHCO₃,then dried and concentrated to a tan solid. This residue waschromatographed (0 to 100% EtOAc/CH₂Cl₂) to afford the sulfonamide as alight yellow solid (1.6 g, 77%). MS (ESI): calculated for C₁₆H₁₂IN₃O₄S,469.0; m/z found, 470 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆): 11.10 (s, 1H),9.07 (d, J=1.8 Hz, 1H), 9.01 (d, J=1.8 Hz, 1H), 8.60 (dd, J=7.4, 1.3 Hz,1H), 8.40 (dd, J=8.5, 1.3 Hz, 1H), 8.04 (dd, J=7.5, 1.0 Hz, 1H), 7.99(d, J=1.6 Hz, 1H), 7.51 (d, J=8.3 Hz, 1H), 7.37 (dd, J=8.3, 1.6 Hz, 1H),3.88 (s, 3H).D. 4-Iodo-2-(Quinoxaline-5-sulfonylamino)benzoic acid. A solution ofLiOH.H₂O (0.16 g, 3.9 mmol) in H₂O (5 mL) was added to a solution of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester (0.37mg, 0.78 mmol) and THF (10 mL), and the mixture was rapidly stirred for16 h. The mixture was concentrated to a volume of 5 mL, then wasadjusted to pH 5 with 1 M HCl. The resulting precipitate was collectedby filtration to provide the acid as a white solid (0.35 g, 99%). MS(ESI): calculated for C₁₅H₁₀IN₃O₄S, 455.0; m/z found, 456 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆): 14.0 (br s, 1H), 11.6 (s, 1H), 9.10 (d, J=1.5 Hz,1H), 9.97 (d, J=1.5 Hz, 1H), 8.60 (d, J=7.4 Hz, 1H), 8.42 (d, J=8.4 Hz,1H), 8.06 (t, J=7.5 Hz, 1H), 7.95 (d, J=1.2 Hz, 1H), 7.51 (d, J=8.3 Hz,1H), 7.37 (dd, J=8.3, 1.2 Hz, 1H).E. Quinoxaline-5-sulfonic acid[5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide

The title compound was prepared and purified by the HATU-mediatedcoupling of 4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid andpiperidine as described by the general procedure in EXAMPLE 1, Step K.MS (ESI): mass calculated for C₂₀H₁₉IN₄O₃S, 522.0; m/z found, 521[M−H]⁻. HPLC (reverse phase): R_(T)=9.53 min. ¹H NMR (500 MHz, CDCl₃,rotameric broadening): 9.07 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H),8.98 (br s, 1H), 8.48 (dd, J=7.0, 1.48 Hz, 1H), 8.35 (dd, J=8.4, 1.4 Hz,1H), 8.02 (d, J=1.5 Hz, 1H), 7.87 (dd, J=8.4, 7.4 Hz, 1H), 7.37 (dd,J=8.0, 1.6 Hz, 1H), 6.74 (d, J=8.0 Hz, 1H), 3.45-3.05 (br m, 2H),2.90-2.80 (br m, 2H), 1.50-1.30 (br m, 6H).

EXAMPLE 5

(R)-4,5-Dichloro-N-[1-(2,4-difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. 4,5-Dichlorophthalic acid monomethyl ester. To a stirred suspensionof 4,5-dichlorophthalic anhydride (15.0 g, 69.1 mmol) in methanol (1 L)was added sodium methoxide (5.40 g, 100 mmol). The mixture was heated atreflux for 12 h becoming homogeneous. The reaction mixture was cooled toroom temperature and concentrated in vacuo to a volume of ˜100 mL, andthen was poured into 0.5 N HCl (1 L) causing precipitation of theproduct. The resulting white powder was collected by suction filtration,washed with H₂O, and dried in vacuo to give 17.1 g (99.5%) of themonomethyl ester. ¹H NMR (400 MHz, CDCl₃): 8.02 (s, 1H), 7.84 (s, 1H),3.94 (s, 3H).B. Methyl 2-amino-4,5-dichlorobenzoate. A suspension of4,5-dichlorophthalic acid monomethyl ester (17 g, 69 mmol) in thionylchloride (100 mL) was heated at reflux for 1 h. The resultinghomogeneous mixture was cooled and concentrated in vacuo to give ayellow oil. The oil was azeotroped in vacuo with toluene (5×5 mL) toremove any remaining thionyl chloride, leaving the acid chloride as ayellow liquid. ¹H NMR (400 MHz, CDCl₃): 7.96 (s, 1H), 7.82 (s, 1H), 3.95(s, 3H). The crude acid chloride was stirred in dry acetone (400 mL) at0° C. as a solution of NaN₃ (18.0 g, 277 mmol) in H₂O (120 mL) was addeddropwise, maintaining the temperature below 10° C. After addition wascomplete, the orange reaction mixture was stirred 1 h at 0° C. Themixture was concentrated in vacuo with no external heating. The residuewas partitioned between H₂O and DCM. The layers were separated and theaqueous phase was extracted with DCM. The combined organic layers weredried (Na₂SO₄) and concentrated to give the crude acyl azide as a tansolid. ¹H NMR indicated the acyl azide methyl ester was contaminatedwith 3 other minor unidentified components. ¹H NMR (400 MHz, CDCl₃):7.87 (s, 1H), 7.78 (s, 1H), 3.94 (s, 3H). The crude tan solid wassuspended in a mixture of acetic acid (240 mL) and H₂O (120 mL) andheated to reflux for 1 h. Rapid gas evolution occurred. The resultingsuspension was concentrated in vacuo, and the solid was collected bysuction filtration and washed with water. The desired methyl2-amino-4,5-dichlorobenzoate was partially purified by stirring thecrude solid in toluene and removing the insoluble material byfiltration. The filtrate was concentrated to a white solid which wasenriched in methyl 2-amino-4,5-dichlorobenzoate (9.10 g, ˜54%, 91% pure)The aminobenzoate was used without further purification. ¹H NMR (400MHz, CDCl₃): 7.92 (s, 1H), 6.78 (s, 1H), 5.77 (br s, 2H), 3.87 (s, 3H).C. 4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)benzoic acid methylester. Methyl 2-amino-4,5-dichlorobenzoate (60 mg, 0.27 mmol),quinoxaline-5-sulfonyl chloride (EXAMPLE 1, Step C; 0.10 g, 0.44 mmol),and pyridine (0.6 mL, 7 mmol) were combined in toluene (0.5 mL) andheated at 60° C. for 1 h. The mixture was cooled, poured into 1 N HCl,and extracted with with DCM (3×). The combined organic layers were dried(Na₂SO₄) and concentrated. The residue was purified by flashchromatography (EtOAc/hexanes) to provide 17 mg (15%) of the desiredsulfonamide as a colorless solid. ¹H NMR (400 MHz, CDCl₃): 11.29 (br s,1H), 8.96 (br s, 2H), 8.60 (dd, J=7.2, 1.2 Hz, 1H), 8.35 (dd, J=8.4, 1.2Hz, 1H), 8.00 (s, 1H), 7.92 (s, 1H), 7.90 (dd, J=8.8, 7.6 Hz, 1H), 3.91(s, 3H).D. 4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)benzoic acid. A mixtureof 4,5-dichloro-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester(17 mg, 0.041 mmol), LiOH (2.0 M in H₂O, 0.25 mL, 0.50 mmol), and THF (5mL) was stirred for 5 h at room temperature. The resulting yellowbiphasic mixture was poured into 1 N HCl and extracted with DCM (4×).The combined organic layers were dried (Na₂SO₄) and concentrated to givethe pure acid as a tan solid (16 mg, 100%).E.(R)-4,5-Dichloro-N-[1-(2,4-difluorophenyl)-ethyl]-2-(Quinoxaline-5-sulfonylamino)-benzamide.4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (8 mg, 0.02mmol) was coupled with (R)-1-(2,4-difluorophenyl)ethylaminehydrochloride (EXAMPLE 2, Method 1, Step C; 8 mg, 0.04 mmol) accordingto the procedure described in EXAMPLE 1, Step K to provide the desiredbenzamide as a colorless solid (9 mg, 82%). MS (ESI): mass calculatedfor C₂₃H₁₆Cl₂F₂N₄O₃S, 536.0; m/z found, 535/537 [M−H]⁻. HPLC (reversephase): R_(T)=10.45 min. ¹H NMR (500 MHz, CDCl₃): 11.15 (s, 1H), 8.85(d, J=1.8 Hz, 1H), 8.79 (d, J=1.8 Hz, 1H), 8.54 (dd, J=7.4, 1.4 Hz, 1H),8.32 (dd, J=7.4, 1.4 Hz, 1H), 7.89 (s, 1H), 7.87 (dd, J=8.2, 7.4 Hz,1H), 7.35 (s, 1H), 7.30 (ddd, J=8.5, 8.5, 6.3 Hz, 1H), 6.93-6.88 (m,1H), 6.88-6.83 (m, 1H), 6.30 (br d, J=6.5 Hz, 1H), 5.35-5.25 (m, 1H),1.54 (d, J=7.0 Hz, 3H).

EXAMPLE 6

Quinoxaline-5-sulfonic acid[5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide.

Method 1.

The title compound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and morpholine and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₁₉H₁₇IN₄O₄S, 524.0; m/z found, 523 [M−H]⁻. HPLC(reverse phase): R_(T)=8.32 min. ¹H NMR (500 MHz, CDCl₃, rotamericbroadening): 9.06 (d, J=1.8 Hz, 1H), 9.02 (d, J=1.8 Hz, 1H), 9.01 (br s,1H), 8.51 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.96(d, J=1.5 Hz, 1H), 7.90 (dd, J=8.4, 7.4 Hz, 1H), 7.38 (dd, J=8.0, 1.6Hz, 1H), 6.76 (d, J=8.0 Hz, 1H), 3.70-3.40 (br m, 6H), 3.30-3.05 (br m,2H).

Alternatively, quinoxaline-5-sulfonic acid[5-iodo-2-(morpholine-4-carbonyl)-phenyl]amide could be prepared by thefollowing procedure:

Method 2.

A. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid methylester. To a solution of methyl 2-amino-4-iodobenzoate (EXAMPLE 4, StepB, 1.6 g, 5.8 mmol) in DCM (45 mL) at room temperature was added4-chlorosulfonyl-2,1,3-benzothiadiazole (1.76 g, 7.51 mmol), andpyridine (0.93 mL, 11 mmol). The mixture was stirred at room temperatureovernight, poured into 1 N HCl (200 mL), and extracted with DCM (2×100mL). The combined organic layers were dried (Na₂SO₄) and concentrated invacuo. The crude residue was purified by flash chromatography(hexanes/EtOAc) to afford the title sulfonamide as a tan solid (1.87 g,68%). MS (ESI): calculated for C₁₄H₁₀IN₃O₄S₂, 474.9; m/z found, 474[M−H]⁻. ¹H NMR (400 MHz, CDCl₃): 11.26 (br s, 1H), 8.40 (dd, J=7.0, 1.0Hz, 1H), 8.24 (dd, J=8.8, 1.0 Hz, 1H), 8.12 (d, J=1.5 Hz, 1H), 7.74 (dd,J=8.8, 7.0 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 7.32 (dd, J=8.5, 1.5 Hz,1H), 3.91 (s, 3H).

B. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid. To astirred suspension of2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid methylester (1.87 g, 3.93 mmol) in THF (20 mL) at room temperature was addedLiOH (2 M in H₂O, 18 mL). The resulting orange mixture was stirredovernight at room temperature then poured into 0.5 M HCl (150 mL)causing precipitation of the desired benzoic acid. After stirring themixture for several minutes to complete precipitation, the product wascollected by suction filtration and air-dried to afford the acid as atan solid (1.24 g, 69%). ¹H NMR (500 MHz, CDCl₃): 11.03 (br s, 1H), 8.34(dd, J=7.2, 1.1 Hz, 1H), 8.19 (dd, J=8.8, 1.1 Hz, 1H), 8.09 (d, J=1.6Hz, 1H), 7.69 (dd, J=8.8, 7.2 Hz, 1H), 7.56 (d, J=8.5 Hz, 1H), 7.30 (dd,J=8.5, 1.6 Hz, 1H), (COOH not observed).

C. Benzo[1,2,5]thiadiazole-4-sulfonic acid[5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide. The title compound wasprepared from the HATU-mediated coupling of2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid andmorpholine and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₁₇H₁₅IN₄O₄S₂, 530.0; m/z found, 531 [M+H]⁺, 553[M+Na]⁺. HPLC (reverse phase): R_(T)=8.50 min. ¹H NMR (400 MHz, CDCl₃):(rotameric broadening) 8.91 (s, 1H), 8.31 (dd, J=7.0, 0.9 Hz, 1H), 8.27(dd, J=8.8, 0.9 Hz, 1H), 7.97 (d, J=1.5 Hz, 1H), 7.74 (dd, J=8.8, 7.0Hz, 1H), 7.41 (dd, J=8.1, 1.6 Hz, 1H), 6.78 (d, J=8.1 Hz, 1H), 3.75-3.05(br m, 8H).

D. Quinoxaline-5-sulfonic acid[5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide. Zinc powder (1.1 g, 19mmol) was added to a mixture of benzo[1,2,5]thiadiazole-4-sulfonic acid[5-iodo-2-(morpholine-4-carbonyl)-phenyl]amide (1.0 g, 1.9 mmol) andAcOH (20 mL), and the resulting mixture was heated at 50° C. for 1 hwith vigorous stirring. The mixture was filtered through a pad ofdiatomaceous earth, rinsing well with methanol, and the clear solutionwas concentrated to a yellow solid. This material was dissolved inmethanol (20 mL) and added to a mixture of glyoxal sodium bisulfiteadduct (1.5 g, 5.7 mmol), AcOH (0.85 mL), NaOAc (0.16 g, 2.0 mmol), andH₂O (6 mL). The reaction was allowed to proceed under reflux for 3 h,then was diluted with EtOAc (200 mL) and filtered through a pad ofdiatomaceous earth, rinsing well with EtOAc. The filtrate was washedwith H₂O (100 mL) and brine (100 mL), then was dried and concentrated toa yellow solid. Purification by flash chromatography gave the titledcompound as a light yellow solid (0.69 g, 70%).

EXAMPLE 7

(R)-4-Chloro-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. S—(S)-2-Methyl-propane-2-sulfinic acid 4-fluorobenzylideneamide. Asuspension of 4-fluorobenzaldehyde (0.53 g, 4.3 mmol),(S)-tert-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrousCuSO₄ (1.2 g, 7.8 mmol) was stirred in DCM (8 mL) overnight. Thereaction mixture was filtered, and the filter cake was washed with DCM.The filtrate was concentrated in vacuo to give the N-sulfinyl imine as aviscous, colorless oil (0.81 g, 84%). ¹H NMR (500 MHz, CDCl₃): 8.55 (s,1H), 7.88-7.85 (m, 2H), 7.18-7.15 (m, 2H), 1.26 (s, 9H).B. S-(S)-2-Methylpropane-2-sulfinic acid1-(R)-[1-(4-fluorophenyl)ethyl]amide.

To a stirred solution of S—(S)-2-methyl-propane-2-sulfinic acid4-fluoro-benzylideneamide (0.81 g, 3.1 mmol) in DCM (20 mL) at −50° C.was added a solution of methyl magnesium bromide (3.0 M in diethylether, 2.4 mL, 7.2 mmol). The reaction mixture was stirred at −50° C.for 1 h then allowed to warm slowly to room temperature overnight. Thereaction was quenched by the addition of a satd. aq. NH₄Cl solution, andthe mixture was poured into H₂O and extracted with DCM (3×). Thecombined organic layers were dried (Na₂SO₄) and concentrated in vacuo.Purification by flash chromatography (EtOAc/hexanes) provided the titlecompound as a colorless viscous oil (0.86 g, 98%, 94% de). Majordiastereomer: ¹H NMR (400 MHz, CDCl₃): 7.33-7.27 (m, 2H), 7.06-6.98 (m,2H), 4.56 (dq, J=6.6, 3.2 Hz, 1H), 3.30 (br d, J=2.3 Hz, 1H), 1.52 (d,J=6.7 Hz, 3H), 1.20 (s, 9H).

C. (R)-1-(4-Fluorophenyl)ethylamine hydrochloride. To a stirred solutionof S-(S)-2-methylpropane-2-sulfinic acid1-(R)-[1-(4-fluorophenyl)ethyl]amide (94% de, 0.86 g, 3.5 mmol) inmethanol (7 mL) at room temperature was added 2 mL of a satd. solutionof HCl (g) in methanol. After several minutes, precipitated aminehydrochloride was visible. The reaction mixture was allowed to stir for2 h at room temperature. The heterogeneous mixture was concentrated invacuo until approximately 2 mL remained, and then the aminehydrochloride was fully precipitated by the addition of diethyl ether(10 mL). The HCl salt was collected by suction filtration, washed withdiethyl ether, and dried in vacuo to give fine white crystals (484 mg,78%, ˜94% ee based on de of starting material). ¹H NMR (400 MHz, CDCl₃):8.67 (brs, 3H), 7.50-7.42 (m, 2H), 7.09-7.00 (m, 2H), 4.36 (br s, 1H),1.64 (d, J=6.8 Hz, 3H).

D.(R)-4-Chloro-N-[1-(4-fluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and (R)-1-(4-fluorophenyl)ethylamine hydrochloride and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₃H₁₈ClFN₄O₃S, 484.1; m/z found, 483 [M−H]⁻. HPLC (reverse phase):R_(T)=9.95 min. ¹H NMR (500 MHz, CDCl₃): 11.40 (s, 1H), 8.84 (d, J=1.8Hz, 1H), 8.77 (d, J=1.8 Hz, 1H), 8.57 (dd, J=7.4, 1.4 Hz, 1H), 8.31 (dd,J=7.4, 1.4 Hz, 1H), 7.87 (dd, J=8.4, 7.4 Hz, 1H), 7.77 (d, J=2.0 Hz,1H), 7.30-7.27 (m, 2H), 7.22 (d, J=8.4 Hz, 1H), 7.08-7.04 (m, 2H), 6.91(dd, J=8.4, 2.0 Hz, 1H), 6.11 (br d, J=6.5 Hz, 1H), 5.24-5.20 (m, 1H),1.53 (d, J=7.0 Hz, 3H).

EXAMPLE 8

(R)-4-Bromo-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and (R)-1-(4-fluorophenyl)ethylamine hydrochloride (EXAMPLE 7, Step C)and purified as described in EXAMPLE 1, Step K. MS (ESI): masscalculated for C₂₃H₁₈BrFN₄O₃S, 528.0; m/z found, 527/529 [M−H]⁻. HPLC(reverse phase): R_(T)=10.03 min. ¹H NMR (500 MHz, CDCl₃): 11.34 (s,1H), 8.85 (d, J=1.8 Hz, 1H), 8.78 (d, J=1.8 Hz, 1H), 8.57 (dd, J=7.4,1.4 Hz, 1H), 8.32 (dd, J=7.4, 1.4 Hz, 1H), 7.92 (d, J=1.8 Hz, 1H), 7.87(dd, J=8.4, 7.4 Hz, 1H), 7.30-7.25 (m, 2H), 7.15 (d, J=8.4 Hz, 1H),7.10-7.00 (m, 2H), 6.91 (dd, J=8.4, 2.0 Hz, 1H), 6.13 (br d, J=6.5 Hz,1H), 5.25-5.15 (m, 1H), 1.53 (d, J=7.0 Hz, 3H).

EXAMPLE 9

(S)-4-Chloro-N-[1-(2,4-dichlorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. (S)-1-(2,4-Dichloroorophenyl)ethylamine hydrochloride. The amine wasprepared according to the procedures described in EXAMPLE 1, Steps Hthrough J, starting with (R)-tert-butanesulfinamide.B.(S)-4-Chloro-N-[1-(2,4-dichlorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.The title compound was prepared from the HATU mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and (S)-1-(2,4-difluorophenyl)ethylamine hydrochloride and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₃H₁₇Cl₃N₄O₃S, 534.0; m/z found, 533/535 [M−H]⁻. HPLC (reverse phase):R_(T)=10.60 min. ¹H NMR (500 MHz, CDCl₃): 11.36 (s, 1H), 8.85 (d, J=1.8Hz, 1H), 8.75 (d, J=1.8 Hz, 1H), 8.55 (dd, J=7.4, 1.4 Hz, 1H), 8.31 (dd,J=7.4, 1.4 Hz, 1H), 7.86 (dd, J=8.4, 7.4 Hz, 1H), 7.79 (d, J=2.0 Hz,1H), 7.47-7.42 (m, 1H), 7.28-7.26 (m, 1H), 7.22-7.20 (m, 2H), 6.92 (dd,J=8.4, 2.0 Hz, 1H), 6.34 (br d, J=6.5 Hz, 1H), 5.45-5.35 (m, 1H), 1.52(d, J=7.0 Hz, 3H).

EXAMPLE 10

Quinoxaline-5-sulfonic acid[5-bromo-2-(1,3,4,5-tetrahydrobenzo[c]azepine-2-carbonyl)phenyl]-amide.

A. 2,3,4,5-Tetrahydrobenzo[c]azepin-1-one. To an ice-cold solution of3,4-dihydro-2H-naphthalen-1-one (4.44 g, 30.4 mol) in concentrated HCl(60 mL) was added NaN₃ (2.02 g, 30.4 mol) in portions. The resultingmixture was allowed to stir at 0° C. for 30 min, then was warmed to roomtemperature and stirred overnight. The reaction mixture was poured ontoice, brought to pH ˜10 with 1 M NaOH, and extracted with DCM (3×). Thecombined organic layers were dried over MgSO₄, filtered, concentrated,and purified by flash chromatography (hexanes/EtOAc) to provide thetitle compound (1.23 g, 25%). HPLC (reverse phase): R_(T)=6.92 min. ¹HNMR (500 MHz, CDCl₃): 7.71 (dd, J=7.6 Hz, 1.3 Hz, 1H), 7.42-7.39 (m,1H), 7.36-7.32 (m, 1H), 7.20-7.19 (m, 1H), 3.15-3.11 (m, 2H), 2.87 (t,J=7.1 Hz, 2H), 2.05-2.00 (m, 2H), (NH not observed).

B. 2,3,4,5-Tetrahydro-1H-benzo[c]azepine.2,3,4,5-Tetrahydro-benzo[c]azepin-1-one (1.23 g, 7.63 mmol) wasdissolved in THF (10 mL) and cooled to 0° C. Lithium aluminum hydride(0.89 g, 23 mmol) was added slowly in small portions. The resultingmixture was heated at reflux for 24 h, cooled to room temperature andquenched with successive dropwise addition of H₂O (0.89 mL), 15% aq.NaOH solution (0.89 mL), and H₂O (2.67 mL). The salts were removed byfiltration and the filtrate was concentrated to provide the titlecompound (0.68 g, 61%). ¹H NMR (400 MHz, CDCl₃): 7.16-7.10 (m, 4H), 3.94(s, 2H), 3.21 (t, J=5.3 Hz, 2H), 2.96-2.94 (m, 2H), 1.73-1.71 (m, 2H).

C. Quinoxaline-5-sulfonic acid[5-bromo-2-(1,3,4,5-tetrahydrobenzo[c]azepine-2-carbonyl)phenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 2,3,4,5-tetrahydro-1H-benzo[c]azepine and purified as described inEXAMPLE 1, Step K. MS (ESI): mass calculated for C₂₅H₂₁BrN₄O₃S, 536.0;m/z found, 537/539 [M+H]⁺. HPLC (reverse phase): R_(T)=9.80 min. ¹H NMR(500 MHz, CDCl₃, mixture of rotamers): 9.07 (br s, 0.5H), 9.00 (br s,0.5H), 8.93 (br s, 1H), 8.84-8.76 (m, 1H), 8.52-8.46 (m, 1H), 8.36-8.32(m, 1H), 7.90-7.84 (m, 2H), 7.48-7.36 (m, 0.5H), 7.25-7.20 (m, 1H),7.14-7.08 (m, 1.5H), 7.06-7.00 (m, 0.5H), 6.78-6.76 (m, 0.5H), 6.62-6.58(m, 0.5H), 6.44-6.42 (m, 0.5H), 4.44-4.28 (m, 1H), 3.90-3.88 (m, 1H),3.7-3.5 (br m, 1H), 3.08-3.01 (m, 1H), 2.90-2.80 (m, 2H), 1.90-1.80 (m,1H), 1.50-1.40 (m, 2H).

EXAMPLE 11

(R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and morpholine and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₁₉H₁₇BrN₄O₄S, 476.0; m/z found, 475/477 [M−H]⁻.HPLC (reverse phase): R_(T)=8.23 min. ¹H NMR (500 MHz, CDCl₃, rotamericbroadening): 9.08 (br s, 1H), 9.06 (d, J=1.8 Hz, 1H), 9.01 (d, J=1.8 Hz,1H), 8.52 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.90(dd, J=8.4, 7.4 Hz, 1H), 7.79 (d, J=1.5 Hz, 1H), 7.17 (dd, J=8.0, 1.6Hz, 1H), 6.92 (d, J=8.0 Hz, 1H), 3.68-3.40 (br m, 6H), 3.35-3.05 (br m,2H).

EXAMPLE 12

(R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.A. (R)-2-(2-Hydroxyethylamino)propan-1-ol. Condensed ethylene oxide (0.8g, 20 mmol) was added to a solution of (R)-2-aminopropan-1-ol (5 g, 70mmol) in H₂O at 0° C. The mixture was stirred overnight with slowwarming to room temperature and then was concentrated in vacuo to give aviscous, colorless oil. The crude product was purified by bulb-to-bulbdistillation under high vacuum to provide the desired diol as a viscousliquid. ¹H NMR (400 MHz, CDCl₃): 3.74-3.64 (m, 2H), 3.61 (dd, J=10.8,3.9 Hz, 1H), 3.33 (dd, J=10.8, 7.3 Hz, 1H), 2.88 (ddd, J=12.3, 6.1, 4.1Hz, 1H), 2.80 (ddq, J=7.2, 6.5, 3.9 Hz, 1H), 2.70 (ddd, J=12.3, 6.0, 4.1Hz, 1H), 1.06 (d, J=6.5 Hz, 3H).B. (R)-3-Methylmorpholine. The crude(R)-2-(2-hydroxyethylamino)propan-1-ol from step A was transferred to asealed tube, and 10 mL concentrated H₂SO₄ was carefully added. The tubewas sealed and heated at 140° C. for 14 h. The dark brown mixture waspoured over crushed ice and made basic by slow addition of 5 N NaOH. Themixture was extracted with diethyl ether (5×). The combined organiclayers were dried (MgSO₄) and concentrated to provide the morpholine asa yellow liquid (1.19 g, 65%). ¹H NMR (500 MHz, CDCl₃): 3.82-3.72 (m,2H), 3.52-3.44 (m, 1H), 3.10 (t, J=10.0 Hz, 1H), 3.03-2.95 (m, 1H),2.95-2.83 (m, 2H), 0.96 (d, J=6.4 Hz, 3H).C. (R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.(R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide was preparedfrom the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and (R)-3-methylmorpholine and purified as described in EXAMPLE 1, StepK. MS (ESI): mass calculated for C₂₀H₁₉BrN₄O₄S, 490.0; m/z found,489/491 [M−H]⁻. HPLC (reverse phase): R_(T)=8.63 min. ¹H NMR (500 MHz,CDCl₃, rotameric broadening): 9.05 (d, J=1.8 Hz, 1H), 9.01 (br s, 1H),9.00 (d, J=1.8 Hz, 1H), 8.56 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4,1.4 Hz, 1H), 7.91 (dd, J=8.4, 7.4 Hz, 1H), 7.72 (d, J=1.5 Hz, 1H), 7.16(dd, J=8.0, 1.6 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 4.50-4.00 (br m, 1H),3.91-3.78 (m, 1H), 3.73-3.58 (m, 1H), 3.50 (dd, J=11.5, 2.7 Hz, 1H),3.40-3.17 (m, 3H), 1.25 (br m, 3H).

EXAMPLE 13

(R)-Quinoxaline-5-sulfonic acid[5-chloro-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and (R)-3-methylmorpholine (EXAMPLE 12, Step B) and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₀H₁₉ClN₄O₄S, 446.1; m/z found, 445 [M−H]⁻. HPLC (reverse phase):R_(T)=8.54 min. ¹H NMR (500 MHz, CDCl₃, rotameric broadening): 9.05 (d,J=1.8 Hz, 1H), 9.04 (br s, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.56 (dd, J=7.0,1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.91 (dd, J=8.4, 7.4 Hz, 1H),7.56 (br s, 1H), 7.01-6.98 (m, 2H), 4.4-4.2 (br m, 1H), 3.90-3.82 (m,1H), 3.68-3.62 (m, 1H), 3.51 (dd, J=11.5, 2.7 Hz, 1H), 3.40-3.20 (m,3H), 1.31-1.23 (br m, 3H).

EXAMPLE 14

(R)-Quinoxaline-5-sulfonic acid[5-chloro-2-(morpholine-4-carbonyl)phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and morpholine and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₁₉H₁₇ClN₄O₄S, 432.1; m/z found, 431 [M−H]⁻. HPLC(reverse phase): R_(T)=8.14 min. ¹H NMR (500 MHz, CDCl₃, rotamericbroadening): 9.11 (br s, 1H), 9.06 (d, J=1.8 Hz, 1H), 9.01 (d, J=1.8 Hz,1H), 8.52 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.90(dd, J=8.4, 7.4 Hz, 1H), 7.63 (d, J=1.5 Hz, 1H), 7.05-6.98 (m, 2H),3.65-3.40 (br m, 6H), 3.50-3.00 (br m, 2H).

EXAMPLE 15

(R)-N-[1-(2,4-Difluorophenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and (R)-1-(2,4-difluorophenyl)ethylamine hydrochloride (EXAMPLE 2,Method 1, Step C) and purified as described in EXAMPLE 1, Step K. MS(ESI): mass calculated for C₂₃H₁₇F₂IN₄O₃S, 594.0; m/z found, 593 [M−H]⁻.HPLC (reverse phase): R_(T)=10.16 min. ¹H NMR (500 MHz, CDCl₃): 11.22(s, 1H), 8.84 (d, J=1.8 Hz, 1H), 8.79 (d, J=1.8 Hz 1H), 8.55 (dd, J=7.4,1.4 Hz, 1H), 8.30 (dd, J=7.4, 1.4 Hz, 1H), 8.11 (d, J=1.8 Hz, 1H), 7.87(dd, J=8.4, 7.4 Hz, 1H), 7.32-7.27 (m, 2H), 6.99 (d, J=8.2, 1H),6.89-6.85 (m, 1H), 6.85-6.80 (m, 1H), 6.33 (br d, J=7.7 Hz, 1H),5.35-5.27 (m, 1H), 1.53 (d, J=7.0 Hz, 3H).

EXAMPLE 16

4-Bromo-N-(2-chloro-4-fluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 2-chloro-4-fluorobenzylamine and purified as described in EXAMPLE 1,Step K. MS (ESI): mass calculated for C₂₂H₁₅BrClFN₄O₃S, 548.0; m/zfound, 549/550 [M+H]⁺, 571/573 [M+Na]⁺. HPLC (reverse phase): R_(T)=9.86min. ¹H NMR (500 MHz, CDCl₃): 11.29 (s, 1H), 8.88 (dd, J=15.3, 6.0 Hz,2H), 8.57 (dd, J=7.4, 1.4 Hz, 1H), 8.32 (dd, J=8.4, 1.8 Hz, 1H), 8.31(d, J=1.8 Hz, 1H), 7.93 (d, J=1.8 Hz, 1H), 7.88 (dd, J=8.4, 7.4 Hz, 1H),7.43 (dd, J=8.5, 6.0 Hz, 1H), 7.16 (dd, J=8.3, 2.6, 1H), 7.14 (d, J=8.4Hz, 1H), 7.07 (dd, J=8.5, 2.1 Hz, 1H), 7.01 (ddd, J=8.2, 8.2, 2.5 Hz,1H), 6.38-6.33 (m, 1H), 4.57 (d, J=6.0 Hz, 1H).

EXAMPLE 17

4-Bromo-N-(2,4-difluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 2,4-difluorobenzylamine and purified as described in EXAMPLE 1, StepK. MS (ESI): mass calculated for C₂₂H₁₅BrF₂N₄O₃S, 532.0; m/z found,533/535 [M+H]⁺, 555/557 [M+Na]⁺. HPLC (reverse phase): R_(T)=9.64 min.¹H NMR (500 MHz, CDCl₃, rotameric broadening): 11.31 (s, 1H), 8.92-8.86(m, 2H), 8.62-8.53 (m, 1H), 8.35-8.29 (m, 1H), 7.96-7.90 (m, 1H),7.90-7.83 (m, 1H), 7.41-7.32 (m, 1H), 7.15-7.10 (m, 1H), 7.09-7.03 (m,1H), 6.94-6.82 (m, 2H), 6.31-6.24 (m, 1H), 4.53 (br s, 2H).

EXAMPLE 18

Quinoxaline-5-sulfonic acid [2-(azepane-1-carbonyl)-5-iodophenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and azepane and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₂₁H₂₁IN₄O₃S, 536.0; m/z found, 535 [M−H]⁻. HPLC(reverse phase): R_(T)=9.42 min. ¹H NMR (500 MHz, CDCl₃, rotamericbroadening): 9.08 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.81 (br s,1H), 8.49 (d, J=7.3, 1H), 8.35 (d, J=8.4, Hz, 1H), 7.98 (s, 1H), 7.88(t, J=8.1 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H),3.30-3.27 (br m, 2H), 2.91-2.89 (m, 2H), 1.66-1.63 (m, 2H), 1.63-1.54(m, 2H), 1.50-1.43 (br m, 4H).

EXAMPLE 19

(R)-Quinoxaline-5-sulfonic acid[5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and (R)-3-methylmorpholine and purified as described in EXAMPLE 1, StepK. MS (ESI): mass calculated for C₂₀H₁₉IN₄O₄S, 538.0; m/z found, 537[M−H]⁻. HPLC (reverse phase): R_(T)=8.71 min. ¹H NMR (400 MHz, CDCl₃,rotameric broadening): 9.05 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H),8.94 (br s, 1H), 8.54 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz,1H), 7.92 (dd, J=8.4, 7.4 Hz, 1H), 7.90-7.89 (m, 1H), 7.37 (dd, J=8.0,1.6 Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.5-4.0 (br m, 1H), 3.90-3.82 (m,1H), 3.66-3.64 (m, 1H), 3.47 (dd, J=11.5, 2.7 Hz, 1H), 3.35-3.25 (m,3H), 1.31-1.21 (br m, 3H).

EXAMPLE 20

Quinoxaline-5-sulfonic acid[4,5-dichloro-2-(morpholine-4-carbonyl)-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid (EXAMPLE 5,Step D) and morpholine and purified as described in EXAMPLE 1, Step K.MS (ESI): mass calculated for C₁₉H₁₆Cl₂N₄O₄S, 466.0; m/z found, 465/467[M−H]⁻. HPLC (reverse phase): R_(T)=8.84 min. ¹H NMR (500 MHz, CDCl₃,rotameric broadening): 9.06 (d, J=1.8 Hz, 1H), 9.03 (d, J=1.8 Hz, 1H),8.51 (dd, J=7.0, 1.5 Hz, 1H), 8.38 (dd, J=8.4, 1.4 Hz, 1H), 8.08 (d,J=1.5 Hz, 1H), 7.91 (dd, J=8.4, 7.4 Hz, 1H), 7.70 (s, 1H), 7.14 (s, 1H),4.35-4.10 (br m, 4H), 3.65-3.48 (br m, 4H).

EXAMPLE 21

Quinoxaline-5-sulfonic acid[2-(azepane-1-carbonyl)-5-bromophenyl]-amide. The title compound wasprepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and azepane and purified as described in EXAMPLE 1, Step K. MS (ESI):mass calculated for C₂₁H₂₁BrN₄O₃S, 488.0; m/z found, 487/489 [M−H]⁻.HPLC (reverse phase): R_(T)=9.34 min. ¹H NMR (500 MHz, CDCl₃, rotamericbroadening): 9.08 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.87 (br s,1H), 8.50 (d, J=7.3 Hz, 1H), 8.34 (d, J=8.4 Hz, 1H), 7.87 (dd, J=8.4,7.4 Hz, 1H), 7.80 (d, J=1.8 Hz, 1H), 7.16 (dd, J=8.1, 1.8 Hz, 1H), 6.91(d, J=8.1 Hz, 1H), 3.33-3.28 (br m, 2H), 2.93-2.91 (m, 2H), 1.68-1.65(m, 2H), 1.58-1.52 (m, 2H), 1.50-1.42 (br m, 4H).

EXAMPLE 22

Quinoxaline-5-sulfonic acid[5-chloro-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide.A. 3,4-Dihydro-2H-benzo[f][1,4]oxazepin-5-one. To a 0° C. solution ofchroman-4-one (2.0 g, 0.014 mol) in concentrated H₂SO₄ (10 mL) was addedNaN₃ (1.1 g, 0.018 mol) in portions. The resulting mixture was stirredat 0° C. for 30 min, then was warmed to room temperature and stirredovernight. The reaction mixture was poured onto ice, basified to pH ˜10with 1 M NaOH, and extracted with EtOAc (3×). The combined organiclayers were dried over MgSO₄, filtered, and concentrated, to provide thetitle compound (1.40 g, 64%). HPLC (reverse phase): R_(T)=6.40 min. ¹HNMR (500 MHz, CDCl₃): 7.98 (dd, J=8.0, 1.8 Hz, 1H), 7.45-7.42 (m, 1H),7.16-7.12 (m, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.68 (br s, 1H), 4.40 (t,J=4.7 Hz, 2H), 3.51 (q, J=5.3 Hz, 2H).B. 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine. To a 0° C. solution of3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one (1.22 g, 7.48 mmol) in THF(20 mL) was added lithium aluminum hydride (0.85 g, 22 mmol) in smallportions. The resulting mixture was heated at reflux for 24 h, cooled toroom temperature, and quenched with successive dropwise addition of H₂O(0.85 mL), 15% aq. NaOH solution (0.85 mL), and H₂O (2.55 mL). The saltswere removed by filtration, and the filtrate was concentrated to yieldthe title compound (0.80 g, 72%). TLC (silica, EtOAc): R_(f)=0.14. ¹HNMR (500 MHz, CDCl₃): 7.19-7.12 (m, 2H), 7.03-6.97 (m, 2H), 4.04 (t,J=4.5 Hz, 2H), 3.96 (s, 2H), 3.23 (t, J=4.5 Hz, 2H), (one H notobserved).C. Quinoxaline-5-sulfonic acid[5-chloro-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and 2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine and purified as describedin EXAMPLE 1, Step K. MS (ESI): mass calculated for C₂₄H₁₉ClN₄O₄S,494.1; m/z found, 495/497 [M+H]⁺. HPLC (reverse phase): R_(T)=9.36 min.¹H NMR (400 MHz, CDCl₃, rotameric broadening): 9.09-8.97 (m, 2H), 8.85(br s, 0.5H), 8.68 (br s, 0.5H), 8.52-8.47 (m, 1H), 8.36-8.34 (m, 1H),7.90-7.86 (m, 1H), 7.71 (br s, 1H), 7.4-7.2 (m, 2H), 7.04-7.00 (m, 1H),6.98 (dd, J=8.2, 1.8 Hz, 1H), 6.98-6.91 (m, 1H), 6.82-6.78 (m, 0.5H),6.65-6.60 (m, 0.5H), 4.55-4.47 (m, 1H), 4.09 (br s, 1H), 3.91 (br s,1.5H), 3.71 (br s, 1.5H), 3.38 (br s, 1H).

EXAMPLE 23

(S)-Quinoxaline-5-sulfonic acid[5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.A. (S)-3-Methylmorpholine. (S)-3-Methylmorpholine was prepared asdescribed for the (R) enantiomer (EXAMPLE 12, Steps A and B) butstarting with (S)-2-aminopropan-1-ol.B. (S)-Quinoxaline-5-sulfonic acid[5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide. The titlecompound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and (S)-3-methylmorpholine and purified as described in EXAMPLE 1, StepK. MS (ESI): mass calculated for C₂₀H₁₉₁N₄O₄S, 538.0; m/z found, 537[M−H]⁻. HPLC (reverse phase): R_(T)=8.52 min. ¹H NMR (400 MHz, CDCl₃,rotameric broadening): 9.05 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H),8.95 (br s, 1H), 8.55 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz,1H), 7.92 (dd, J=8.4, 7.4 Hz, 1H), 7.90 (br s, 1H), 7.37 (dd, J=8.0, 1.6Hz, 1H), 6.78 (d, J=8.0 Hz, 1H), 4.30 (br m, 1H), 3.90-3.82 (m, 1H),3.67-3.61 (m, 1H), 3.48 (dd, J=11.5, 2.7 Hz, 1H), 3.35-3.20 (m, 2H),1.30-1.20 (br m, 3H), 1.0-0.9 (m, 1H).

EXAMPLE 24

Quinoxaline-5-sulfonic acid[5-bromo-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.

A. 7-Fluoro-2,3,4,5-tetrahydro-benzo[c]azepin-1-one. A suspension of6-fluorotetralone (0.60 g, 3.6 mmol) in concentrated HCl at 0° C. wastreated with NaN₃ (260 mg, 4.0 mmol). The reaction was stirred 30 min at0° C. then was allowed to warm to room temperature and was stirred for14 h. The reaction mixture was poured over crushed ice, and theresulting mixture was made basic by the addition of 5 M NaOH, and wasextracted with DCM (3×). The combined organic extracts were dried(Na₂SO₄) and concentrated. The residue was purified by flashchromatography (EtOAc/hexanes) to provide 0.38 g (59%) of the titleamide as a tan solid. ¹H NMR (400 MHz, CDCl₃): 7.72 (dd, J=8.5, 5.9 Hz,1H), 7.02 (ddd, J=8.4, 8.4, 2.6 Hz, 1H), 6.91 (dd, J=9.2, 2.6 Hz, 1H),6.25 (br s, 1H), 3.14 (q, J=6.5 Hz, 2H), 2.86 (t, J=7.1 Hz, 2H),2.09-1.98 (m, 2H).

B. 7-Fluoro-2,3,4,5-tetrahydro-1H-benzo[c]azepine. To a suspension oflithium aluminum hydride (280 mg, 7.4 mmol) in THF (10 mL) at roomtemperature was added a solution of7-fluoro-2,3,4,5-tetrahydrobenzo[c]azepin-1-one (0.38 g, 2.1 mmol) inTHF (10 mL) dropwise via syringe. The syringe was rinsed with anadditional 5 mL of THF that was added to the reaction mixture. Thereaction mixture was heated at reflux for 5 h, cooled to roomtemperature, and quenched by the addition of H₂O (0.3 mL) followed by15% aq. NaOH (0.3 mL). After 5 min, H₂O (0.9 mL) was added, and themixture was stirred rapidly for 30 min resulting in precipitation ofaluminum salts. The mixture was filtered and washed with THF.Concentration in vacuo provided the desired azepine (340 mg, 98%) as ayellow oil. ¹H NMR (400 MHz, CDCl₃): 7.06 (dd, J=8.2, 5.8 Hz, 1H), 6.86(dd, J=9.5, 2.6 Hz, 1H), 6.77 (ddd, J=8.4, 8.4, 2.7 Hz, 1H), 3.9 (s,2H), 3.20 (t, J=5.2 Hz, 2H), 2.95-2.88 (m, 2H), 1.78-1.66 (m, 2H), 1.33(br s, 1H).

C. Quinoxaline-5-sulfonic acid[5-bromo-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 7-fluoro-2,3,4,5-tetrahydro-1H-benzo[c]azepine and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculatedC₂₅H₂₀BrFN₄O₃S, 554.0; m/z found, 553/555 [M−H]⁻. HPLC (reverse phase):R_(T)=9.73 min. ¹H NMR (400 MHz, CDCl₃, rotameric broadening): 9.06-9.01(m, 1H), 8.98-8.94 (m, 1H), 8.85-8.78 (m, 1H), 8.54-8.47 (m, 1H), 8.35(dd, J=8.5, 1.3 Hz, 1H), 7.90-7.84 (m, 1H), 7.84 (d, J=1.8 Hz, 1H),7.38-7.31 (m, 1H), 7.10 (dd, J=8.1, 1.7 Hz, 1H), 6.92-6.80 (m, 1.5H),6.78-6.68 (m, 1H), 6.64-6.60 (m, 0.25H), 6.39-6.33 (m, 0.25H), 4.42-4.31(m, 2H), 3.93-3.90 (m, 1H), 3.70-3.55 (m, 1H), 3.15-3.07 (m, 1H),2.90-2.82 (m, 2H), 1.87-1.78 (m, 0.5H), 1.58-1.49 (m, 0.5H).

EXAMPLE 25

(R,S)-Quinoxaline-5-sulfonic acid[2-(3,5-dimethylmorpholine-4-carbonyl)-5-iodophenyl]-amide.A. (S,S)-3,5-Dimethylmorpholine-4-carboxylic acid tert-butyl ester and(S,R)-meso-3,5-Dimethylmorpholine-4-carboxylic acid tert-butyl ester. Amixture of (S)-2-aminopropan-1-ol (8.5 g, 110 mmol), hydroxyacetone(10.9 g, 147 mmol), and PtO₂ (0.10 g, 0.44 mmol) was combined withmethanol (200 mL) in a 1 L Parr bottle. The reaction vessel was placedon a Parr shaker for 14 h under an atmosphere of 30 psi of hydrogen. Thecatalyst was removed by filtration through a pad of diatomaceous earth,rinsing with excess methanol. The filtrate was concentrated in vacuo toprovide a mixture of diastereomeric aminodiols as a viscous yellowliquid [7:5 (S,S):(S,R) based on crude ¹H NMR]. The crude diol mixture(5.0 g, 37.5 mmol) was stirred in a 150 mL thick-walled sealablereaction vessel as 40 mL concentrated H₂SO₄ was added slowly(significant exotherm observed). The vessel was sealed and heated at140° C. for 7 h. The dark brown mixture was poured into 100 mL crushedice, and the flask was rinsed into the reaction mixture with 50 mL ofH₂O. The resulting mixture was cooled in an ice bath and made basic bythe slow addition of 10 N NaOH. The aqueous mixture was extracted withdiethyl ether (3×300 mL). Salts began to precipitate from the aqueouslayer. The aqueous layer was filtered through a sintered glass funnel,and the precipitated salts were washed with H₂O (100 mL). The aqueousfiltrate was further extracted with diethyl ether (6×200 mL). Thecombined organic layers were dried (MgSO₄) and concentrated in vacuo togive a mixture of cis- and trans-dimethylmorpholines as an orange liquid(1.8 g, 41%). To a mixture of the unpurified dimethylmorpholine isomers(1.8 g, 16 mmol), NaOH (1.2 g, 30 mmol), and H₂O (7 mL) was addeddi-tert-butyl-dicarbonate (3.2 g, 15 mmol) in one portion at roomtemperature. The mixture was stirred overnight, then was poured into H₂O(30 mL) and extracted with diethyl ether (3×30 mL). The combined organiclayers were dried (MgSO₄) and concentrated in vacuo to give the mixtureof Boc-protected morpholines as an orange liquid. The diastereomers wereseparated by flash chromatography (EtOAc/petroleum ether) to provide(S,S)-3,5-dimethylmorpholine-4-carboxylic acid tert-butyl ester (2.0 g,59%). TLC (10% EtOAc/petroleum ether): R_(f)=0.41. ¹H NMR (500 MHz,CDCl₃): 3.85-3.78 (m, 4H), 3.49-3.43 (m, 2H), 1.47 (s, 9H), 1.29 (d,J=6.4 Hz, 6H). In addition,(S,R)-meso-3,5-dimethylmorpholine-4-carboxylic acid tert-butyl ester(0.90 g, 27%) was obtained. TLC (10% EtOAc/petroleum ether): R_(f)=0.33.¹H NMR (500 MHz, CDCl₃): 3.93 (dq, J=7.0, 3.9 Hz, 2H), 3.70 (d, J=11.5Hz, 2H), 3.55 (dd, J=11.5, 3.9 Hz, 2H), 1.47 (s, 9H), 1.30 (d, J=7.0 Hz,6H).B. (S,S)-3,5-Dimethylmorpholine. Hydrogen chloride gas was bubbled intoa stirred solution of. (S,S)-3,5-dimethylmorpholine-4-carboxylic acidtert-butyl ester (2.0 g, 9.2 mmol) in methanol (20 mL) at 0° C. over a10 min period. The reaction was allowed to stir for 20 min at 0° C. thenfor 5 h at room temperature. The methanol was removed in vacuo, and theresidue was partitioned between diethyl ether and 2 N NaOH. The layerswere separated, and the aqueous layer was extracted with diethyl ether(4×). The combined organic layers were dried (MgSO₄) and concentrated invacuo to give the title morpholine as a yellow oil (0.64 g, 61%). ¹H NMR(500 MHz, CDCl₃): 3.70 (dd, J=11.0, 3.1 Hz, 2H), 3.31 (dd, J=11.0, 5.7Hz, 2H), 3.20-3.12 (m, 2H), 1.47 (br s, 1H), 1.12 (d, J=6.7 Hz, 6H).C. (S,R)-meso-3,5-Dimethylmorpholine. Hydrogen chloride gas was bubbledinto a stirred solution of(S,R)-meso-3,5-dimethylmorpholine-4-carboxylic acid tert-butyl ester(0.90 g, 4.2 mmol) in methanol (20 mL) at 0° C. over a 10 min period.The reaction was allowed to stir for 20 min at 0° C. then for 5 h atroom temperature. The methanol was removed in vacuo, and the residue waspartitioned between diethyl ether and 2 N NaOH. The layers wereseparated, and the aqueous layer was extracted with diethyl ether (4×).The combined organic layers were dried (MgSO₄) and concentrated in vacuoto give the title morpholine as a yellow oil. ¹H NMR (500 MHz, CDCl₃):3.78-3.68 (m, 2H), 3.02-2.92 (m, 4H), 1.50 (br s, 1H), 0.97 (d, J=7.5Hz, 6H).D. (R,S)-Quinoxaline-5-sulfonic acid[2-(3,5-dimethylmorpholine-4-carbonyl)-5-iodophenyl]-amide. A suspensionof 4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, StepD; 0.050 g, 0.14 mmol) was heated at reflux in thionyl chloride (5 mL)for 30 min. The reaction became homogeneous. The thionyl chloride wasremoved in vacuo, and the residue was re-concentrated from toluene (3×)to remove residual thionyl chloride. The acid chloride was obtained asan off-white solid. The acid chloride was stirred in toluene (5 mL) at90° C. with (S,R)-meso-3,5-dimethylmorpholine (50 mg, 0.43 mmol) for 1h. The reaction mixture was poured into 1 N HCl and extracted with DCM(3×). The combined organic layers were dried (Na₂SO₄) and concentrated.The residue was purified by flash chromatography (EtOAc/hexanes) toprovide 32 mg (50%) of the desired amide as a solid. MS (ESI): masscalculated for C₂₁H₂₁IN₄O₄S, 552.0; m/z found, 551 [M−H]⁻. HPLC (reversephase): R_(T) 8.77 min. ¹H NMR (400 MHz, CDCl₃, rotameric broadening):9.04 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.58 (br s, 1H), 8.56(dd, J=7.0, 1.5 Hz, 1H), 8.38 (dd, J=8.4, 1.4 Hz, 1H), 7.93 (dd, J=8.4,7.4 Hz, 1H), 7.81 (d, J=1.4 Hz, 1H), 7.38 (dd, J=8.0, 1.6 Hz, 1H), 6.84(d, J=8.0 Hz, 1H), 4.15-4.02 (br m, 2H), 3.74 (d, J=11.6 Hz, 2H), 3.56(dd, J=11.5, 3.6 Hz, 2H), 1.34 (d, J=7.0 Hz, 6H).

EXAMPLE 26

Quinoxaline-5-sulfonic acid[2-(4-hydroxy-piperidine-1-carbonyl)-5-iodo-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 4, Step D)and 4-hydroxypiperidine and purified as described in EXAMPLE 1, Step K.MS (ESI): mass calculated for C₂₀H₁₉IN₄O₄S, 538.0; m/z found, 539 [M+H].HPLC (reverse phase): R_(T)=7.77 min. ¹H NMR (400 MHz, CDCl₃, rotamericbroadening): 9.07 (d, J=1.8 Hz, 1H), 9.02 (d, J=1.8 Hz, 1H), 8.90 (br s,1H), 8.50 (dd, J=7.0, 1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.95(d, J=1.5 Hz, 1H), 7.89 (dd, J=8.4, 7.4 Hz, 1H), 7.39 (dd, J=8.0, 1.6Hz, 1H), 6.77 (d, J=8.0 Hz, 1H), 3.94-3.90 (m, 1H), 3.80-3.75 (m, 1H),3.2-2.8 (m, 3H), 2.05-2.01 (m, 2H), 1.7-1.3 (m, 3H).

EXAMPLE 27

meso-Quinoxaline-5-sulfonic acid[2-(3,5-dimethylmorpholine-4-carbonyl)-5-bromophenyl]-amide.

The title compound was prepared and purified as described in EXAMPLE 25,Step D from (S,R)-meso-3,5-dimethylmorpholine and4-bromo-2-(quinoxaline-5-sulfonylamino)-benzoic acid (EXAMPLE 1, StepG). MS (ESI): mass calculated for C₂₁H₂₁BrN₄O₄S, 504.0; m/z found,503/505 [M−H]⁻. HPLC (reverse phase): R_(T)=8.67 min. ¹H NMR (400 MHz,CDCl₃, rotameric broadening): 9.04 (d, J=1.8 Hz, 1H), 9.00 (d, J=1.8 Hz,1H), 8.64 (br s, 1H), 8.56 (dd, J=7.0, 1.5 Hz, 1H), 8.38 (dd, J=8.4, 1.4Hz, 1H), 7.92 (dd, J=8.4, 7.4 Hz, 1H), 7.63 (d, J=1.7 Hz, 1H), 7.18 (dd,J=8.1, 1.8 Hz, 1H), 6.99 (d, J=8.1 Hz, 1H), 4.18-4.02 (br m, 2H),3.76-3.73 (m, 2H), 3.58 (dd, J=11.7, 3.6 Hz, 2H), 1.35 (d, J=7.0 Hz,6H).

EXAMPLE 28

(S)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of 4bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and (S)-3-methylmorpholine (EXAMPLE 23, Step A) and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₀H₁₉BrN₄O₄S, 490.0; m/z found, 489/491 [M−H]⁻. HPLC (reverse phase):R_(T)=8.36 min. ¹H NMR (400 MHz, CDCl₃, rotameric broadening): 9.05 (d,J=1.8 Hz, 1H), 9.01 (br s, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.56 (dd, J=7.0,1.5 Hz, 1H), 8.37 (dd, J=8.4, 1.4 Hz, 1H), 7.91 (dd, J=8.4, 7.4 Hz, 1H),7.72 (d, J=1.4 Hz, 1H), 7.16 (dd, J=8.0, 1.6 Hz, 1H), 6.94 (d, J=8.0 Hz,1H), 4.30 (br m, 1H), 3.91-3.82 (m, 1H), 3.68-3.63 (m, 1H), 3.50 (dd,J=11.5, 2.7 Hz, 1H), 3.38-3.22 (m, 2H), 1.35-1.15 (br m, 3H), 1.0-0.9(m, 1H).

EXAMPLE 29

(S)-4-Chloro-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. S—(R)-2-Methylpropane-2-sulfinic acid 2,4-difluorobenzylideneamide. Asuspension of 2,4-difluorobenzaldehyde (0.61 g, 4.3 mmol),(S)-tert-butanesulfinamide (0.47 g, 3.9 mmol), and powdered anhydrousCUSO₄ (1.2 g, 7.8 mmol) was stirred in DCM (8 mL) overnight. Thereaction mixture was filtered, and the filter cake was washed with DCM.The filtrate was concentrated in vacuo to give the crude. N-sulfinylimine as a viscous yellow oil. Purification by flash chromatography(EtOAc/hexanes) provided 0.81 g (84%) of the N-sulfinyl imine as a paleyellow viscous oil. ¹H NMR (400 MHz, CDCl₃): 8.83 (s, 1H), 8.05-7.99 (m,1H), 7.01-6.96 (m, 1H), 6.94-6.87 (m, 1H), 1.27 (s, 9H).B. S-(R)-2-Methylpropane-2-sulfinic acid[1-(S)-(2,4-difluorophenyl)-2,2,2-trifluoroethyl]-amide. To a solutionof S-(R)-2-methylpropane-2-sulfinic acid 2,4-difluorobenzylideneamide(0.32 g, 1.3 mmol) and tetrabutylammonium difluorotriphenylsilicate(TBAT, 770 mg, 1.4 mmol) in THF (20 mL) at −55° C. was added a solutionof trifluoromethyl trimethylsilane (222 mg, 1.56 mmol) in THF (5 mL).The reaction was allowed to stir for 1 h at −55° C., and then wasallowed to warm slowly to room temperature overnight. The reaction wasquenched with 20 mL satd. aq. NH₄Cl and extracted with 3×20 mL EtOAc.The combined organic layers were dried (MgSO₄) and concentrated invacuo. The crude residue was purified by flash chromatography(EtOAc/hexanes) to provide recovered starting N-sulfinyl imine (166 mg,52%) and the desired trifluoromethylated adduct as a colorless liquid(126 mg, 31%, 90% de). Major diastereomer: ¹H NMR (500 MHz, CDCl₃):7.41-7.35 (m, 1H), 6.98-6.93 (m, 1H), 6.93-6.87 (m, 1H), 5.12-5.05 (m,1H), 3.86 (brd, J=7.9 Hz, 1H), 1.26 (s, 9H).C. (S)-1-(2,4-Difluorophenyl)-2,2,2-trifluoroethylamine hydrochloride.To a stirred solution of the above sulfinamide (90% de, 0.13 g, 0.40mmol) in methanol (10 mL) at room temperature was added 2 mL of a satd.solution of HCl (g) in methanol. The reaction mixture was allowed tostir for 2 h at room temperature. The mixture was concentrated in vacuountil the amine hydrochloride salt began to precipitate, and thendiethyl ether (20 mL) was added to fully precipitate the salt. Thehydrochloride salt was collected by suction filtration, washed withdiethyl ether, and dried in vacuo to provide fine white crystals (62 mg,63%, 90% ee based on the de of the starting material). ¹H NMR (500 MHz,CD₃OD): 7.70-7.63 (m, 1H), 7.28-7.19 (m, 2H), 5.59 (q, J=7.3 Hz, 1H).D.(S)-4-Chloro-N-[1-(2,4-difluorophenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and (S)-1-(2,4-difluorophenyl)-2,2,2-trifluoroethylamine hydrochlorideand purified as described in EXAMPLE 1, Step K. MS (ESI): masscalculated for C₂₃H₁₄ClF₅N₄O₃S, 556.0; m/z found, 555/557 [M−H]⁻. HPLC(reverse phase): R_(T)=9.98 min. ¹H NMR (400 MHz, CDCl₃): 11.07 (s, 1H),8.84-8.83 (m, 2H), 8.56 (dd, J=7.4, 1.4 Hz, 1H), 8.31 (dd, J=7.4, 1.4Hz, 1H), 7.87 (dd, J=8.4, 7.4 Hz, 1H), 7.81 (d, J=2.0 Hz, 1H), 7.43-7.37(m, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.03-6.93 (m, 3H), 6.81-6.79 (m, 1H),6.08-6.00 (m, 1H).

EXAMPLE 30

(S)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and. (S)-1-(2,4-difluorophenyl)-2,2,2-trifluoroethylamine hydrochloride(EXAMPLE 29, Step C) and purified as described in EXAMPLE 1, Step K. MS(ESI): mass calculated for C₂₃H₁₄BrF₅N₄O₃S, 600.0; m/z found, 599/601[M−H]⁻. HPLC (reverse phase): R_(T)=10.06 min. ¹H NMR (400 MHz, CDCl₃):11.02 (s, 1H), 8.84-8.83 (m, 2H), 8.56 (dd, J=7.4, 1.4 Hz, 1H), 8.31(dd, J=7.4, 1.4 Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.87 (dd, J=8.4, 7.4Hz, 1H), 7.43-7.37 (m, 1H), 7.22 (d, J=8.5 Hz, 1H), 7.13 (dd, J=8.5, 1.8Hz, 1H), 7.03-6.93 (m, 2H), 6.82-6.80 (m, 1H), 6.06-5.99 (m, 1H).

EXAMPLE 31

Quinoxaline-5-sulfonic acid[2-(4-hydroxy-piperidine-1-carbonyl)-5-bromo-phenyl]-amide.

The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 4-hydroxypiperidine and purified as described in EXAMPLE 1, Step K.MS (ESI): mass calculated for C₂₀H₁₉BrN₄O₄S, 490.0; m/z found, 491/493[M+H]⁺, 513/515 [M+Na]⁺. HPLC (reverse phase): R_(T)=7.68 min. ¹H NMR(400 MHz, CDCl₃, rotameric broadening): 9.08 (d, J=1.8 Hz, 1H), 9.02 (d,J=1.8 Hz, 1H), 8.95 (br s, 1H), 8.52-8.50 (m, 1H), 8.38-8.36 (m, 1H),7.92-7.88 (m, 1H), 7.75 (d, J=1.6 Hz, 0.7H), 7.68 (d, J=1.6 Hz, 0.3H),7.20-7.17 (m, 1H), 6.96-6.92 (m, 1H), 3.96-3.91 (m, 1H), 3.85-3.75 (m,1H), 3.2-2.8 (m, 3H), 2.05-1.95 (m, 2H), 1.7-1.3 (m, 3H).

EXAMPLE 32

Quinoxaline-5-sulfonic acid[5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide. The title compound wasprepared and purified by the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and piperidine as described by the general procedure in EXAMPLE 1, StepK. MS (ESI): mass calculated for C₂₀H₁₉BrN₄O₃S, 474.0; m/z found,475/477 [M+H]⁺, 497/499 [M+Na]⁺. HPLC (reverse phase): R_(T)=9.19 min.¹H NMR (500 MHz, CDCl₃, rotameric broadening): 9.07 (d, J=1.8 Hz, 1H),9.05 (br s, 1H), 9.00 (d, J=1.8 Hz, 1H), 8.49 (dd, J=7.0, 1.5 Hz, 1H),8.34 (dd, J=8.4, 1.4 Hz, 1H), 7.87 (dd, J=8.4, 7.4 Hz, 1H), 7.84 (d,J=1.5 Hz, 1H), 7.15 (dd, J=8.0, 1.6 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H),3.40-3.20 (br m, 2H), 2.92-2.80 (br m, 2H), 1.55-1.25 (br m, 6H).

EXAMPLE 33

(R)-4-Bromo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared and purified by the HATU-mediatedcoupling of 4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE1, Step G) and (R)-N-methyl(1-phenylethyl)amine as described by thegeneral procedure in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₄H₂₁BrN₄O₃S, 524.0; m/z found, 523/525 [M−H]⁻. HPLC (reverse phase):R_(T)=9.75 min. ¹H NMR (500 MHz, CDCl₃, mixture of rotamers): 9.07-8.94(m, 3H), 8.59 (br d, J=7.3 Hz, 1H), 8.37 (br d, J=8.4 Hz, 1H), 7.93 (m1H), 7.77-7.68 (m, 1H), 7.42-7.35 (m, 3H), 7.33-7.30 (m, 1H), 7.13-7.10(m, 1H), 7.00-6.98 (m, 1H), 6.15-6.05 (m, 0.5H), 5.05-4.90 (m, 0.5H),3.0-2.5 (m, 3H), 1.6-1.5 (m, 3H), (one H not observed).

EXAMPLE 34

(R)-4-Iodo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared and purified by the HATU-mediatedcoupling of 4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE4, Step D) and (R)-N-methyl(1-phenylethyl)amine as described by thegeneral procedure in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₄H₂₁IN₄O₃S, 572.0; m/z found, 571 [M−H]⁻. HPLC (reverse phase):R_(T)=9.81 min. ¹H NMR (500 MHz, CDCl₃, mixture of rotamers): 9.08-8.98(m, 2H), 9.00-8.92 (m, 1H), 8.62-8.58 (m, 1H), 8.40-8.32 (m, 1H),7.98-7.90 (m, 2H), 7.42-7.35 (m, 3H), 7.35-7.27 (m, 2H), 6.87-6.80 (m,1H), 6.15-6.05 (m, 0.5H), 5.02-4.92 (m, 0.5H), 3.0-2.5 (m, 3H), 1.6-1.5(m, 3H), (one H not observed).

EXAMPLE 35

N-(4-Fluorobenzyl)-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide.

The title compound was prepared and purified by the HATU-mediatedcoupling of 4-iodo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE4, Step D) and N-methyl-4-fluorobenzylamine as described by the generalprocedure in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₃H₁₈FlN₄O₃S, 576.0; m/z found, 575 [M−H]⁻. HPLC (reverse phase):R_(T)=9.65 min. ¹H NMR (500 MHz, CDCl₃, 2:1 mixture of rotamers):9.0-8.9 (m, 3H), 8.58-8.51 (m, 1H), 8.39-8.37 (m, 1H), 7.96 (s, 1H),7.95-7.88 (m, 1H), 7.3-7.2 (m, 3H), 7.06-7.02 (m, 3H), 4.40-4.35 (m,1.3H), 4.22-4.14 (m, 0.7H), 2.85-2.79 (m, 1H), 2.52-2.46 (m, 2H).

EXAMPLE 36

(R)-N-[1-(2,4-Difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzamide.A. 2-Nitro-4-trifluoromethylbenzoic acid methyl ester. To a stirredsolution of 2-nitro-4-trifluoromethylbenzoic acid (4.3 g, 0.018 mol) inDMF (10 mL) was added DBU (5.4 mL, 0.036 mol) under a nitrogenatmosphere. The reaction mixture was stirred for 15 min after whichiodomethane (2.2 mL, 0.036 mol) was added at 0° C. The mixture waswarmed to room temperature and stirred overnight. The mixture wasdiluted with EtOAc (60 mL) and washed with H₂O (3×). The organic layerwas dried over MgSO₄, filtered, concentrated, and purified by flashchromatography (hexanes/EtOAc) to provide the title compound (4.30 g,96%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.55. ¹H NMR (500 MHz,CDCl₃): 8.22 (s, 1H), 7.96 (d, J=7.5 Hz, 1H), 7.88 (d, J=8.0 Hz, 1H),3.97 (s, 3H).B. 2-Amino-4-trifluoromethyl-benzoic acid methyl ester. A solution of2-nitro-4-trifluoromethylbenzoic acid methyl ester (4.3 g, 0.017 mol)was dissolved in a mixture of DCM (20 mL) and EtOAc (20 mL) followed byaddition of SnCl₂.2H₂O (19 g, 0.086 mol). The mixture was stirredovernight at room temperature, then was neutralized by shaking with asatd. aq. NaHCO₃ solution. The resulting salts were removed byfiltration through a pad of diatomaceous earth. The filtrate wasextracted with DCM (3×). The combined organic layers were dried overMgSO₄, filtered, and concentrated in vacuo to provide the title compound(3.38 g, 91%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.60. HPLC(reverse phase): R_(T)=9.31 min. ¹H NMR (500 MHz, CDCl₃): 7.95 (d, J=8.3Hz, 1H), 6.90 (s, 1H), 6.84 (d, J=9.3 Hz, 1H), 5.91 (br s, 2H), 3.90 (s,3H).C. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoicacid methyl ester. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (1.77 g, 7.52mmol) was added to a solution of 2-amino-4-trifluoromethylbenzoic acidmethyl ester (1.50 g, 6.84 mmol) and pyridine (1.10 mL, 13.7 mmol) inDCM (10 mL). After standing overnight at room temperature, the reactionmixture was quenched with 1 N HCl and diluted with H₂O. The aqueouslayer was extracted with DCM (3×). The combined organic layers weredried over MgSO₄, filtered, concentrated, and purified by flashchromatography (hexanes/EtOAc) to provide the title compound (1.78 g,62%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.47. MS (ESI): masscalculated for C₁₅H₁₀F₃N₃O₄S₂, 417.01; m/z found, 415.9/416.9/417.9[M−H]⁻. HPLC (reverse phase): R_(T)=9.95 min. ¹H NMR (500 MHz, CDCl₃):11.33 (s, 1H), 8.41 (dd, J=7.1, 1.0 Hz, 1H), 8.23 (dd, J=8.9, 1.0 Hz,1H), 8.04 (s, 1H), 7.98 (d, J=8.2 Hz, 1H), 7.72 (dd, J=8.8, 7.1 Hz, 1H),7.20 (dd, J=8.3, 1.1 Hz, 1H), 3.96 (s, 3H).D. 2-(Quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzoic acid methylester. Zinc powder (2.00 g, 30.7 mmol) was added to a mixture of2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethylbenzoicacid methyl ester (1.28 g, 3.07 mmol) and AcOH (20 mL), and theresulting mixture was heated at 50° C. for 2 h with vigorous stirring.The mixture was filtered through a pad of diatomaceous earth, rinsedwith methanol, and concentrated to a yellow solid. This material wasdissolved in methanol (15 mL) and added to a mixture of glyoxal sodiumbisulfite adduct (2.46 g, 9.24 mmol), AcOH (0.9 mL), NaOAc (0.25 g, 3.98mmol), and H₂O (4.5 mL). The reaction mixture was heated at reflux for 3h, then was allowed to come to room temperature, diluted with DCM,filtered through a pad of diatomaceous earth, and rinsed with DCM. Thefiltrate was washed with H₂O, dried over MgSO₄, concentrated, andpurified by flash chromatography (hexanes/EtOAc) to provide titlecompound (0.70 g, 56%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.24. ¹HNMR (500 MHz, CDCl₃): 11.38 (s, 1H), 8.95 (dd, J=7.7, 1.8 Hz, 2H), 8.62.(dd, J=7.4, 1.4 Hz, 1H), 8.33 (dd, J=8.5, 1.3 Hz, 1H), 8.14 (s, 1H),7.95 (d, J=8.3 Hz, 1H), 7.88 (dd, J=8.4, 7.5 Hz, 1H), 7.17 (dd, J=8.3,1.2 Hz, 1H), 3.94 (s, 3H).E. 2-(Quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzoic acid. To astirred solution of2-(quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzoic acid methylester (0.86 g, 2.1 mmol) in THF (10 mL) and H₂O (5 mL) was addedLiOH.H₂O (0.44 g, 10.4 mmol). The reaction mixture was stirred at roomtemperature overnight. The solution was acidified to pH ˜2 withconcentrated HCl and diluted with H₂O. The aqueous layer was extractedwith DCM (3×). The combined organic layers were dried over MgSO₄,filtered, and concentrated in vacuo to provide the title compound (0.81g, 98%). MS (ESI): mass calculated for C₁₆H₁₀F₃N₃O₄S, 397.03; m/z found,396/397/398 [M−H]⁻. HPLC (reverse phase): R_(T)=8.76 min. ¹H NMR (400MHz, CDCl₃): 11.35 (s, 1H), 8.96 (dd, J=4.7, 1.8 Hz, 1H), 8.64 (dd,J=7.4, 1.4 Hz, 1H), 8.35 (dd, J=8.5, 1.3 Hz, 1H), 8.16 (s, 1H), 8.05 (d,J=8.3 Hz, 1H), 7.90 (dd, J=8.4, 7.4 Hz, 1H), 7.21 (dd, J=7.8, 1.0 Hz,1H).F.(R)-N-[1-(2,4-Difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethylbenzamide.To a solution of2-(quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzoic acid (0.028 g,0.071 mmol) in DMF (0.40 mL) at room temperature was added pyridine(0.017 mL, 0.21 mmol) followed by HATU (0.053 g, 0.14 mmol). Thereaction mixture was agitated for 1 h on a shaker.(R)-1-(2,4-Difluorophenyl)ethylamine hydrochoride (EXAMPLE 2, Method 1,Step C; 0.027 g, 0.14 mmol) was added followed by Hünig's base (0.024mL, 0.14 mmol). The reaction mixture was agitated for 2 h. TFA (0.10 mL)was added to quench the reaction. The mixture was diluted with DMF (1mL) and the product amide was obtained by purification of the entirereaction mixture by preparative reverse-phase chromatography. The titleamide was obtained as a solid (8 mg, 21%). MS (ESI): mass calculated forC₂₄H₁₇F₅N₄O₃S, 536.09; m/z found, 537/538/539 [M+H]⁺. HPLC (reversephase): R_(T)=9.81 min. ¹H NMR (400 MHz, CDCl₃): 11.18 (s, 1H), 8.85 (d,J=1.8 Hz, 1H), 8.81 (d, J=1.8 Hz, 1H), 8.56 (dd, J=7.4, 1.4 Hz, 1H),8.30 (dd, J=8.5, 1.4 Hz, 1H), 8.04 (s, 1H), 7.86 (dd, J=8.4, 7.4 Hz,1H), 7.42 (d, 7.42, 1H), 7.32-7.27 (m, 1H), 7.19 (dd, J=8.1, 1.1 Hz,1H), 6.91-6.82 (m, 2H), 6.43 (d, J=7.5 Hz, 1H), 5.36-5.29 (m, 1H), 1.55(d, J=7.0 Hz, 3H).

EXAMPLE 37

(R)-N-[1-(2,4-Dichlorophenyl)-ethyl]-4-fluoro-2-(quinoxaline-5-sulfonylamino)-benzamide.A. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluorobenzoic acidmethyl ester. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (1.40 g, 5.94mmol) was added to a solution of 2-amino-4-fluorobenzoic acid methylester (0.67 g, 4.0 mmol) and pyridine (0.64 mL, 7.9 mmol) in DCM. (5mL). After standing overnight at room temperature the reaction mixturewas quenched with 1 N HCl and diluted with H₂O. The aqueous layer wasextracted with DCM (3×). The combined organic layers were dried overMgSO₄, filtered, concentrated, and purified by silica gel chromatography(hexanes/EtOAc) to provide the title compound (1.26 g, 87%). TLC(silica, 50% EtOAc/hexanes): R_(f)=0.47. MS (ESI): mass calculated forC₁₄H₁₀FN₃O₄S₂, 367.01; m/z found, 366/367/368 [M−H]⁻. HPLC (reversephase): R_(T)=9.52 min. ¹H NMR (500 MHz, CDCl₃): 11.50 (s, 1H), 8.40(dd, J=7.1, 1.0 Hz, 1H), 8.23 (d, J=8.3 Hz, 1H), 7.89 (dd, J=8.9, 6.4Hz, 1H), 7.73 (dd, J=8.8, 7.1 Hz, 1H), 7.47 (dd, J=11.1, 2.5 Hz, 1H),6.67-6.63 (m, 1H), 3.92 (s, 3H).B. 4-Fluoro-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester.Zinc powder (2.24 g, 34.3 mmol) was added to a mixture of2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-fluorobenzoic acid methylester (1.26 g, 3.43 mmol) and AcOH (20 mL). The resulting mixture washeated to 50° C. for 2 h with vigorous stirring. The mixture wasfiltered through a pad of diatomaceous earth, rinsing with methanol, andwas concentrated to a yellow solid. This material was dissolved inmethanol (15 mL) and added to a mixture of glyoxal sodium bisulfiteadduct (2.72 g, 10.2 mmol), AcOH (0.9 mL), NaOAc (0.28 g, 3.42 mmol),and H₂O (4.5 mL). The reaction was allowed to proceed at reflux for 3 h.The resulting mixture was diluted with DCM and filtered through a pad ofdiatomaceous earth, rinsing with DCM. The filtrate was washed with H₂O,dried over MgSO₄, concentrated, and purified by flash chromatography(hexanes/EtOAc) to provide the title compound (0.18 g, 15%). TLC(silica, 50% EtOAc/hexanes): R_(f)=0.20. MS (ESI): mass calculated forC₁₆H₁₂FN₃O₄S, 361.05; m/z found, 360/361/362 [M−H]⁻. HPLC (reversephase): R_(T)=9.12 min. ¹H NMR (500 MHz, CDCl₃): 11.53 (s, 1H), 8.96(dd, J=16.6, 1.6 Hz, 2H), 8.61 (dd, J=7.4, 1.4 Hz, 1H), 8.33 (dd, J=8.5,1.4 Hz, 1H), 7.89-7.85 (m, 2H), 7.57 (dd, J=11.4, 2.5 Hz, 1H), 6.63-6.59(m, 1H), 3.90 (s, 3H).C. 4-Fluoro-2-(quinoxaline-5-sulfonylamino)benzoic acid. To a stirredsolution of 4-fluoro-2-(quinoxaline-5-sulfonylamino)benzoic acid methylester (0.18 g, 0.50 mmol) in THF (4 mL) and H₂O (2 mL) was addedLiOH.H₂O (0.10 g, 2.50 mmol). The reaction mixture was stirred at roomtemperature overnight. The solution was acidified to pH ˜2 withconcentrated HCl and diluted with H₂O. The aqueous layer was extractedwith DCM (3×). The combined organic layers were dried over MgSO₄,filtered, and concentrated in vacuo to provide the title compound (0.15g, 88%). MS (ESI): mass calculated for C₁₅H₁₀FN₃O₄S, 347.04; m/z found,346/347/348 [M−H]⁻. HPLC (reverse phase): R_(T)=8.23 min. ¹H NMR (400MHz, CD₃OD): 8.95 (dd, J=4.9, 1.8 Hz, 2H), 8.61 (dd, J=7.4, 1.3 Hz, 1H),8.33 (dd, J=8.5, 1.4 Hz, 1H), 7.96 (dd, J=8.5, 7.4 Hz, 1H), 7.89 (dd,J=8.9, 6.5 Hz, 1H), 7.45 (dd, J=11.4, 2.5 Hz), 6.70-6.64 (m, 1H).D.(R)-N-[1-(2,4-Dichlorophenyl)ethyl]-4-fluoro-2-(Quinoxaline-5-sulfonylamino)-benzamide.To a solution of 4-fluoro-2-(quinoxaline-5-sulfonylamino)benzoic acid(0.024 g, 0.070 mmol) in DMF (0.40 mL) at room temperature was addedpyridine (0.017 ml, 0.21 mmol) followed by HATU (0.053 g, 0.14 mmol).The reaction mixture was agitated for 1 h on a shaker.(R)-1-(2,4-Dichlorophenyl)ethylamine hydrochoride (EXAMPLE 1, Step J;0.032 g, 0.14 mmol) was added followed by Hünig's base (0.024 mL, 0.14mmol). The reaction mixture was agitated for 2 h. TFA (0.10 mL) wasadded to quench the reaction. The mixture was diluted with DMF (1 mL)and the product amide was obtained by purification of the resultingmixture by preparative reverse-phase chromatography. The title amide wasobtained as a solid (26 mg, 72%). MS (ESI): mass calculated forC₂₃H₁₇Cl₂FN₄O₃S, 518.0; m/z found, 519/521 [M+H]⁺; 541/543 [M+Na]⁺. HPLC(reverse phase): R_(T)=9.95 min. ¹H NMR (400 MHz, CDCl₃): 11.58 (s, 1H),8.84 (d, J=1.8 Hz, 1H), 8.73 (d, J=1.8 Hz, 1H), 8.54 (dd, J=7.4, 1.4 Hz,1H), 8.30 (dd, J=8.5, 1.4 Hz, 1H), 7.85 (dd, J=8.5, 7.4 Hz, 1H), 7.52(dd, J=11.2, 2.5 Hz, 1H), 7.44 (t, J=1.2 Hz, 1H), 7.34 (dd, J=22.7, 2.7Hz, 1H), 7.23 (d, J=1.2 Hz, 2H), 6.64 (dd, J=2.6, 1.2 Hz, 1H), 6.47-6.44(m, 1H), 5.44-5.39 (m, 1H), 1.53 (d, J=7.0 Hz, 3H).

EXAMPLE 38

(R)-4-Cyano-N-[1-(2,4-difluoro-phenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide.A. 4-Methyl-3-nitrobenzonitrile. Nitric acid (20 mL) was added dropwiseto a 0° C. mixture of 4-tolunitrile (11 g, 0.098 mol) in H₂SO₄ (20 mL)over 1 h. The reaction mixture was stirred at 0° C. for a further hour,then was poured onto crushed ice. The resulting precipitate wascollected by filtration, providing the title compound as a white solid(15.2 g, 95%). ¹H NMR (500 MHz, CDCl₃): 8.27 (d, J=1.6 Hz, 1H), 7.78(dd, J=8.0, 1.7 Hz, 1H), 7.51 (d, J=8.0 Hz, 1H), 2.69 (s, 3H).B. 4-Cyano-2-nitrobenzoic acid. To a 0° C. solution of4-methyl-3-nitrobenzonitrile (5.0 g, 0.031 mol) in H₂SO₄ (83 mL) wasadded dropwise over 2 h a mixture of Na₂Cr₂O₇ (14 g, 0.047 mol) andH₂SO₄ (15 mL). The reaction mixture was allowed to warm to roomtemperature with stirring over 48 h. The resulting green mixture waspoured onto crushed ice, and the precipitate was collected byfiltration. The filtered solids were dissolved in 5% aq. Na₂CO₃ (60 mL)and the residual solids were removed by filtration. The filtrate wastreated with dilute HCl and the resulting precipitate was collected byfiltration and dried in air to provide the title compound as a whitesolid (2.7 g, 46%). ¹H NMR (500 MHz, CD₃OD): 8.39 (d, J=1.3 Hz, 1H),8.12 (dd, J=8.0, 1.3 Hz, 1H), 8.00 (d, J=8.0, 1H).C. 4-Cyano-2-nitro-benzoic acid methyl ester. To a stirred solution of4-cyano-2-nitrobenzoic acid (2.7 g, 0.014 mol) in DMF (10 mL) was addedDBU (3.9 mL, 0.028 mol). The reaction mixture was stirred for 15 minafter which iodomethane (1.8 mL, 0.028 mol) was added at 0° C. Themixture was warmed to room temperature and stirred overnight. Themixture was diluted with EtOAc and washed with H₂O (3×). The organiclayer was dried over MgSO₄, filtered, concentrated, and purified byflash chromatography (hexanes/EtOAc) to provide the title compound (2.63g, 91%). HPLC (reverse phase): R_(T)=8.26 min. ¹H NMR (400 MHz, CDCl₃):8.24 (d, J=1.4 Hz, 1H), 7.97 (dd, J=8.0, 1.5 Hz, 1H), 7.87 (d, J=7.8 Hz,1H), 3.97 (s, 3H).D. 2-Amino-4-cyano-benzoic acid methyl ester. A solution of4-cyano-2-nitro-benzoic acid methyl ester (2.41 g, 0.012 mol) wasdissolved in a mixture of DCM (15 mL) and EtOAc (15 mL) followed by theaddition of SnCl₂.2H₂O (11 g, 0.047 mol). The mixture was stirredovernight at room temperature, then was neutralized by shaking with anaq. NaHCO₃ solution. The resulting salts were removed by filtrationthrough a pad of diatomaceous earth. The filtrate was extracted with DCM(3×). The combined organic layers were dried over MgSO₄, filtered, andconcentrated in vacuo to provide the title compound (1.95 g, 95%). TLC(silica, 50% EtOAc/hexanes): R_(f)=0.55. MS (ESI): mass calculated forC₉H₈N₂O₂, 176.06; m/z found, 175.1 [M−H]⁻. HPLC (reverse phase):R_(T)=8.19 min. ¹H NMR (400 MHz, CDCl₃): 7.93 (d, J=8.2 Hz, 1H), 6.94(d, J=1.4 Hz, 1H), 6.87 (dd, J=8.2, 1.6 Hz, 1H), 5.93 (s, 2H), 3.90 (s,3H).E. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-cyanobenzoic acidmethyl ester. 4-Chlorosulfonyl-2,1,3-benzothiadiazole (1.99 g, 8.51mmol) was added to a solution of 2-amino-4-cyanobenzoic acid methylester (1.00 g, 5.68 mmol) and pyridine (0.92 mL, 11 mmol) in DCM (10mL). After standing overnight at room temperature the reaction mixturewas acidified with 1 N HCl and diluted with H₂O. The aqueous layer wasextracted with DCM (3×). The combined organic layers were dried overMgSO₄, filtered, concentrated, and purified by flash chromatography(hexanes/EtOAc) to provide the title compound (1.25 g, 59%). TLC(silica, 50% EtOAc/hexanes): R_(f)=0.40. MS (ESI): mass calculated forC₁₅H₁₀N₄O₄S₂, 374.0; m/z found, 373 [M−H]⁻. HPLC (reverse phase):R_(T)=9.11 min. ¹H NMR (500 MHz, CDCl₃): 11.35 (s, 1H), 8.43 (dd, J=7.1,1.0 Hz, 1H), 8.26 (dd, J=8.8, 1.0 Hz, 1H), 8.06 (d, J=1.5 Hz, 1H), 7.98(d, J=8.2 Hz, 1H), 7.76 (dd, J=8.8, 7.1 Hz, 1H), 7.23 (dd, J=8.2, 1.5Hz, 1H), 3.97 (s, 3H).F. 4-Cyano-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester.Zinc powder (2.18 g, 33.4 mmol) was added to a mixture of2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-cyano-benzoic acid methylester (1.25 g, 3.34 mmol) and ACOH (20 mL), and the resulting mixturewas heated at 50° C. for 2 h with vigorous stirring. The mixture wasfiltered through a pad of diatomaceous earth, rinsed with methanol, andconcentrated to a yellow solid. This material was dissolved in methanol(15 mL) and added to a mixture of glyoxal sodium bisulfite adduct (2.70g, 10.0 mmol), AcOH (0.9 mL), NaOAc (0.27 g, 3.3 mmol), and H₂O (4.5mL). The reaction was allowed to proceed at reflux for 3 h. Theresulting mixture was diluted with DCM and filtered through a pad ofdiatomaceous earth, rinsing with DCM. The filtrate was washed with H₂O,dried over MgSO₄, concentrated, and purified by flash chromatography(hexanes/EtOAc) to provide the title compound (0.28 g, 23%). TLC(silica, 50% EtOAc/hexanes): R_(f)=0.13. MS (ESI): mass calculated forC₁₇H₁₂N₄O₄S, 368.1; m/z found, 367 [M−H]⁻. HPLC (reverse phase):R_(T)=8.72 min. ¹H NMR (400 MHz, CDCl₃): 11.42 (s, 1H), 8.96 (dd, J=4.4,1.8 Hz, 2H), 8.63 (dd, J=7.4, 1.4 Hz, 1H), 8.36 (dd, J=8.5, 1.4 Hz, 1H),8.16 (d, J=1.4 Hz, 1H), 7.97-7.90 (m, 2H), 7.20 (dd, J=8.2, 1.5 Hz, 1H),3.94 (s, 3H).G. 4-Cyano-2-(quinoxaline-5-sulfonylamino)benzoic acid. To a stirredsolution of 4-cyano-2-(quinoxaline-5-sulfonylamino)benzoic acid methylester (0.28 g, 0.76 mmol) in THF (5 mL) and H₂O (2.5 mL) was addedLiOH.H₂O (0.16 g, 3.8 mmol). The reaction mixture was stirred at roomtemperature overnight. The solution was acidified to pH ˜2 withconcentrated HCl and diluted with H₂O. The aqueous layer was extractedwith DCM (3×). The combined organic layers were dried over MgSO₄,filtered, and concentrated in vacuo to provide the title compound (0.21g, 81%). MS (ESI): mass calculated for C₁₆H₁₀N₄O₄S, 354.0; m/z found,353 [M−H]⁻. HPLC (reverse phase): R_(T)=7.91 min. ¹H NMR (400 MHz,CD₃OD): 8.94 (dd, J=10.7, 1.8 Hz, 2H), 8.64 (dd, J=7.4, 1.3 Hz, 1H),8.34 (dd, J=8.5, 1.3 Hz, 1H), 8.03 (d, J=1.4 Hz, 1H), 7.97 (t, J=7.3 Hz,2H), 7.28 (dd, J=8.2, 1.5 Hz, 1H).H.(R)-4-Cyano-N-[1-(2,4-difluorophenyl)ethyl]-2-(Quinoxaline-5-sulfonylamino)-benzamide.To a solution of 4-cyano-2-(quinoxaline-5-sulfonylamino)-benzoic acid(0.025 g, 0.071 mmol) in DMF (0.40 mL) at room temperature was addedpyridine (0.017 ml, 0.21 mmol) and HATU (0.053 g, 0.14 mmol). Thereaction mixture was agitated for 1 h on a shaker.(R)-1-(2,4-Difluorophenyl)-ethylamine hydrochoride (EXAMPLE 2, Method 1,Step C; 0.027 g, 0.14 mmol) was added followed by Hünig's base (0.024mL, 0.14 mmol). The reaction mixture was agitated for 2 h. TFA (0.10 mL)was added to quench the reaction. The mixture was diluted with DMF (1mL) and the product was obtained by purification of the entire reactionmixture by preparative reverse-phase chromatography. The title amide wasobtained as a solid (10 mg, 29%). MS (ESI): mass calculated forC₂₄H₁₇F₂N₅O₃S, 493.10; m/z found, 494/495/496 [M+H]⁺; 516/517 [M+Na]⁺.HPLC (reverse phase): R_(T)=9.19 min. ¹H NMR (400 MHz, CDCl₃): 11.18 (s,1H), 8.87 (d, J=1.8 Hz, 1H), 8.83 (d, J=1.8 Hz, 1H), 8.58 (dd, J=7.4,1.3 Hz, 1H), 8.33 (dd, J=8.5, 1.4 Hz, 1H), 8.04 (d, J=1.4 Hz, 1H), 7.90(dd, J=8.4, 7.4 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 7.35-7.30 (m, 1H),7.25-7.22 (m, 1H), 6.90-6.83 (m, 2H), 6.46 (d, J=7.8 Hz, 1H), 5.35-5.29(m, 1H), 1.56 (d, J=7.0 Hz, 3H).

EXAMPLE 39

Quinoxaline-5-sulfonic acid[5-bromo-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)phenyl]-amide.A. 3-(3-Fluorophenoxy)propionitrile. A solution of 3-fluorophenol (12.1mL, 0.13 mol), Triton B (2.1 mL) and acrylonitrile (44 mL, 0.67 mol) washeated at reflux for 20 h. The mixture was cooled to room temperature,diluted with diethyl ether, and washed successively with 1 N NaOH, 1 NHCl, and H₂O. The organic extract was dried over MgSO₄, and concentratedto provide title compound (13.0 g, 59%). TLC (silica, 40%EtOAc/hexanes): R_(f)=0.54. HPLC (reverse phase): R_(T)=8.18 min. ¹H NMR(400 MHz, CDCl₃): 7.28-7.23 (m, 1H), 6.74-6.69 (m, 2H), 6.64-6.61 (m,1H), 4.17 (t, J=6.3 Hz, 2H), 2.84 (t, J=6.3 Hz, 2H).B. 3-(3-Fluorophenoxy)propionic acid. A mixture of3-(3-fluorophenoxy)-propionitrile (13 g, 0.079 mol) and concentrated HCl(60 mL) was heated at reflux for 16 h. The reaction mixture was cooledto room temperature and the resulting solid was collected, washed withH₂O, then diluted with 1 N NaOH (300 mL). The insolubles were removed byfiltration. The filtrate was acidified with concentrated HCl. The solidwas collected, washed with H₂O, and dried to afford title compound (12.3g, 85%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.24. HPLC (reversephase): R_(T)=7.82 min. ¹H NMR (500 MHz, CDCl₃): 7.23-7.20 (m, 1H),6.70-6.61 (m, 3H), 4.24 (t, J=6.2 Hz, 2H), 2.86 (t, J=6.2 Hz, 2H).C. 7-Fluorochroman-4-one. To a solution of 3-(3-fluorophenoxy)propionicacid (2.2 g, 0.011 mol) in toluene (25 mL) was added thionyl chloride(4.0 mL, 0.054 mol). The solution was heated at reflux for 1.5 h andconcentrated in vacuo. The residue was dissolved in CHCl₃ (25 mL),cooled to −65° C. and treated dropwise with trifluoromethanesulfonicacid (1.5 mL, 0.017 mol). The mixture was allowed to warm to roomtemperature with stirring for 2 h. After the addition of H₂O, the layerswere separated, and the organic layers were washed with 1 N NaOH. Thecombined organic extracts were dried over MgSO₄, filtered, concentrated,and purified by flash chromatography (hexanes/EtOAc) to provide thetitle compound (0.96 g, 53%). HPLC (reverse phase): R_(T)=8.22 min. ¹HNMR (500 MHz, CDCl₃): 7.92 (dd, J=8.8, 6.7 Hz, 1H), 6.75-6.72 (m, 1H),6.66 (dd, J=9.9, 2.4 Hz, 1H), 4.55 (t, J=6.4 Hz, 2H), 2.80 (t, J=6.5 Hz,2H).D. 8-Fluoro-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one. To an ice coldsolution of 7-fluoro-chroman-4-one (0.94 g, 5.7 mmol) in H₂SO₄ (8 mL)was added NaN₃ (0.55 g, 8.5 mmol) in portions. The resulting mixture wasstirred at 0° C. for 30 min, then was allowed to warm to roomtemperature and was stirred overnight. The reaction mixture was pouredonto ice, basified to pH ˜10 with 1 M NaOH, and extracted with DCM (3×).The combined organic layers were dried over MgSO₄, filtered,concentrated, and purified by flash chromatography (hexanes/EtOAc) toprovide the title compound (0.33 g, 33%). HPLC (reverse phase):R_(T)=6.96 min. ¹H NMR (500 MHz, CDCl₃): 8.07 (dd, J=9.0, 6.8 Hz, 1H),6.85-6.81 (m, 1H), 6.71 (dd, J=9.9, 2.5 Hz, 1H), 6.39 (s, 1H), 4.41 (t,J=4.5 Hz, 2H), 3.55-3.52 (m, 2H).E. 8-Fluoro-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine. To a 0° C.solution of 8-fluoro-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one (0.33 g,1.8 mmol) in THF (10 mL) was added lithium aluminum hydride (0.21 g, 5.5mmol) in small portions. The resulting mixture was heated at reflux for24 h, and then was cooled to room temperature. The reaction was quenchedby the successive dropwise addition of H₂O (0.21 mL), 15% aq. NaOHsolution (0.21 mL), and H₂O (0.63 mL). The salts were removed byfiltration. The filtrate was dried over MgSO₄ and concentrated to yieldthe title compound (0.24 g, 80%). HPLC (reverse phase): R_(T)=5.81 min.¹H NMR (500 MHz, CDCl₃): 7.07 (dd, J=8.2, 6.7 Hz, 1H), 6.75 (dd, J=9.8,2.6 Hz, 1H), 6.73-6.67 (m, 1H), 4.05 (t, J=4.4 Hz, 2H), 3.92 (s, 2H),3.21 (t, J=4.5 Hz, 2H), 1.58 (br s, 1H).F. Quinoxaline-5-sulfonic acid[5-bromo-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-bromo-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 1, Step G)and 8-fluoro-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₄H₁₈BrFN₄O₄S, 556.0; m/z found, 557/559 [M+H]⁺, 579/581 [M+Na]⁺. HPLC(reverse phase): R_(T)=9.41 min. ¹H NMR (500 MHz, CDCl₃, mixture ofamide rotamers): 9.06-8.94 (m, 3H), 8.50 (br d, J=7.2 Hz, 1H), 8.36 (d,J=8.3 Hz, 1H), 7.89 (t, J=7.9, 1H), 7.85 (d, J=1.7 Hz, 1H), 7.36-7.30(m, 0.3H), 7.14 (dd, J=8.2, 1.8 Hz, 1H), 6.86-6.80 (m, 0.7H), 6.76-6.71(m, 2H), 6.69-6.63 (m, 0.7H), 6.59-6.53 (m, 0.3H), 4.51-4.45 (m, 0.6H),4.12-4.06 (m, 1.4H), 3.91-3.60 (m, 3H), 3.44-3.37 (m, 1H).

EXAMPLE 40

Quinoxaline-5-sulfonic acid[5-chloro-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide.A. 3-(3,5-Difluorophenoxy)propionitrile. A solution of 3,5-fluorophenol(2.8 mL, 0.021 mol), Triton B (0.83 mL), and acrylonitrile (7.0 mL, 0.11mol) was heated at reflux for 20 h. The mixture was cooled to roomtemperature, diluted with diethyl ether, and washed successively with 1N NaOH, 1 N HCl, and H₂O. The organic extract was dried over MgSO₄ andconcentrated to provide title compound (1.33 g, 35%). HPLC (reversephase): R_(T)=8.66 min. ¹H NMR (400 MHz, CDCl₃): 6.84-6.43 (m, 3H), 4.16(t, J=6.3 Hz, 2H), 2.85 (t, J=6.3 Hz, 2H).B. 3-(3,5-Difluorophenoxy)propionic acid. A mixture of3-(3,5-difluoro-phenoxy)propionitrile (1.33 g, 7.26 mmol) andconcentrated HCl (10 mL) was heated at reflux for 16 h. After thereaction mixture was cooled to room temperature, the resulting solid wascollected by filtration, washed with H₂O, and diluted with 1 N NaOH (30mL). The remaining solids were removed by filtration. The filtrate wasacidified with concentrated HCl. The resulting precipitate wascollected, washed with H₂O, and dried to afford the title compound (1.11g, 76%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.15. MS (ESI): masscalculated for C₉H₈F₂O₃, 202.04; m/z found, 201 [M−H]⁻. HPLC (reversephase): R_(T)=8.02 min. ¹H NMR (400 MHz, CDCl₃): 6.45-6,41 (m, 3H), 4.21(t, J=6.2 Hz, 2H), 2.86 (t, J=6.2 Hz, 2H).C. 5,7-Difluorochroman-4-one. To a solution of3-(3,5-difluorophenoxy)-propionic acid (1.11 g, 5.49 mol) in toluene (10mL) was added thionyl chloride (2.0 mL, 27 mmol). The solution washeated at reflux for 1.5 h, then was concentrated in vacuo. The residuewas dissolved in CHCl₃ (10 mL), cooled to −65° C., and treated dropwisewith trifluoromethanesulfonic acid (0.73 mL, 8.2 mmol). The mixture wasallowed to warm to room temperature with stirring over 2 h. After theaddition of H₂O, the layers were separated. The organic layer was washedwith 1 N NaOH, then dried over MgSO₄, filtered, concentrated, andpurified by flash chromatography (hexanes/EtOAc) to provide the titlecompound (0.73 g, 73%). TLC (silica, 50% EtOAc/hexanes): R_(f)=0.43. ¹HNMR (400 MHz, CDCl₃): 6.52-6.47 (m, 2H), 4.54 (t, J=6.4 Hz, 2H), 2.80(t, J=6.4 Hz, 2H).D. 6,8-Difluoro-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one. To an icecold solution of 5,7-difluorochroman-4-one (0.73 g, 4.0 mmol) in H₂SO₄(10 mL) was added NaN₃ (0.39 g, 5.9 mmol) in portions. The resultingmixture was allowed to stir at 0° C. for 30 min, then was warmed to roomtemperature and stirred overnight. The reaction mixture was poured ontoice, basified to pH ˜10 with 1 M NaOH, and extracted with DCM (3×). Thecombined organic layers were dried over MgSO₄, filtered, concentrated,and purified by flash chromatography (hexanes/EtOAc) to provide thetitle compound (0.44 g, 56%). HPLC (reverse phase): R_(T)=6.64 min. ¹HNMR (500 MHz, CDCl₃): 6.98 (br s, 1H), 6.73-6.70 (m, 1H), 6.64-6.62 (m,1H), 4.34 (t, J=5.5 Hz, 2H), 3.47-3.44 (m, 2H).E. 6,8-Difluoro-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine. To a 0° C.solution of 6,8-fluoro-3,4-dihydro-2H-benzo[f][1,4]oxazepin-5-one (0.56g, 2.8 mmol) in THF (15 mL) was added BH₃.THF (1 M in THF, 5.62 mL, 5.62mmol). The resulting mixture was heated at reflux for 24 h, then cooledto room temperature. Excess borane was destroyed by careful addition ofmethanol (8 mL). The solvent was removed in vacuo, and the resulting oilwas treated with HCl (4.0 M in 1,4-dioxane) and heated at reflux for 3h. The mixture was concentrated, and the residue was suspended in H₂O,basified with 1 M NaOH, and extracted with DCM (3×). The combinedorganic extracts were dried over MgSO₄, filtered, and concentrated toyield title compound (0.45 g, 87%). ¹H NMR (400 MHz, CDCl₃): 6.59-6.50(m, 2H), 4.11-4.08 (m, 2H), 4.00 (s, 2H), 3.23 (t, J=4.6 Hz, 2H), (NHhot observed).F. Quinoxaline-5-sulfonic acid[5-chloro-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide.The title compound was prepared from the HATU-mediated coupling of4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid (EXAMPLE 3, Step B)and 8-fluoro-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine and purified asdescribed in EXAMPLE 1, Step K. MS (ESI): mass calculated forC₂₄H₁₇ClF₂N₄O₄S, 530.1; m/z found, 531 [M+H]⁺, 553 [M+Na]⁺. HPLC(reverse phase): R_(T)=9.38 min. ¹H NMR (500 MHz, CDCl₃, mixture ofamide rotamers): 9.0-8.9 (m, 3H), 8.51 (br d, J=6.7 Hz, 1H), 8.34 (dd,J=8.4, 1.3 Hz, 1H), 7.91-7.88 (m, 1H), 7.65 (d, J=1.6 Hz, 1H), 6.99-6.94(m, 1H), 6.82-6.72 (m, 1H), 6.6-6.5 (m, 2H), 4.8-4.6 (m, 1H), 4.3-3.9(m, 3H), 3.85-3.72 (m, 1H), 3.6-3.4 (m, 1H).

Examples 41 through 96 were prepared using the methods described above.

Assay Methods

Binding Assay

Assay Development

Zinc Finger Proteins (ZFP) specific for the CCK2R gene were identifiedby Sangamo Biosciences. The ZFP domain was fused with the herpes simplexvirus VP16 activation domain, and the fusion protein was subsequentlycloned into the pcDNA3 mammalian expression vector (Invitrogen, SanDiego, Calif.). Tet-inducible cell lines expressing the coding regionfrom the ZFP vector were created using the T-REx-293™ cell line(Invitrogen). After 2 weeks of selection in culture medium containing400 mg/mL Zeocin (Invitrogen), sixty drug-resistant stable clones wereisolated and analyzed for ZFP expression as well as CCK2R induction uponaddition of doxycycline to the culture medium. The cell line with themost appropriate CCK2R ZFP construct was used in all further assays andwas termed the HEKZFP cell line.

Cell Culture

HEKZFP cells were grown in DMEM supplemented with L-glutamine (2 mM),penicillin (50 units/mL) and streptomycin (50 μg/mL) and 10% FBS (v/v).HEKZFP cells were treated with 2 mM doxycycline (Sigma-Aldrich, MO; USA)for 2 days to de-repress the tet-regulated expression of the CCK2receptor selective zinc finger proteins and were harvested using arubber cell scraper.

Membrane Preparation

Membranes were prepared from the HEKZFP cells after induction. Frozencell pellets (−40° C.) were thawed in 14 mL of buffer A (10 mM HEPES,130 mM NaCl, 4.7 mM KCl, 5 mM MgCl, 1 mM EGTA and 15.4 mg/100 mLbacitracin at pH 7.2), adapted from E. A. Harper et al. (Br. J.Pharmacol. (1996) 118(7):1717-1726). The thawed pellets were homogenizedusing a Polytron PT-10 (7×1 s). The homogenates were centrifuged for 5min at 1500 rpm (600×g), and the resulting pellets were discarded. Thesupernatants were re-centrifuged in order to collect thereceptor-membrane pellets (25 min 15,000 rpm; 39,800×g), which werere-suspended in buffer A.

Incubation Conditions

All assays were conducted in 96-well plates (GF/B millipore filterplates) using buffer A. For the optimal cell number determinationexperiments, cells in concentrations ranging from 2.5×10⁵ to 12.5×10⁵cells/well were incubated with 20 pM [¹²⁵I]-BH-CCK-8S (50 μL 60 pMsolution) in a total volume of 150 μL. Total binding of [¹²⁵I]-BH-CCK-8Swas determined in the presence of 15 μL of buffer A. Non-specificbinding of [¹²⁵I]-BH-CCK-8S was determined in the presence of 15 μL of10 μM YF476, a CCK-2 receptor selective antagonist that is structurallyunrelated to the radioligand [¹²⁵]-BH-CCK-8S. The assay preparation wasincubated for 1 h at 21±3° C., and then the assay was terminated byrapid filtration of the preparation under reduced pressure. The loadedfilters were washed three times using undiluted PBS (100 μL), and then100 μL of scintillation fluid was added to the filter plate. Boundradioactivity was determined using a Topcount (Packard BioScience,Meriden, Conn.) with a count time of 1 min. From these experiments acell concentration of 1 pellet in 15 mL of buffer was chosen for use inother assays. To validate the radioligand concentration and incubationtime for the assay, saturation and kinetic binding studies were alsoconducted (see M. F. Morton, The Pharmacological Characterization ofCholecystokinin Receptors in the Human Gastrointestinal Tract. PhDThesis, University of London, 2000). The affinity of novel compounds wasestimated by incubating membrane preparations with 15 μL of competingligand (0.1 pM-1 mM) for 60 min at 21±3° C. The assay was thenterminated according to the procedure outlined above.

Data Analysis

The pKi values were determined using the equation of Y.-C. Cheng and W.H. Prusoff (Biochem. Pharmacol., 1973, 22(23):3099-3108):$K_{i} = \frac{{IC}_{50}}{1 + \frac{\lbrack L\rbrack}{K_{D}}}$

To circumvent problems associated with computer-assisted data analysisof compounds with low affinity, the data obtained in the current studywere weighted according to a method described by Morton. In brief, 100%and 0% specific binding were defined independently using total bindingand binding obtained in the presence of a high concentration of thereference antagonist, 2-NAP. TABLE 1 EX pK_(i) 1 8.1 2 7.7 3 7.9 4 7.6 57.8 6 7.5 7 7.5 8 7.4 9 7.4 10 7.3 11 7.2 12 7.1 13 6.8 14 6.5 15 7.9 167.4 17 7.2 18 7.2 19 7.1 20 7.1 21 6.9 22 6.8 23 6.6 24 6.5 25 6.5 266.5 27 6.5 28 6.4 29 6.3 30 6.2 32 7.2 33 7.9 34 8.1 35 7.8 36 7.6 376.7 38 6.5 39 7.1 40 6.6 42 7.6 43 8.0 45 7.5 48 7.7 50 7.2 53 7.6 547.4 56 7.4 57 7.4 58 7.2 61 7.4 62 7.8 63 7.5 64 7.6 66 7.3 67 6.2 717.1 72 7.0 73 7.1 74 7.5 75 7.2 76 7.6 77 7.3 78 7.4 79 6.6 92 7.1 946.4 96 6.2Guinea-Pig Gastric Corpeal Muscle Assay

CCK2 receptor-mediated muscle contraction was measured in an isolatedmuscle-strip assay of guinea-pig gastric corpeal muscle according to themethods described by Roberts et al. (S. P. Roberts, E. A. Harper, G. F.Watt, V. P. Gerskowitch, R. A. Hull, N. P. Shankley, and J. W. Black,Br. J. Pharmacol., 1996, 118(7):1779-1789). In brief, strips of musclewere dissected and suspended in isolated tissue organ baths for isotonicmuscle contraction recording. The baths, containing Krebs-Henseleitsolution, were maintained at 24° C. and gassed continuously with 95% O₂and 5% CO₂. CCK1 receptors known to be present in this assay wereblocked using a selective concentration of a suitable CCK1 receptorantagonist (e.g. 2-NAP). The effectiveness of the test compounds wasassessed by measuring their effect on contractile concentration-responsecurves obtained using a well-characterized surrogate for the hormonegastrin (pentagastrin). The title compound of Example 2 behaved as acompetitive antagonist in this assay with a pK_(B) value of 8.8.

1. A compound having CCK2 antagonist activity of formula (1):

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)—,benzoylC₀₋₃alkyl-(CR^(s) ₂)—, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R^(q), R^(q) isindependently selected from the group consisting of C₁₋₄alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 2. The compound of claim 1wherein R¹ and R² are independently selected from the group consistingof H, a) C₁₋₇alkyl, ethenyl, propenyl, butenyl, ethynyl, propynyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl,cyclohexenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl,6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl, cyclobutylC₁₋₄alkyl,cyclopentylC₁₋₄alkyl, cyclohexylC₁₋₄alkyl, cycloheptylC₁₋₄alkyl, b)phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or4-yl, optionally 5,6,7 or 8 oxo substituted, benzyl,6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-ylmethyl, optionally5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3 or4-ylmethyl, optionally 5,6,7 or 8 oxo substituted, 1-phenyleth-1-yl,benzhydryl, naphthylmethyl, benzoylmethyl, 1-benzoyleth-1-yl, c)pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl, pyridazinylmethyl,quinolin-2,3 or 4-ylmethyl, isoquinolin-1,3 or 4-ylmethyl, quinazolin-2or 4-ylmethyl, quinoxalin-2 or 3-ylmethyl, d) furanylmethyl,thiophenylmethyl, 1-(H or C₁₋₄alkyl)pyrrolylmethyl, oxazolylmethyl,thiazolylmethyl, pyrazolylmethyl, imidazolylmethyl, isoxazolylmethyl,isothiazolylmethyl, benzofuran-2 or 3-ylmethyl, benzothiophen-2 or3-ylmethyl, 1-(H or C₁₋₄alky)-1H-indol-2 or 3-ylmethyl, 1-(H orC₁₋₄alkyl)-1H-benzimidazol-2-ylmethyl, benzooxazol-2-ylmethyl,benzothiazol-2-ylmethyl, e) quinolin-5,6,7 or 8-ylmethyl,isoquinolin-5,6,7 or 8-ylmethyl, quinazolin-5,6,7 or 8-ylmethyl,quinoxalin-5,6,7 or 8-ylmethyl, f) benzofuran-4,5,6 or 7-ylmethyl,benzothiophen-4,5,6 or 7-ylmethyl, 1-(H or C₁₋₄alky)-1H-indol-4,5,6 or7-ylmethyl, 1-(H or C₁₋₄alkyl)-1H-benzimidazol-4,5,6 or 7-ylmethyl,benzooxazol-4,5,6 or 7-ylmethyl, benzothiazol-4,5, 6 or 7-ylmethyl, g)C₁₋₄alkylO- and HSC₁₋₄alkyl, where each of a) to g) is substituted with0, 1, 2, or 3 of R¹ and for those groups in which R^(s) is hydrogen, upto one R^(s) may be other than hydrogen.
 3. The compound of claim 1wherein R¹ and R² are independently selected from the group consistingof hydrogen, methyl, ethyl, butyl, hexyl, phenyl,6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl, optionally 5,6,7,8 or 9 oxosubstituted, benzyl, 1-phenyleth-1-yl, furanylmethyl, benzoylethyl,1-benzoyleth-1-yl, methylo-, cyclohexyl, cyclohexylmethyl, pyridylethyl,naphthylmethyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, benzhydryl, whereeach member is substituted with 0, 1, 2, or 3 of R^(q) and, optionally,for those groups in which R^(s) is hydrogen, up to one R^(s) may beother than hydrogen.
 4. The compound of claim 1 wherein R¹ and R² areindependently selected from the group consisting of hydrogen, methyl,ethyl, butyl, phenyl, benzyl, 2-bromobenzyl, 2-chlorobenzyl,4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl,2,6-dichlorobenzyl, 2,4,6-trichlorobenzyl, 2-fluorobenzyl,4-fluorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl,2,4,6-trifluorobenzyl, 2-chloro-4-fluorobenzyl, 2-fluoro-4-bromobenzyl,2-fluoro-4-chlorobenzyl, 2-methylbenzyl, 2-methylsulfanylbenzyl,2-trifluoromethylbenzyl, 1-phenyleth-1-yl, 1-phenylprop-1-yl,1-(4-bromophenyl)eth-1-yl, 1-(4-fluorophenyl)eth-1-yl,1-(2,4-dibromophenyl)eth-1-yl, 1-(2,4-dichlorophenyl)eth-1-yl,1-(3,4-dichlorophenyl)eth-1-yl, 1-(2,4-difluorophenyl)eth-1-yl,2-fluoro-1-(2,4-difluorophenyl)eth-1-yl,2-fluoro-1-(4-fluorophenyl)eth-1-yl, 1-(4-methylphenyl)eth-1-yl,1-methyl-1-phenyleth-1-yl, 2,2,2-trifluoro-1-phenyleth-1-yl,2,2,2-trifluoro-1-(2,4-difluorophenyl)eth-1-yl,1-phenyl-2-dimethylaminoeth-1-yl, 1-benzoyleth-1-yl, cyclohexyl,1-cyclohexyleth-1-yl, furan-2-ylmethyl, naphth-1-ylmethyl, methoxy,methylSethyl, 6-methyl-6-hydroxyhept-2-yl, pyrid-2-ylethyl,1,2,3,4-tetrahydro-naphthalen-1-yl, 1-phenyl-2-hydroxyeth-1-yl,benzhydryl, 4-hydroxymethylpiperidin-1-yl, 1-furan-2-yl-2-phenyleth-1-yland 9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl.
 5. The compoundof claim 1 wherein R¹ and R² is H or C₁₋₄alkyl where the other is not Hor C₁₋₄alkyl.
 6. The compound of claim 1 wherein one of R¹ and R² is H,methyl or ethyl.
 7. The compound of claim 1 wherein at least one of R¹and R² are selected from the groups consisting of

with the proviso that said R^(s) is not hydrogen, said phenyl isoptionally fused at two adjacent carbon atoms to R^(f) and, except inpositions where “R^(s)” or “H” is specifically indicated, each member issubstituted with 0, 1, 2, or 3 of R^(q).
 8. The compound of claim 1wherein R^(f) is selected from the group consisting of —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— and —(C═O)CH₂CH₂CH₂—.
 9. The compoundof claim 1 wherein R^(s) is selected from the group consisting ofhydrogen, methyl, ethyl, propyl, trifluoromethyl, halomethyl,aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,methoxymethyl, thiomethyl, methylthiomethyl and phenyl.
 10. The compoundof claim 1 wherein R^(s) is selected from the group consisting of H,methyl, ethyl, hydroxymethyl, fluoromethyl and dimethylaminomethyl. 11.The compound of claim 1 wherein R^(q) is selected from the groupconsisting of methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro,bromo, iodo, trifluoromethyl, aminomethyl, methylaminomethyl,dimethylaminomethyl, hydroxymethyl, methoxymethyl, thiomethyl,methylthiomethyl, methoxy, ethoxy, methylmercapto and ethylmercapto. 12.The compound of claim 1 wherein R is selected from the group consistingof methyl, hydroxy, fluoro, chloro, bromo, iodo and trifluoromethyl. 13.The compound of claim 1 wherein R¹ and R² taken together with thenitrogen to which they are attached are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl, ii)2-pyrrolin-1-yl, 3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl,3-(H or R^(p))imidazolidin-1-yl, piperidin-1-yl, morpholin-4-yl,thiomorpholin-4-yl, 3-(H or R^(p))piperazin-1-yl, azepan-1-yl,thiazolidin-3-yl, oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl,azetidin-1-yl, where each member of ii) in each ring has 0 or 1unsaturated bond and has 0, 1 or 2 carbon members which is a carbonyl,iii) 3,4-dihydro-2H-quinolin-1-yl, 3,4-dihydro-2H-quinolin-2-yl,2,3-dihydro-indol-1-yl, 1,3-dihydro-isoindol-2-yl,1-oxo-1,3-dihydro-isoindol-2-yl, tetrahydro-benzo[b, c or d]azepin-1-yl,2,3-dihydro-benzo[e or f][1,4]oxazepin-4-yl, where each member of iii)in each ring has 0 or 1 unsaturated bond and has 0, 1 or 2 carbonmembers which are a carbonyl, iv) decahydro-quinolin-1-yl,octahydro-isoquinolin-2-yl, octahydro-[1 or 2]pyrindin-1 or 2-yl,octahydro-indol-1-yl, octahydro-isoindol-2-yl,hexahydro-cyclopenta[b]pyrrol-1-yl, hexahydro-cyclopenta[c]pyrrol-2-yl,(5,6,7 or 8-H or R^(p))-decahydro-[1,5 or 1,6 or 1,7 or1,8]naphthyridin-1-yl, (5,6,7 or 8-H or R^(p))-decahydro-[2,5 or 2,6 or2,7 or 2,8]naphthyridin-2-yl, 1-H orR^(p)-octahydro-pyrrolo[2,3-c]pyridin-6-yl, 2-H orR^(p)-octahydro-pyrrolo[3,4-c]pyridin-5-yl, 1-H orR^(p)-octahydro-pyrrolo[3,2-c]pyridin-5-yl, 1-H orR^(p)-octahydro-pyrrolo[2,3-b]pyridin-7-yl, 6-H orR^(p)-octahydro-pyrrolo[3,4-b]pyridin-1-yl, 1-H orR^(p)-octahydro-pyrrolo[3,2-b]pyridin-4-yl, 5-H orR^(p)-octahydro-pyrrolo[3,4-c]pyridin-2-yl, 6-H orR^(p)-octahydro-pyrrolo[2,3-c]pyridin-1-yl, 1-H orR^(p)-octahydro-pyrrolo[3,4-b]pyridin-6-yl, 7-H orR^(p)-octahydro-pyrrolo[2,3-b]pyridin-1-yl,octahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl, where each memberof iv) in each ring has 0, 1 or 2 carbon members which is a carbonyl,each ring of attachment has 0 or 1 unsaturated bonds and each secondaryring has 0, 1 or 2 unsaturated bonds, v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,where each member of i), ii), iii), iv) or v) is further substitutedwith 0, 1 or 2 of R^(p).
 14. The compound of claim 1 wherein R¹ and R²taken together with the nitrogen to which they are attached are selectedfrom the group consisting of10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl, 2-pyrrolin-1-yl,3-pyrrolin-1-yl, pyrrolidin-1-yl, 2-imidazolin-1-yl, imidazolidin-1-yl,piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl,azepan-1-yl, tetrahydro-benzo[c]azepin-1-yl,tetrahydro-halobenzo[c]azepin-1-yl,2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,2,3-dihydro-halobenzo[f][1,4]oxazepin-4-yl, thiazolidin-3-yl,oxazolidin-3-yl, 2,5-dihydro-pyrrol-1-yl,8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,azetidin-1-yl, octahydro-quinolin-1-yl, 3,4-dihydro-2H-quinolin-1-yl,3,4-dihydro-2H-quinolin-2-yl, where each member is further substitutedwith 0, 1 or 2 of R^(p).
 15. The compound of claim 1 wherein R¹ and R²taken together with the nitrogen to which they are attached are selectedfrom the group consisting of1-methyl-10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl, azetidin-1-yl,pyrrolidin-1-yl, 2-hydroxymethylpyrrolidin-1-yl,2,4-dimethyl-3-ethylpyrrolidin-1-yl, piperidin-1-yl,2-methylpiperidin-1-yl, 4-hydroxypiperidin-1-yl,4-hydroxymethylpiperidin-1-yl, 4-phenylpiperidin-1-yl, azepan-1-yl,tetrahydro-benzo[c]azepin-1-yl, 7-fluoro-tetrahydro-benzo[c]azepin-1-yl,2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,8-fluoro-2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,6,8-difluoro-2,3-dihydro-benzo[f][1,4]oxazepin-4-yl,4-(2-hydroxyphenyl)piperazin-1-yl, morpholin-4-yl,2-methylmorpholin-4-yl, 2,6-dimethylmorpholin-4-yl,octahydro-isoquinolin-2-yl, decahydro-quinolin-1-yl, thiazolidin-3-yl,2,5-dimethyl-2,5-dihydro-pyrrol-1-yl,8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yland 3,4-dihydro-2H-quinolin-2-yl.
 16. The compound of claim 1 whereinR^(p) is selected from the group consisting of hydroxy, methyl, ethyl,propyl, hydroxymethyl, hydroxyethyl, phenyl, p-halophenyl, m-halophenyl,o-halophenyl, phenyl and p-hydoxyphenyl.
 17. The compound of claim 1wherein R^(p) is selected from the group consisting of hydroxy, methyl,ethyl, hydroxymethyl, hydroxyethyl, phenyl, mono-fluorosubstitutedphenyl and mono-chlorosubstituted phenyl.
 18. The compound of claim 1wherein R^(a) is selected from the group consisting of methyl, ethyl,propyl, ethenyl, propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl,thienyl, pyrrol-1-yl, benzyl, methoxy, ethoxy, propoxy, cyclopropoxy,cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, —SH, -Smethyl, -Sethyl,—S-t-butyl, -Scyclopropyl, -Sphenyl, -Sbenzyl, nitro, cyano, amino,dimethylamino, (cyclohexylmethyl)amino, acetyl, —SCF₃, I, F, Cl, Br,trifluoromethyl, —OCF₃ and carboxymethyl.
 19. The compound of claim 1wherein there is one R^(a).
 20. The compound of claim 1 wherein there isone R^(a) positioned on the ring para to the amide substituent.
 21. Thecompound of claim 1 wherein two adjacent R^(a) are taken together withthe carbons of attachment to form a fused ring, the fused ring isphenyl.
 22. The compound of claim 1 wherein R^(a) is selected from thegroup consisting of nitro, cyano, F, Cl, Br, fused phenyl, I, CF₃,methoxy, ethoxy, propoxy, i-propoxy, ethenyl, cyclopentoxy, 2-propenyl,phenyl, furanyl, thienyl, amino, pyrrol-1-yl, dimethylamino,(cyclohexylmethyl)amino, —SCH₃, -Sethyl, —S-t-butyl, -Sbenzyl, —SCF₃,i-propyl and methyl.
 23. The compound of claim 1 wherein R is absent orselected from the group consisting of methyl, ethyl, I, F, Cl and Br.24. The compound of claim 1 wherein R^(b) is absent.
 25. The compound ofclaim 1 wherein said pharmaceutically acceptable salt is an effectiveamino addition salt.
 26. The compound of claim 1 wherein saidpharmaceutically acceptable salt is selected from the group consistingof hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate,oxalate, valerate, oleate, palmitate, stearate, laurate, borate,benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,succinate, tartrate, naphthylate, mesylate, glucoheptonate,lactiobionate, and laurylsulfonate.
 27. The compound of claim 1 selectedfrom the group consisting of:(R)-4-Bromo-N-[1-(2,4-dichlorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Chloro-N-[1-(2,4-difluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4,5-Dichloro-N-[1-(2,4-difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Chloro-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Bromo-N-[1-(4-fluorophenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Chloro-N-[1-(2,4-dichlorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(2,4-Difluorophenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-(2-chloro-4-fluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-(2,4-difluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Chloro-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-2,2,2-trifluoroethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Bromo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Iodo-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;N-(4-Fluorobenzyl)-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(2,4-Difluorophenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethylbenzamide;(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-4-fluoro-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Cyano-N-[1-(2,4-difluoro-phenyl)ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;N-Benzyl-4-bromo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;N-Benzyl-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Chloro-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-(4-fluoro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-(4-fluoro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-(4-chloro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-(4-chloro-benzyl)-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;N-(4-Chloro-benzyl)-4-iodo-N-methyl-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-[1-(4-chloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-[1-(4-chloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;N-[1-(4-Chloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-[1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-[1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;N-[1-(4-Fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-(2,4-difluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;N-(2,4-Difluoro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;N-(2,4-Difluoro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-(2,4-dichloro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-(2,4-dichloro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;N-(2,4-Dichloro-benzyl)-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Chloro-N-(2-chloro-4-fluoro-benzyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-4-Chloro-N-methyl-N-(1-phenyl-ethyl)-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(4-Fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Bromo-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-N-[1-(2,4-Difluoro-phenyl)-2,2,2-trifluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(2,4-Dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-4-trifluoromethyl-benzamide;(R)-4-Cyano-N-[1-(2,4-dichloro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(R)-N-[1-(2,4-Difluoro-phenyl)-ethyl]-4-fluoro-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Bromo-N-[2-fluoro-1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Chloro-N-[2-fluoro-1-(4-fluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-N-[2-Fluoro-1-(4-fluoro-phenyl)-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;4-Bromo-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;N-[1-(2,4-Difluoro-phenyl)-2-fluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Bromo-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-N-[1-(2,4-Difluoro-phenyl)-2-fluoro-ethyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-benzamide;(S)-4-Chloro-N-[1-(2,4-difluoro-phenyl)-2-fluoro-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide;and Quinoxaline-5-sulfonic acid[6-bromo-2-(2,4-difluoro-benzyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-amide.28. The compound of claim 1 selected from the group consisting of:Quinoxaline-5-sulfonic acid[5-iodo-2-(piperidine-1-carbonyl)-phenyl]-amide; Quinoxaline-5-sulfonicacid [5-iodo-2-(morpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-bromo-2-(1,3,4,5-tetrahydrobenzo[c]azepine-2-carbonyl)phenyl]-amide;(R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(morpholine-4-carbonyl)-phenyl]-amide;(R)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide;(R)-Quinoxaline-5-sulfonic acid[5-chloro-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide;(R)-Quinoxaline-5-sulfonic acid[5-chloro-2-(morpholine-4-carbonyl)phenyl]-amide; Quinoxaline-5-sulfonicacid [2-(azepane-1-carbonyl)-5-iodophenyl]-amide;(R)-Quinoxaline-5-sulfonic acid[5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[4,5-dichloro-2-(morpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(azepane-1-carbonyl)-5-bromophenyl]-amide; Quinoxaline-5-sulfonicacid[5-chloro-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide;(S)-Quinoxaline-5-sulfonic acid[5-iodo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-bromo-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide;(R,S)-Quinoxaline-5-sulfonic acid[2-(3,5-dimethylmorpholine-4-carbonyl)-5-iodophenyl]-amide;Quinoxaline-5-sulfonic acid[2-(4-hydroxy-piperidine-1-carbonyl)-5-iodo-phenyl]-amide;meso-Quinoxaline-5-sulfonic acid[2-(3,5-dimethylmorpholine-4-carbonyl)-5-bromophenyl]-amide;(S)-Quinoxaline-5-sulfonic acid[5-bromo-2-(3-methylmorpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(4-hydroxy-piperidine-1-carbonyl)-5-bromo-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-bromo-2-(piperidine-1-carbonyl)-phenyl]-amide; Quinoxaline-5-sulfonicacid[5-bromo-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)phenyl]-amide;Quinoxaline-5-sulfonic acid[5-chloro-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-chloro-2-(piperidine-1-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-chloro-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-iodo-2-(1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-bromo-2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide;(S)-Quinoxaline-5-sulfonic acid[5-chloro-2-(3-methyl-morpholine-4-carbonyl)-phenyl]-amide;meso-Quinoxaline-5-sulfonic acid[5-chloro-2-(3,5-dimethyl-morpholine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-chloro-2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(7-fluoro-1,3,4,5-tetrahydro-benzo[c]azepine-2-carbonyl)-5-iodo-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(azepane-1-carbonyl)-5-chloro-phenyl]-amide; Quinoxaline-5-sulfonicacid[5-chloro-2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(8-fluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(piperidine-1-carbonyl)-5-trifluoromethyl-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(morpholine-4-carbonyl)-5-trifluoromethyl-phenyl]-amide;Quinoxaline-5-sulfonic acid[5-bromo-2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-phenyl]-amide;Quinoxaline-5-sulfonic acid[2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-iodo-phenyl]-amide;and Quinoxaline-5-sulfonic acid[2-(6,8-difluoro-2,3-dihydro-5H-benzo[f][1,4]oxazepine-4-carbonyl)-5-trifiuoromethyl-phenyl]-amide.29. A pharmaceutical composition comprising a pharmaceuticallyacceptable carrier and a therapeutically effective amount of compoundhaving CCK2 antagonist activity of formula (I):

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)—,benzoylC₀₋₃alkyl-(CR^(s) ₂)—, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R^(q), R^(q) isindependently selected from the group consisting of C₁₋₄alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 30. A method for thetreatment or prevention of pancreatic adenocarcinoma, pain, eatingdisorders, gastro-esophageal reflux disease, gastroduodenal ulcers,reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatictumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia,pernicious anaemia and Zollinger-Ellison syndrome in mammals comprisingthe step of administering to a mammal suffering there from atherapeutically effective amount of compound having CCK2 antagonistactivity of formula (I):

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)—,benzoylC₀₋₃alkyl-(CR^(s) ₂)—, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R^(q), R^(q) isindependently selected from the group consisting of C₁₋₄ alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 31. A method for thetreatment or prevention of pancreatic adenocarcinoma, pain,gastro-esophageal reflux disease, gastroduodenal ulcers, refluxesophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors andgastric tumors in mammals comprising the step of administering to amammal suffering there from a therapeutically effective amount ofcompound having CCK2 antagonist activity of formula (I):

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)—,benzoylC₀₋₃alkyl-(CR^(s) ₂)—, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R¹, R^(q) isindependently selected from the group consisting of C₁₋₄alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 32. A method for makingamidophenyl-sulfonylamino-quinoxalines comprising the steps of reducingcompound A6:

and condensing resultant compound A7:

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)-,benzoylC₀₋₃alkyl-(CR^(s) ₂)-, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R q R^(q) isindependently selected from the group consisting of C₁₋₄alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 33. A method for makingamidophenyl-sulfonylamino-quinoxalines comprising the steps ofsulfonylating compound A5:

with compound D1:

wherein R¹ and R² are each independently selected from the groupconsisting of a) H, C₁₋₇alkyl, C₂₋₇alkenyl, C₂₋₇alkynyl, C₃₋₇cycloalkyl,C₃₋₇cycloalkenyl, benzo-fusedC₄₋₇cycloalkyl where the point ofattachment is a carbon atom adjacent to the ring junction,C₃₋₇cycloalkylC₁₋₇alkyl, b) naphthyl-(CR^(s) ₂)—,benzoylC₀₋₃alkyl-(CR^(s) ₂)—, phenyl, said phenyl optionally fused attwo adjacent carbon atoms to R^(f), phenyl-(CR^(s) ₂)—, said phenyloptionally fused at two adjacent carbon atoms to R^(f), R^(f) is alinear 3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturatedbonds and having 0, 1 or 2 carbon members which is a carbonyl, c)Ar⁶—(CR^(s) ₂)—, where Ar⁶ is a 6-membered heteroaryl having carbon as apoint of attachment, having 1 or 2 heteroatom members which are —N=andoptionally benzo fused, d) Ar⁵—(CR^(s) ₂)—, where Ar⁵ is a 5-memberedheteroaryl having carbon as a point of attachment, having 1 heteroatommember selected from the group consisting of O, S, >NH or >NC₁₋₄alkyl,having 0 or 1 additional heteroatom member which is —N=and optionallybenzofused, e) Ar⁶⁻⁶—(CR^(s) ₂)—, where Ar⁶⁻⁶ is phenyl having the pointof attachment and fused to a 6-membered heteroaryl having 1 or 2heteroatom members which are —N═, f) Ar⁶⁻⁵—(CR^(s) ₂)—, where Ar⁶⁻⁵ isphenyl having the point of attachment and fused to a 5-memberedheteroaryl having 1 heteroatom member selected from the group consistingof O, S, >NH or >NC₁₋₄alkyl and having 0 or 1 additional heteroatommember which is —N═, g) C₁₋₄alkylO— and HSC₁₋₄alkyl, where R¹ and R² arenot simultaneously H and, except in positions where R^(s) is indicated,each of a) to g) is substituted with 0, 1, 2, or 3 of R^(q), R^(q) isindependently selected from the group consisting of C₁₋₄alkyl, hydroxy,fluoro, chloro, bromo, iodo, trifluoromethyl, aminoC₁₋₄alkyl,C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl, HO—C₁₋₄alkyl,C₁₋₄alkylO-C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyl, C₁₋₄alkoxy andC₁₋₄alkylS-, R^(s) is independently selected from the group consistingof H, C₁₋₄alkyl, perhaloC₁₋₄alkyl, mono- or di-haloC₁₋₄alkyl,aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, diC₁₋₄alkylaminoC₁₋₄alkyl,HO—C₁₋₄alkyl, HS—C₁₋₄alkyl, C₁₋₄alkylO-C₁₋₄alkyl, C₁₋₄alkylS-C₁₋₄alkyland phenyl; or, alternatively, R¹ and R² may be taken together with thenitrogen to which they are attached and are selected from the groupconsisting of i) 10-oxa-4-aza-tricyclo[5.2.1.0^(2,6)]dec-4-yl,optionally mono- or di-substituted with R^(p), R^(p) is independentlyselected from the group consisting of hydroxy, C₁₋₄alkyl,hydroxyC₁₋₄alkyl, phenyl, mono-, di- or tri-halo substituted phenyl andhydroxyphenyl, ii) a 4-7 membered heterocyclic ring said heterocyclicring having 0 or 1 additional heteroatom members separated from thenitrogen of attachment by at least one carbon member and selected fromO, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0,1 or 2 carbon members which is a carbonyl, optionally having one carbonmember which forms a bridge and having. 0, 1 or 2 substituents R^(p),iii) a benzo fused 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0 or 1 additional unsaturated bonds, having0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halosubstituents on the benzene ring only and having 0, 1 or 2 substituentsR^(p), iv) a 4-7 membered heterocyclic ring said heterocyclic ringhaving 0 or 1 additional heteroatom members separated from the nitrogenof attachment by at least one carbon member and selected from O, S,—N═, >NH or >NR^(p), having 0, 1 or 2 unsaturated bonds, having 0, 1 or2 carbon members which is a carbonyl and optionally having one carbonmember which forms a bridge, the heterocyclic ring fused at two adjacentcarbon atoms forming a saturated bond or an adjacent carbon and nitrogenatom forming a saturated bond to a 4-7 membered hydrocarbon ring, having0 or 1 possibly additional heteroatom member, not at the ring junction,selected from O, S, —N═, >NH or >NR^(p), having 0, 1 or 2 unsaturatedbonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0,1 or 2 substituents R^(p); v)8-oxo-1,5,6,8-tetrahydro-2H,4H-1,5-methano-pyrido[1,2-a][1,5]diazocin-3-yl,optionally having 0, 1 or 2 substituents R^(p); R^(a) is independentlyselected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,C₃₋₆cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH,—OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC₁₋₆alkyl,—SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN, —NO₂, —N(R^(y))R^(z) (whereinR^(y) and R^(z) are independently selected from H, C₁₋₄alkyl orC₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃, halo, —CF₃, —OCF₃, and—COOC₁₋₄alkyl, or, alternatively, two adjacent R^(a), may be takentogether with the carbons of attachment to form a fused ring andselected from the group consisting of phenyl, pyridyl and pyrimidinyl;or alternatively, R² and one of R^(a) can be taken together to be —CH₂—or >C═O and to form a fused ring to the phenyl; R^(b) is, independently,selected from the group consisting of C₁₋₄alkyl and halogen; andenantiomers, diastereomers, hydrates, solvates and pharmaceuticallyacceptable salts, esters and amides thereof.
 34. A method for makingamidophenyl-sulfonylamino-quinoxalines comprising the step of peptidecoupling compound C3:

wherein R^(a) is independently selected from the group consisting ofC₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, phenyl, furanyl, thienyl,benzyl, pyrrol-1-yl, —OH, —OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl,-Obenzyl, —SH, —SC₁₋₆alkyl, —SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN,—NO₂, —N(R^(y))R^(z) (wherein R^(y) and R^(z) are independently selectedfrom H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃,halo, —CF₃, —OCF₃, and —COOC₁₋₄alkyl, or, alternatively, two adjacentR^(a), may be taken together with the carbons of attachment to form afused ring and selected from the group consisting of phenyl, pyridyl andpyrimidinyl; or alternatively, R² and one of R^(a) can be taken togetherto be —CH₂— or >C═O and to form a fused ring to the phenyl; R^(b) is,independently, selected from the group consisting of C₁₋₄alkyl andhalogen; and enantiomers, diastereomers, hydrates, solvates andpharmaceutically acceptable salts, esters and amides thereof.
 35. Themethod of claim 34, which comprises the initial steps of reducingcompound B3:

and condensing resultant compound B4:

to produce compound C3.
 36. A method for makingamidophenyl-sulfonylamino-quinoxalines comprising the steps ofsulfonylating compound C1:

with compound D1:

to produce a compound C2:

wherein R^(a) is independently selected from the group consisting ofC₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, phenyl, furanyl, thienyl,benzyl, pyrrol-1-yl, —OH, —OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl,-Obenzyl, —S H, —SC₁₋₆alkyl, —SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN,—NO₂, —N(R^(y))R^(z) (wherein R^(y) and R^(z) are independently selectedfrom H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃,halo, —CF₃, —OCF₃, and —COOC₁₋₄alkyl, or, alternatively, two adjacentR^(a), may be taken together with the carbons of attachment to form afused ring and selected from the group consisting of phenyl, pyridyl andpyrimidinyl; or alternatively, R² and one of R^(a) can be taken togetherto be —CH₂— or >C═O and to form a fused ring to the phenyl; R^(b) is,independently, selected from the group consisting of C₁₋₄alkyl andhalogen; and enantiomers, diastereomers, hydrates, solvates andpharmaceutically acceptable salts, esters and amides thereof.
 37. Acompound useful in the production ofamidophenyl-sulfonylamino-quinoxalines of the general formula:

wherein R^(a) is independently selected from the group consisting ofC₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, phenyl, furanyl, thienyl,benzyl, pyrrol-1-yl, —OH, —OC₁₋₆alkyl, —OC₃₋₆cycloalkyl, -Ophenyl,-Obenzyl, —SH, —SC₁₋₆alkyl, —SC₃₋₆cycloalkyl, -Sphenyl, -Sbenzyl, —CN,—NO₂, —N(R^(y))R^(z) (wherein R^(y) and R^(z) are independently selectedfrom H, C₁₋₄alkyl or C₁₋₆cycloalkylC₁₋₄alkyl), —(C═O)C₁₋₄alkyl, —SCF₃,halo, —CF₃, —OCF₃, and —COOC₁₋₄alkyl, or, alternatively, two adjacentR^(a), may be taken together with the carbons of attachment to form afused ring and selected from the group consisting of phenyl, pyridyl andpyrimidinyl; or alternatively, R² and one of R^(a) can be taken togetherto be —CH₂— or >C═O and to form a fused ring to the phenyl; R^(b) is,independently, selected from the group consisting of C₁₋₄alkyl andhalogen; and enantiomers, diastereomers, hydrates, solvates andpharmaceutically acceptable salts, esters and amides thereof.
 38. Acompound useful in the production ofamidophenyl-sulfonylamino-quinoxalines of the general formula:

wherein R^(b) is, independently, selected from the group consisting of—C₁₋₄alkyl and halogen.